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 Abstract 
Resistance to β-lactam antibiotics in Campylobacter is often associated with the production 
of a β-lactamase; to date the genomically encoded blaOXA-61 and the closely related cj0299 
are the only described β-lactamase genes of Campylobacter.  
Cj0299 of C. jejuni NCTC11168 was assigned a novel oxacillinase number OXA-193. 
Previously, a novel β-lactamase (CjBla2) was identified in two blaOXA-193 negative isolates, 
P843 and P854. Southern blotting with a probe for blaOXA-193 confirmed that Bla2 is not the 
product of a mutated blaOXA-193 gene.  A further thirteen veterinary isolates of 
Campylobacter have been identified that have the same phenotype as P843 and P854. 
Whole genome sequencing of P854 revealed four putative beta-lactamase genes, one of 
which, P854_1490, encodes a completely novel oxacillinase (OXA-184). PCR screening and 
sequencing of the other putative CjBla2 producers revealed six to contain the novel 
oxacillinase.  A further five encode a variant of this novel OXA in which a point mutation has 
led to an amino acid coding change from leucine to isoleucine (OXA-185). These isolates 
represent a selection of flaA types and were isolated from two separate locations at 
different times, therefore it is unlikely that they are a clonal population. 
Two conjugative plasmids, each approximately 45Kb in size, have been identified from two 
veterinary isolates of Campylobacter. These plasmids have been shown to horizontally 
transfer resistance to tetracycline and to the β-lactams penicillin, ampicillin and oxacillin, 
between Campylobacter, a process never previously described. The two β-lactam resistance 
encoding plasmids thought to contain a β-lactamase gene(s) have been named pBla1 and 
pBla2.  
The role of efflux in beta-lactam resistance has also been investigated; inactivation of the 
efflux pump gene cmeB in the reference strain NCTC11168 resulted in increased 
susceptibility to a range of beta-lactams including the cephalosporins which Campylobacter 
are reported to be innately resistant to and have been included in some Campylobacter 
selective media.  
The work completed as part of this PhD program has furthered the understanding of beta-
lactam resistance in Campylobacter and has demonstrated that it is clearly a multi-faceted 
mechanism incorporating various chromosomally encoded beta-lactamases, putative 
transferable beta-lactamases and efflux.  
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Chapter 1 – Introduction 
1.1 Campylobacter jejuni  
Campylobacter jejuni sub species jejuni (C. jejuni) is the most commonly isolated species of 
the Campylobacter genera (HPA 2006; HPA 2007; ECDC 2009). Other clinically important 
species include Campylobacter coli and Campylobacter foetus. Two other closely related 
genera, Helicobacter and Wolinella along with the Campylobacter genera make up the order 
of the Campylobacterales which belong to the epsilon class of proteobacteria.  
Although Campylobacter have only been recognised as human pathogens for the last 40 
years, their presence may have been noted in clinical samples as early as 1886 when 
Theodore Escherich described un-culturable Campylobacter-like organisms in the stools of 
infants who had died of ‘cholera infantum’ (Kist 1985). From this time until the 1960s, all the 
information about Campylobacter was gained through the field of veterinary medicine. 
 A five year survey into the causes of abortion in sheep was set up in 1906 by the English 
board of agriculture and fisheries and was led by John McFadyean and Stewart Stockholm; 
they were the first to define “vibrionic abortion” after isolating a “vibrio” from the uterine 
mucus of a calf and the stomach contents of her foetus (McFadyean and Stockholm 1913). 
One hundred years later, it is clear that what they were actually describing is Campylobacter 
foetus.  
In 1931, Jones et al., described an organism isolated from the jejunal mucosa of calves and 
cattle with an enteric fever or “winter dysentery” similar to “Vibrio foetus” but distinct 
antigenically, which they termed “Vibrio jejuni”(Jones, Orcutt et al. 1931). This name persists 
in the form of Campylobacter jejuni although none of the original isolates do; some 
2 
 
speculate this is because no-one was willing to continue with time consuming work of 
isolating these organisms without the advantage of selective media (Skirrow and Butzler 
2000).  
A major contribution to the history of Campylobacter was made by Elizabeth King who 
studied isolates labelled as “Vibrio foetus” and made the distinction between the usual 
isolates e.g. Vibrio cholerae and those with a higher optimal growth temperature, 
Campylobacter jejuni and coli, which she gave the temporary name of  “related Vibrios” 
(King 1957; King 1962). In 1963, the term Campylobacter (Greek for ‘curved rod’) was 
suggested  to re-classify those “vibrios” that were both serologically and biochemically 
different from the classical Vibrios (e.g. Vibrio cholerae) (Sebald and Veron 1963). 
The isolation of Campylobacter from the faeces of patients with enteritis was first achieved 
by Dekeyser and Butzler in 1972 (Dekeyser, Gossuin-Detrain et al. 1972; Butzler, Dekeyser et 
al. 1973) by using the filtration method that Dekeyser, as a veterinary microbiologist, was 
familiar with, as it was used routinely to isolate “Vibrio foetus” from cattle suffering  septic 
abortion (Dekeyser, Gossuin-Detrain et al. 1972). These experiments were repeated by 
Skirrow in 1977 and Campylobacter was shown to be the most common bacterial pathogen 
isolated from the stool samples of patients with diarrhoea (Skirrow 1977). Since then the 
understanding of Campylobacter has benefited dramatically from the sequencing of an 
exemplar genome and other genetic elements (Parkhill, Wren et al. 2000; Bacon, Alm et al. 
2002). 
1.1.1 Microbiology 
C. jejuni is a small (1.5-6.0µm in length and 0.2-0.5µm in width), Gram negative, spiral 
bacterium with a characteristic corkscrew motility that can distinguish it from other bacteria 
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when viewed under a phase contrast microscope. Single, un-sheathed polar flagella are 
usually present at one or both ends of the cell (Figure 1.1) (Snelling, Matsuda et al. 2005; 
LaGier, Pratt et al. 2009). C. jejuni is microaerophilic and optimal growth of the organism is 
achieved in an atmosphere of 3-15% O2 and 3-5% CO2; the 42°C optimal growth temperature 
of this thermophile is thought to be a consequence of the natural habitat of C. jejuni being 
within the gastrointestinal tract of birds (and other animals) whose body temperature is 
higher than that of humans (Ketley 1997; Snelling, Matsuda et al. 2005). 
The process of obtaining pure cultures of Campylobacter is simplified by the use of 
compounds in medium that inhibit the growth of other bacterial species and so promotes 
the growth of Campylobacter. Common Campylobacter selective media include modified 
CCDA, a blood free agar which contains instead charcoal, ferrous sulphate and sodium 
pyruvate; this medium with the selective supplements amphotericin and cefoperazone is 
recommended for the isolation of Campylobacter from clinical specimens plus food and 
water specimens (HPA 2004).  
Skirrow's selective supplement contains vancomycin, polymyxin and trimethoprim and is 
added to a blood agar or Columbia agar base to make Skirrow’s medium which is also 
recommended for the isolation of Campylobacter from clinical specimens (HPA 2004). 
1.1.2 Campylobacter genetics 
1.1.2.1 Sequenced genomes 
The genome of C. jejuni NCTC 11168 was sequenced in 2000 (Parkhill, Wren et al. 2000) and 
re-annotated in 2007 (Gundogdu, Bentley et al. 2007), as a result considerable amount data 
is available about the genome of this pathogen. This exemplar genome of C. jejuni is 1.6Mb  
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Figure 1.1 Scanning electron micrograph of Campylobacter jejuni 
 
 
 
 
Scanning electron micrograph of Campylobacter jejuni with labelled bipolar terminal flagella 
(LaGier, Pratt et al. 2009). 
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in size and is now thought to encode 1643 proteins (initially thought to be 1654). Few 
insertion sequences or phage-associated sequences have been found and it has been noted 
that the genome has a lower than average GC content (30.6% G+C) (Parkhill, Wren et al. 
2000; Gundogdu, Bentley et al. 2007). Hyper variability was found in several genes relating 
to surface proteins, Parkhill et al., postulated that this was likely to be a survival mechanism 
of C. jejuni (Parkhill, Wren et al. 2000). 
The NCBI Entrez Genome Project now lists twenty C. jejuni sequencing projects (Table 1.1) 
and five Campylobacter plasmid sequencing projects (NCBI 2010). 
1.1.2.2 Mechanisms of horizontal gene transfer in bacteria 
The ability of bacteria to acquire genes from within and between bacterial species has 
enabled them to adapt to and exploit a multitude of ecological niches.  The proportion of 
horizontally acquired genes varies greatly between species, some organisms with smaller 
genomes e.g. Mycoplasma genitalium, contain virtually no acquired genes whereas in others 
non-native DNA can contribute to nearly 17% of the organism’s genome e.g. Escherichia coli 
K12 and Synechocystis (Figure 1.2) (Ochman, Lawrence et al. 2000; Pallen and Wren 2007). 
There are three main ways in which bacteria can acquire ‘foreign’ DNA by horizontal 
transfer; transformation, transduction and conjugation. 
Transformation 
Transformation does not require the donor and recipients to be in physical contact with each 
other as the process involves the recipient cell taking up ‘naked DNA’ from the environment. 
This process has the potential to allow un-related species to exchange DNA. It has been 
demonstrated that during natural transformation Campylobacter show a preference for the  
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Table 1.1 Campylobacter jejuni genome sequencing projects as of September 2010 
 
Isolate Sequencing Body Status 
NCBI 
Project  
ID: 
Campylobacter jejuni subsp. jejuni NCTC 11168 Sanger Institute Complete 8 
Campylobacter jejuni subsp. jejuni 81116 BBSRC Institute of Food Research Complete 17953 
Campylobacter jejuni subsp. jejuni 81-176 TIGR Complete 16135 
Campylobacter jejuni subsp. doylei 269.97 TIGR Complete 17163 
Campylobacter jejuni RM1221 TIGR Complete 303 
Campylobacter jejuni subsp. jejuni HB93-13 TIGR Draft Assembly 16267 
Campylobacter jejuni subsp. jejuni CG8486 NMRC Draft Assembly 17055 
Campylobacter jejuni subsp. jejuni CG8421 NMRC Draft Assembly 21037 
Campylobacter jejuni subsp. jejuni CF93-6 TIGR Draft Assembly 16265 
Campylobacter jejuni subsp. jejuni BH-01-0142 NMRC Draft Assembly 27797 
Campylobacter jejuni subsp. jejuni 84-25 TIGR Draft Assembly 16367 
Campylobacter jejuni subsp. jejuni 81-176 Yale University Draft Assembly 17341 
Campylobacter jejuni subsp. jejuni 260.94 TIGR Draft Assembly 16229 
Campylobacter jejuni subsp. jejuni M1 Danish Technical University In Progress 38041 
Campylobacter jejuni subsp. jejuni IA3902 Iowa State University In Progress 28907 
Campylobacter jejuni subsp. jejuni DFVF1099 Copenhagen University In Progress 41639 
Campylobacter jejuni subsp. jejuni 327 Copenhagen University In Progress 41643 
Campylobacter jejuni subsp. jejuni 305 Copenhagen University In Progress 41641 
Campylobacter jejuni 414 University of Liverpool In Progress 33821 
Campylobacter jejuni 1336 University of Liverpool In Progress 33777 
 
Information from the NCBI  as of 20/09/2010 (NCBI 2010). 
BBSRC; Biotechnology and Biological Sciences Research Council, TIGR; The institute for 
genomic research, NMRC; US Naval Medical Research Centre.  
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Figure 1.2 Distribution of horizontally acquired (foreign) DNA in sequenced 
bacterial genomes 
 
 
 
 
Lengths of bars denote the amount of protein-coding DNA. For each bar, the native DNA is 
blue; foreign DNA identifiable as mobile elements, including transposons and 
bacteriophages, is yellow and other foreign DNA is red. The percentage of foreign DNA is 
noted to the right of each bar. `A' denotes an Archaeal genome (Ochman, Lawrence et al. 
2000). 
  
8 
 
uptake of its own DNA (Wang and Taylor 1990; Wilson, Bell et al. 2003). Surface 
polysaccharides have recently been shown to limit natural transformation in C. jejuni; 
mutations in both lipooligosaccharide and capsular polysaccharide genes in C. jejuni results 
in a 97 fold increase in transformation frequency (Jeon, Muraoka et al. 2009). 
Campylobacter is one of over 40 species of bacteria that are naturally competent. Others 
include Neisseria gonorrhoeae, Haemophilus influenzae and Streptococcus pneumoniae 
(Dubnau 1999). However, it has become common laboratory practice to make bacteria that 
are not naturally competent, such as Escherichia coli, competent by the process of heat 
shocking or electroporation or can be made chemically competent so that they can take up 
not only linear fragments of DNA but also circular DNA i.e. plasmids. 
Transduction 
The introduction of DNA into a bacterium by a bacteriophage is termed transduction. When 
replicating within the ‘donor’ bacterium the phage can package either random pieces of its 
host DNA (generalised transduction) or host DNA adjacent to the phage attachment site 
(specialized transduction) into its capsid and can then transfer this DNA into the next 
bacterium it infects. This process is limited by (i) the amount of DNA that can fit within the 
phage capsid (although this may be greater than 100 kilobases) and (ii) by the need for the 
‘recipient’ to express the receptors the phage requires for attachment (Ochman, Lawrence 
et al. 2000). When the Campylobacter jejuni NCTC11168 genome was sequenced virtually no 
phage associated sequences were found (Parkhill, Wren et al. 2000). Sequencing of further 
Campylobacter strains revealed the presence of a small number of phage associated regions; 
C. jejuni RM1221 was found to contain four phage associated regions, C. lari RM2100 and C. 
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upsaliensis RM3195 each contain one phage associated region whereas C. coli RM2228 
contains no phage associated regions at all (Fouts, Mongodin et al. 2005). 
Conjugation 
Conjugation or bacterial ‘mating’ allows the transfer of plasmids, autonomous, self 
replicating pieces of DNA from a donor to a recipient cell. Plasmids are usually closed, 
circular double stranded DNA molecules, although linear double stranded DNA molecules 
have also been described, for example in Borrelia burgdorferi (Hinnebusch and Tilly 1993; 
Stewart, Byram et al. 2005).  
The size range of Campylobacter plasmids has been shown to be 3kb to 178kb (Ansary and 
Radu 1992; Aquino, Filgueiras et al. 2002; Fouts, Mongodin et al. 2005) and these are 
thought to constitute up to nine incompatibility groups (plasmids from the same 
incompatibility group have too similar mechanisms of replication to allow them to co-exist in 
the same bacterial cell) (Miller, Heath et al. 2007). Plasmids can be either self transmissible 
or mobilisable; the former are usually larger and have a low copy number, the latter usually 
small and of a high copy number. Hfr (high frequency of recombination) plasmids that 
integrate into the host chromosome can also be responsible for the transfer of bacterial 
genomic DNA from one bacterium to another when they are excised imprecisely (Ramirez-
Arcos, Fernandez-Herrero et al. 1998; Papke, Koenig et al. 2004). 
Besides plasmids other conjugative elements exist including conjugative transposons which 
encode proteins required for their own excision from the donor bacterium’s chromosome, 
formation of a ‘conjugative bridge’ and transfer to the recipient bacterium (Bellanger, 
Roberts et al. 2009). 
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1.1.3 Typing 
Due to the high numbers of human cases of Campylobacter infection and the many possible 
sources of those infections, it is vital to establish typing methods capable of determining the 
sources of outbreaks of Campylobacter illness. Traditional phenotypic methods such as 
phage typing and Penner serotyping (which is based on heat-stable antigens) are becoming 
less popular as laboratories switch to molecular typing methods (On, McCarthy et al. 2008). 
Two such commonly used molecular typing methods are described below. 
1.1.3.1 flaA  
Campylobacter possess two flagellin genes, flaA and flaB which can be used to type isolates. 
Originally flaA RFLP (restriction fragment length polymorphism) was the only available 
method of flaA typing; the flaA gene and its flanking region was amplified by PCR, digested 
with a single or combination of restriction enzymes and then electrophoresed (Nachamkin, 
Ung et al. 1996). A molecular method of flaA analysis known as flaA SVR (short variable 
region) sequencing is now favoured over RFLP, as this method relies on sequencing of the 
SVR region of flaA it is much more reproducible (Meinersmann, Helsel et al. 1997; 
Ragimbeau, Schneider et al. 2008). The Campylobacter flaA database 
(http://pubmlst.org/campylobacter/) currently lists 1429 flaA alleles coding for 332 peptides 
(last accessed 29/10/2010). 
1.1.3.2 Multilocus sequence typing (MLST) 
Multilocus sequence typing (MLST) exploits the natural sequence variation of housekeeping 
genes to establish relationships between isolates. An MLST system has been established in 
Campylobacter based on seven ‘housekeeping’ genes (Figure 1.3)  
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Figure 1.3 Locations of MLST loci on the chromosome of Campylobacter jejuni 
NCTC 11168 
 
 
(Dingle, Colles et al. 2001) 
 
Housekeeping Gene Gene product 
aspA aspartase A 
glnA glutamine synthetase 
gltA citrate synthase 
glyA serine hydroxymethyltransferase 
pgm phosphoglucomutase 
tkt transketolase 
uncA ATP synthase α subunit 
 
The inner circle shows the 1,641,481-bp genome divided into sixteen segments with each segment 
representing 164,148-bp. The loci of the seven genes targeted for MLST are indicated on the diagram 
and the products of these genes are listed in the table. 
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(Maiden, Bygraves et al. 1998; Dingle, Colles et al. 2001; Maiden 2006). Each allelic variant of 
a gene is assigned a different integer; the seven integers representing each gene are then 
combined to define the sequence type of a particular isolate. As the results rely on DNA 
sequence data they are unambiguous and are easily reproducible by different laboratories. 
Advantages of this technique include excellent reproducibility and the ever decreasing cost 
of DNA sequencing. The Campylobacter jejuni and Campylobacter coli MLST isolate database 
(http://pubmlst.org/campylobacter/) developed by Keith Jolley and Man-Suen Chan (Jolley, 
Chan et al. 2004) currently contains information on 10580 isolates of Campylobacter jejuni 
and Campylobacter coli (last accessed 29/09/2010).  
1.1.4 Epidemiology and transmission of Campylobacter  
For 2008, the HPA reported that there were 49,880 laboratory identified cases of 
Campylobacter infection in the England and Wales; and provisional data published by the 
HPA suggest that the infection rate rose 19% in 2009 (HPA 2009; HPA 2009). Although large, 
this number is thought to be a gross under estimation of actual cases as the vast majority 
require no medical treatment and so go un-reported (HPA 2007). Despite suspected under-
reporting the number of cases of bacterial gastroenteritis caused by Campylobacter vastly 
outnumbers those caused by Salmonella enterica (serovar Enteritidis plus serovar 
Typhimurium) and Escherichia coli (Figure 1.4). 
In the developed world most Campylobacter infections are sporadic and peak during the 
summer and early autumn although some outbreaks do occur (Blaser and Reller 1981; Finch 
and Riley 1984; Skirrow 1987; Humphrey, O'Brien et al. 2007). In developing countries there 
has been no proven link to seasonality (Biswas, Lyon et al. 1996). 
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Figure 1.4 Number of gastrointestinal infections in England and Wales between 
1991 and 2008 published by the HPA 
 
 
 
Based on data from HPA (HPA 2009). 
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Campylobacteriosis is a zoonotic disease. The most common route of human infection in 
developed countries is through contact with contaminated meat, especially under cooked 
poultry (Sahin, Morishita et al. 2002; Humphrey, O'Brien et al. 2007). Fifty seven and a half 
percent of chicken at retail was positive for Campylobacter (Humphrey, O'Brien et al. 2007) 
but  waterborne transmission is also a  problem in both developed and developing nations 
(Blaser, Taylor et al. 1983; Schonberg-Norio, Takkinen et al. 2004; Carrique-Mas, Andersson 
et al. 2005). C. jejuni is a commensal and can colonise the gastrointestinal tracts of food 
animals (including cattle, sheep and poultry) and also domestic animals (including cats and 
dogs), making transmission from animal-human either directly or in-directly (i.e. water 
contaminated with animal faeces)  a common occurrence (Blaser, Taylor et al. 1983; 
Humphrey, O'Brien et al. 2007).  
Other foods that have been implicated in sporadic outbreaks include bird-pecked milk (Neal 
and Slack 1997), bottled mineral water (Evans, Ribeiro et al. 2003), salad vegetables (Evans, 
Ribeiro et al. 2003), un-pasteurised milk (Neimann, Engberg et al. 2003) and grapes 
(Neimann, Engberg et al. 2003).  
As chickens clearly play an important role in Campylobacter infection in humans, limiting 
colonisation of poultry is seen as one possible way of controlling Campylobacter infection in 
humans.  It has been demonstrated there are various routes by which broilers can become 
colonised by Campylobacter, these include horizontal transmission, via vectors including  
flies (Hald, Skovgard et al. 2004) and from protozoa found in the birds drinking water which 
harbour internalised Campylobacter (Axelsson-Olsson, Waldenstrom et al. 2005; Snelling, 
McKenna et al. 2005; Snelling, McKenna et al. 2006; Snelling, Stern et al. 2008). 
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Although C. jejuni has fastidious growth requirements in the laboratory it has been 
recovered from various harsh environmental sources including river water, sea water, sand 
and sewage treatment plants (Rollins and Colwell 1986; Bolton, Coates et al. 1987; Jacob, 
Bindemann et al. 1991; Frias-Lopez, Zerkle et al. 2002).  There is some dispute as to whether 
stressful environments (low temperature and low nutrient availability, high oxygen 
concentrations) cause Campylobacter to enter a ‘viable but non-culturable’ (VBNC) state, 
which can be seen microscopically as a change from their usual spiral, motile form to a 
coccoid from which, it is postulated, they revert back to the infective, spiral form following 
passage in animals (Rollins and Colwell 1986; Murphy, Carroll et al. 2006).  It has been 
reported that VBNC forms microscopically detected in water could colonise chickens; other 
groups reported similar findings within laboratory animals (Saha, Saha et al. 1991; Pearson, 
Greenwood et al. 1993; Stern, Jones et al. 1994).   
Contradictory reports show that VBNC cannot initiate colonisation or disease (Beumer, de 
Vries et al. 1992; Medema, Schets et al. 1992; Hazeleger, Janse et al. 1995) and are in fact a 
degenerative rather than dormant stage of C. jejuni’s life cycle (Vandamme 2000). 
1.1.5 Disease and Pathogenesis 
1.1.5.1 Pathogenesis 
Immune Avoidance 
Campylobacter has several highly variable regions in its genome due to the presence of 
homopolymeric tracts. These are runs of approximately eight to thirteen base pairs of a 
single nucleotide, commonly guanine/cytosine often in a coding region and with guanine on 
the coding strand; the number of residues in the tract varies at a high frequency typically 10-
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3 per generation, due to strand or polymerase slippage during transcription or replication 
(Parkhill, Wren et al. 2000). These regions contain the genes encoding proteins that are 
responsible for the production/modification of the bacteria’s surface carbohydrates 
including lipooligosaccharide (LOS), capsular polysaccharide and flagella; phase switching by 
this mechanism is often involved in glycan synthesis or modification (e.g. glycosyl 
transferases) thereby allowing the organism to vary its immune exposed surface antigens 
(Parkhill, Wren et al. 2000).  
Some strains of Campylobacter also contain unusual capsular polysaccharides containing 
sugars such as 6‑deoxy‑d-manno-heptose and d‑xylose which have been shown to be 
present in the capsule of strain RM1221 (Gilbert, Mandrell et al. 2007). 
Adhesion and Invasion 
Campylobacter are orally acquired pathogens so before they are able to access their usual 
site of infection (the intestine) they first have to survive the acidity of the stomach and the 
highly alkaline secretions of the bile duct in the small intestine. 
Colonisation of the gastrointestinal tract by adhesion to intestinal epithelial cells and 
components of the extracellular matrix has long been considered essential for disease 
production (Fauchere, Rosenau et al. 1986; Konkel, Garvis et al. 1997). The bacterial 
polysaccharide capsule is essential for adhesion (Bacon, Szymanski et al. 2001; Watson and 
GalÃ¡n 2008) but several specific adhesins have also been identified; these include PEB-1, 
CadF and JlpA (Kervella, Pages et al. 1993; Pei and Blaser 1993; Konkel, Garvis et al. 1997; Jin, 
Joe et al. 2001).  
Motility has been demonstrated to be essential for invasion of epithelial cells in many 
studies (Wassenaar, Bleumink-Pluym et al. 1991; Grant, Konkel et al. 1993; Carrillo, Taboada 
17 
 
et al. 2004), although one theory suggested that the flagellum itself is required for invasion; 
a study in which non-motile mutant with an intact flagellum was created demonstrated that 
such mutants are not able to invade epithelial cells (Yao, Burr et al. 1994). 
Cytolethal distending toxin  
Cytolethal distending toxin (CDT) is produced by most Campylobacter strains and causes cell 
cycle arrest at the G2/M phase which leads to progressive cellular distension and apoptotic 
cell death (Lara-Tejero and Galan 2000; Lara-Tejero 2001; Frisan, Cortes-Bratti et al. 2002). 
CDT has been proven to be immunogenic in human infection as pooled human sera from 
patients previously infected with Campylobacter has been shown to neutralise CDT (Abuoun, 
Manning et al. 2005). CDT does not appear to be necessary for colonisation of chickens 
(Biswas, Fernando et al. 2006). 
1.1.5.2 Gastrointestinal Disease 
C. jejuni illness usually presents as an acute gastroenteritis. Incubation times have been 
estimated to be between 2-11 days, with an estimated average of 3 days (Skirrow and Blaser 
2000); a twenty four hour period of generalised fever and malaise often precedes the onset 
of diarrhoea which is typically bile stained and can become bloody, leukocytes are often 
present upon microscopic examination. Diarrhoea usually lasts from 2-5 days (but can 
become chronic and last for 7 days or more) and the patient can continue to suffer from 
abdominal pain for a further week. Relapses often occur (25% of cases) and so the average 
time away from work is between 10-14 days (Skirrow 1977; Blaser, Taylor et al. 1983; 
Snelling, Matsuda et al. 2005). Infective doses have been shown to be as low as 500-800 
organisms (Robinson 1981; Black, Levine et al. 1988). 
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The sometimes extreme abdominal pain caused by Campylobacter infection can be 
misdiagnosed as appendicitis, termed ‘pseudo-appendicitis’ as the appendix is usually not 
involved, although there have been some cases of Campylobacter enteritis linked 
appendicitis (Blaser, Berkowitz et al. 1979; Skirrow and Blaser 2000). 
Socio-economic status has been found to affect the presentation of Campylobacter enteritis; 
in less developed countries infection is much more common in children and diarrhoea is 
typically watery (rather than bile stained and bloody). It is thought that this type of 
childhood infection may help to immunise against adult disease (Blaser, Glass et al. 1980; 
Blaser, Taylor et al. 1983; Young, Davis et al. 2007). 
1.1.5.3 Non-gastrointestinal Campylobacter disease and sequelae 
Infection with C. jejuni outside of the gastrointestinal tract including; bacteraemia, hepatitis, 
peritonitis and myocarditis, have all been previously reported (McKendrick, Geddes et al. 
1982; Florkowski, Ikram et al. 1984; McNeil, Buttoo et al. 1984; Skirrow, Jones et al. 1993). 
A major complication post-infection with C. jejuni is Guillain-Barré syndrome (Rhodes and 
Tattersfield 1982), an auto-immune disease of the peripheral nervous system that results in 
a flaccid paralysis similar to polio (Nachamkin, Allos et al. 2000). Although this is a self 
limiting disease, recovery may take months and during this time the patient may need to be 
ventilated (which carries risks of its own) and between 15-20% may suffer with neurological 
deficits (Briscoe, Mcenamia et al. 1987; Rantala, Uhari et al. 1991; Adams and Victor 1993). 
Guillain-Barré syndrome is thought to arise following 1 in every 1000 Campylobacter 
infections and arises because Campylobacter LOS (lipooligosaccharide) can display molecular 
mimicry to human neuronal gangliosides (Yu, Usuki et al. 2006) . 
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Reactive arthritis (previously known as Reiter syndrome) is also thought to be a post-
infection complication associated with C. jejuni. Reactive arthritis is an auto-immune disease 
that results from infection and usually has three symptoms; inflammation of the eye, 
urethritis and inflammation of the joints (Snelling, Matsuda et al. 2005). It is still somewhat 
unclear how Campylobacter infection triggers this disease (Hill Gaston and Lillicrap 2003). 
1.1.6 Treatment 
Campylobacter infections in healthy individuals are usually self-limiting, meaning that the 
disease is resolved without the need for antibiotic treatment; although electrolyte 
replacement and re-hydration therapy may be required (Peterson 1994; Koenraad, 
Rombouts et al. 1997).  
Hospitalisation for Campylobacter infection is uncommon, except in patients with persistent 
or unusually severe disease or patients such as HIV/AIDs patients in whom Campylobacter 
infection can prove fatal (Manfredi, Nanetti et al. 1999). 
The British National Formulary (BNF) recommends the use of ciprofloxacin (a 
fluoroquinolone) or erythromycin (a macrolide) for the treatment of ‘severe’ Campylobacter 
enteritis. However most treatment for diarrhoea is empirical (i.e. before any diagnosis has 
been made) and so ciprofloxacin is usually favoured as it has activity against all the major 
bacterial causes of diarrhoea, including shigellosis, and salmonellosis (BNF 2009). Treatment 
can differ in pregnant women as the BNF recommendations regarding antibiotics and 
pregnancy discourage the use of macrolides (BNF 2009). 
Beta-lactams may be prescribed when treatment with the preferred agents, ciprofloxacin 
and erythromycin, is not possible due to allergy or when underlying illness makes treatment 
with a particular class of antibiotic unwise. For instance, patients with renal failure in whom 
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the use of aminoglycosides could be problematic may be prescribed the  beta-lactam 
imipenem as an alternative (Nachamkin, Engberg et al. 2000). Although the prescribing of 
beta-lactams is not currently routine practice, the increasing amounts of fluoroquinolone 
resistance may make exploration of other previously un-favoured classes such as the beta-
lactams, a viable and even necessary step. 
1.2 Antibiotic resistance 
1.2.1 Determining and defining resistance 
Susceptibilities to antibiotics in Campylobacter are usually determined by the agar dilution 
method (McDermott, Bodeis et al. 2004) because the disc diffusion method can be 
unreliable due to the un-even growth of Campylobacter. Mueller Hinton agar plates that 
contain a doubling dilution series of an antibiotic are inoculated with bacterial test strains. 
Control plates that do not contain any antibiotics are also inoculated. All plates are 
incubated for 24-48 hours then the test plates are compared to the control. The minimum 
inhibitory concentration (MIC) of an antibiotic for a bacterial strain is usually defined as the 
concentration at which growth is inhibited by 90% compared to the antibiotic free control 
plate. 
Bacteria are defined as ‘suceptible’ or ‘resistant’ to an antibiotic based on the value of their 
MIC and whether it falls above or below a pre-determined value or ‘breakpoint’ 
concentration; these differ between species and agent. Breakpoint concentrations are 
assigned by institutions such as the British Society for Antimicrobial Chemotherapy (BSAC), 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical 
and Laboratory Standards Institute in the US (CLSI, previously known as NCCLS) to 
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standardise the reporting of strains as ‘resistant’ or ‘sensitive’. However, breakpoints issued 
by the different institutions vary and so this must be taken into account when comparing the 
studies that use different guidelines. 
There are very few breakpoint concentration guidelines for Campylobacter. The only 
breakpoint concentrations given by BSAC for Campylobacter are for erythromycin (resistant: 
MIC>0.5mg/L) and ciprofloxacin (resistant: MIC>1mg/L)(BSAC 2008). EUCAST also give 
breakpoint concentrations for erythromycin (resistant: MIC>4mg/L) and ciprofloxacin 
(resistant: MIC>1), plus levofloxacin (resistant: MIC>2mg/L) and ofloxacin (resistant: 
MIC>1mg/L) (EUCAST 2008). Tentative Campylobacter breakpoint MICs were given for 
erythromycin, ciprofloxacin, tetracycline, and doxycycline in a 2007 CLSI document (M45-A), 
but the breakpoint concentration values they give for Enterobacteriaceae are sometimes 
applied for example, ciprofloxacin (resistant: MIC 4). It is worthy of note that beta-lactam 
breakpoint concentrations for Campylobacter are not given by BSAC, EUCAST or CLSI, so if 
resistance in Campylobacter to beta-lactams is to be reported, it must first be defined. 
1.2.2 Mechanisms of antimicrobial resistance  
There are several mechanisms by which bacteria can become resistant to an antibiotic; 
destruction or inactivation of the antibiotic, alteration or protection of the target site of the 
antibiotic, reduction of intracellular concentration either by reduced entry into, or enhanced 
efflux from the cell, and metabolic bypass (so the enzyme the drug targets is no longer 
necessary). C. jejuni utilizes a combination of these mechanisms for different agents (Table 
1.2). 
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Table 1.2 Mechanisms of antibiotic resistance in C. jejuni 
 
Type of Resistance Antibiotic Class Mechanism 
Resistance 
genes/mutations 
Reference 
Destruction or 
inactivation of 
antibiotic 
β-lactams Inactivation by  β-
lactamase 
blaOXA-61 (Taylor, Gradis et al. 1981; 
Alfredson 2004; Alfredson 
and Korolik 2005) 
Aminoglycosides Inactivation by 
aminoglycoside 
phosphotransferase 
aph (Tenover, Gilbert et al. 
1989) 
Chloramphenicol Inactivation by 
chloramphenicol acetyl 
transferase 
cat (Wang and Taylor 1990) 
Alteration or 
protection of 
target site 
Macrolides Mutation in target A to G at position 2230 
in the 23S rDNA gene 
(Engberg, Aarestrup et al. 
2001; Jensen and 
Aarestrup 2001) 
Sulphonamides Mutation in target Mutation in folP (Gibreel and Skold 1999) 
Tetracyclines Protection of target tet(O) (Manavathu, Hiratsuka et 
al. 1988) 
Prevention of 
accumulation 
Multiple classes Multidrug efflux cmeABC, cmeDEF (Pumbwe and Piddock 
2002; Pumbwe, Randall et 
al. 2004) 
Metabolic bypass Trimethoprim Replacement of sensitive 
enzyme 
dfr (Gibreel and Skold 1998; 
Gibreel and Skold 2000) 
 
Adapted  and updated from (Aarestrup and Engberg 2001). 
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1.2.3 Beta-lactam antibiotics 
Beta-lactams are a group of antibiotics (Table 1.3) that share a common structural feature, a 
highly reactive four-member, or beta-lactam, ring (Donowitz and Mandell 1988). Their 
antibacterial effect is achieved by interfering with the final stage of bacterial cell wall 
synthesis. Peptidoglycan is the main component of bacterial cell walls and is made up of 
alternating units of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG); adjacent 
strands are cross-linked to give the peptidoglycan a flexible, ‘net-like’ structure. The final 
cross-linking step is catalysed by transpeptidases (also known as penicillin-binding proteins 
or PBPs). Beta-lactam antibiotics are competitive inhibitors of the bacterial transpeptidase 
due to their structural similarity to the terminal D-Ala D-Ala motif of NAM. When a 
transpeptidase uses a beta-lactam as a substrate it becomes acylated and so is unavailable 
to perform its usual biological function and cell wall synthesis is hindered. Consequently the 
cell wall becomes compromised allowing an influx of water into the cell which eventually 
leads to cell-lysis and cell death (Ghuysen, Charlier et al. 1996; Goffin and Ghuysen 1998).  
1.2.4 Beta-lactamases 
The most important mechanism of beta-lactam resistance in Gram negative bacteria is the 
production of beta-lactamases. Beta-lactamases are enzymes with structural similarity to 
PBPs but with a higher affinity for beta-lactams, allowing them to act as antagonists. Beta-
lactamases hydrolyse the beta-lactam ring (Figure 1.5) of the antibiotic, as this site is crucial 
in modifying the PBP, the functionality of the drug is lost (Medeiros 1997; Bush and 
Mobashery 1998; Massova and Mobashery 1998; Bush 2001). The first beta-lactamase was 
described in an article in 1940, before the first beta-lactam, penicillin, was readily available 
(Abraham and Chain 1940).  
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Table 1.3 Beta-lactam antibiotics 
Penicillins Cephalosporins Carbapenems Monobactams Cephamycins 
Natural penicillins 
Benzylpenicillin (penicillin G) 
Phenoxymethylpenicillin 
(penicillin V) 
 
Extended spectrum 
penicillins 
Aminopenicillins 
(Ampicillin, Amoxicillin) 
Carboxypenicillins 
(Carbenicillin, Ticarcillin) 
 
Anti-staphylococcal  
 (to target staphylococcal 
penicillinase producers) 
Cloxacillin 
Meticillin 
Oxacillin 
1
st
 generation 
(narrow spectrum) 
Cephalothin 
Cephalexin 
 
2
nd
 generation 
(extended spectrum) 
Cefuroxime 
Cefamandole 
Cefaclor 
 
3
rd
 generation 
(broad spectrum) 
Cefotaxime 
Ceftriaxone 
 
4
th
 generation (broad 
spectrum) 
Cefepime 
Cefpirome 
 
5
th
 generation (anti-
MRSA) 
Ceftobiprole  
Meropenem 
Ertopenem 
Imipenem 
Aztreonam Cefmetazole 
Cefoxitin 
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Figure 1.5 Beta-lactams and their hydrolysis by beta-lactamases 
 
a) 
 
b) 
 
 
a) Adapted 3D-structure of Benzylpenicillin showing the beta-lactam ring (Csoregh and Palm 1977). 
 
b) Mode of action of a β-lactamase on a β-lactam ring, the core molecule of all β-lactam antibiotics. Hydrolysis 
of the β-lactam (e.g. penicillin) results in the production of the corresponding acid (e.g. penicilloic acid). The 
same is true for all classes of β-lactams including the cephalosporins, although they may produce an unstable 
acid that is then broken down into smaller fragments (Greenwood, Finch et al. 2007). 
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It is thought that beta-lactamases are an evolutionary response first elicited when some 
microorganisms gained the ability to produce beta-lactams (which would give them an 
advantage in their environmental niche) (Medeiros 1997). Structurally all beta-lactamases 
are very similar, typically containing both alpha-helices and beta-pleated sheets. The 
enzymes vary in their substrate specificities, response to inhibitors and even in the nature of 
their active site which is either serine or metallo (requiring two zinc ions for activation). 
Over 700 distinct beta-lactamases have been described (Perez, Endimiani et al. 2007)  and 
with them several classification systems. Both the more traditional Ambler class system and 
the Bush-Medeiros-Jacoby functional classification system are commonly used in the 
literature (Ambler 1980; Ambler, Coulson et al. 1991; Bush 1995) (Table 1.4). 
1.2.4.1 Beta-lactamase inhibitors  
Beta-lactamase inhibitors structurally resemble penicillin but on their own have little 
discernable antimicrobial activity; they are often referred to as ‘suicide inhibitors’ as they 
have a much higher affinity for beta-lactamases, occupy the active site of the enzyme for 
significantly longer and are essentially ‘trapped’ by the enzymes allowing an antibiotic 
delivered alongside the inhibitor to interact with the penicillin binding proteins (Helfand, 
Totir et al. 2003; Pagan-Rodriguez, Zhou et al. 2004; Babic, Hujer et al. 2006). 
Three such inhibitors are currently available clinically; clavulanic acid, sulbactam and 
tazobactam. These inactivate serine type beta-lactamases (such as the TEM series enzymes 
found in Gram negative bacteria) but have no activity against metallo-beta-lactamases. 
Metal chelators such as EDTA and dipicolinic acid inhibit metallo-beta-lactamases but are 
not relevant clinically as they cannot be used medically for treatment (Bebrone 2007). 
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Table 1.4 Classification of beta-lactamases 
 
Ambler 
Class 
Structural 
Class 
Preferred 
substrates 
Type of β-
lactamase 
Inhibited by: Representative 
enzymes Clavulanic acid EDTA 
A 2a Penicillins Serine   Penicillinases from 
Gram positive bacteria 
2b Penicillins, 
cephalosporins 
Serine   TEM-1 series and SHV 
series 
2c Penicillins, 
carbenicillin 
Serine   PSE series 
2e Cephalosporins Serine   Cephalosporinases from 
Proteus vulgaris 
2f Carbapenems Serine   Sme-1 from Serratia 
marcescens 
B 3a, 3b, 3c All classes except 
monobactams 
Metallo   L1 from Xanthormas 
maltophilia, CcrA from 
Bacteroides fragilis 
C 1 Cephalosporins Serine   AmpC enzymes from 
Gram negative bacteria, 
MIR 1 
D 2d Penicillins, 
cloxacillin 
Serine  
(weak ) 
 OXA series 
Not 
included 
4 Penicillins Serine   Penicillinase from 
Pseudomonas cepacia 
 
Adapted from (Bush 1995; Bush 2001; Greenwood, Finch et al. 2007) 
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Common beta-lactam plus inhibitor combinations (that can be used against beta-lactamases 
such as TEM and SHV groups) include augmentin/co-amoxyclav (ampicillin + clavulanic acid), 
TazocinTM (piperacillin + tazobactam) and UnasynTM (ampicillin + sulbactam). 
1.2.4.2 OXA beta-lactamases 
Oxacillinase (OXA) type beta-lactamases belong to Ambler class D and are named for their 
ability to hydrolyse oxacillin (and cloxacillin) at a rate that is 50% higher than the rate at 
which they hydrolyse penicillin G (Naas and Nordmann 1999). Historically, they are narrow 
spectrum beta-lactamases, giving resistance to penicillin, ampicillin, amoxicillin, cloxacillin 
and oxacillin; they may show limited ability to hydrolyse first generation cephalosporins 
(such as cephalothin) but are unable to hydrolyse extended spectrum cephalosporins and 
they are poorly inhibited by clavulanic acid (Naas, Poirel et al. 2008). OXA type beta-
lactamases have been found in many Gram negative organisms including the 
Enterobacteriaceae (usually associated with a plasmid) but are most commonly found in 
Pseudomonas aeruginosa (Naas and Nordmann 1999). The Lahey clinic currently list 193 
distinct (by at least one amino acid) OXA beta-lactamases as of 01/10/2010 (Jacoby and Bush 
2010). OXA enzymes with extended substrate profiles (often these are derivatives of OXA-
10) that encompass the extended spectrum cephalosporins are becoming more common 
(Jacoby and Bush 2010).  
The original definition of an extended spectrum beta-lactamase (ESBL) cannot be applied to 
OXA type enzymes with extended spectra, as the original definition stated that ESBLs were 
susceptible to inhibitors (such as clavulanic acid), to which OXA enzymes show only weak 
susceptibility. Nonetheless; OXA type enzymes with activity against second and third 
generation cephalosporins are often referred to as ESBLs (Naas, Poirel et al. 2008). 
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1.2.4.3 Plasmids containing genes encoding beta-lactamases  
Plasmid mediated beta-lactam resistance began to arise in the 1960s following the 
introduction of ampicillin. By 1968, plasmid mediated resistance to ampicillin was being 
reported in 17% of surgical patients in a London hospital (found to be carrying ampicillin 
resistant Enterococci in their faeces) (Datta 1969). Conjugation experiments using E. coli K12 
revealed that the majority of isolates could transfer resistance to other strains (Datta 1969). 
The release of third generation (extended spectrum) cephalosporins in the 1980s was soon 
followed by the selection of variants of plasmids encoding TEM and SHV enzymes able to 
hydrolyse an ‘extended spectrum’ of beta-lactam substrates including monobactams and the 
new third generation cephalosporins such as cefotaxime and ceftazidime. These ‘extended 
spectrum’ beta-lactamases (ESBLs) were spread throughout the world, particularly by 
Klebsiella spp. and E. coli (Jacoby and Medeiros 1991). Another class of ESBL is currently 
causing a significant clinical problem worldwide, the CTX-M enzymes in particular CTX-M-14 
and CTX-M-15 (Hawkey 2008).  
As yet there have been no instances where plasmid encoded beta-lactam resistance has 
been described in Campylobacter. 
1.3 Antibiotic resistance in Campylobacter jejuni  
1.3.1 Campylobacter plasmids giving antimicrobial resistance 
Transferrable antimicrobial resistance in Campylobacter was first described by Taylor in 1980 
for tetracycline resistance (Taylor, DeGrandis et al. 1980). In 1981, they further showed that 
plasmid associated tetracycline resistance could be transferred from C. jejuni to both C. 
jejuni and C. coli but not to E. coli strains K-12 and J53-1 (Taylor, Gradis et al. 1981). The gene 
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responsible for tetracycline resistance, tet(O), was identified from a conjugative plasmid 
conferring tetracycline resistance in 1988 (Manavathu, Hiratsuka et al. 1988). 
The Campylobacter tetracycline resistance gene, tet(O), can be located either 
chromosomally or on a plasmid. One report showed that 54% of clinical isolates of C. jejuni 
that carried the tet(O) gene carried it on a plasmid whereas all of the C. coli isolates carried 
tet(O) on their chromosome (Dasti, Grob et al. 2007).  
Tetracycline resistance is Campylobacter is usually, but not exclusively, associated with 
tet(O). For instance, Randall et al., demonstrated that tet(O) could not be amplified from 
24% (31/128) of tetracycline resistant isolates in their study (Randall, Ridley et al. 2003). 
Similarly Piddock et al., found eight isolates of tetracycline resistant Campylobacter from 
which tet(O) could not be amplified.  
Although tetracycline resistance is the most well characterised plasmid encoded antibiotic 
resistance in Campylobacter, transferrable resistance to several other classes of antibiotics 
has also been described. 
In 1990, Wang and Taylor described the cloning of a chloramphenicol acetyl transferase (cat) 
gene from Campylobacter coli plasmid pNR9589 originally identified in an isolate from Japan 
(Wang and Taylor 1990). A kanamycin resistance determinant 3’-aminoglycoside 
phosphotransferase (aphA-3) was also shown to be located on this plasmid downstream of 
the cat gene (Wang and Taylor 1990). Previously, Tenover and Elvrum had identified two 
distinct plasmid encoded kanamycin resistance genes (aphA-3 and aphA-7) in Campylobacter 
(Tenover and Elvrum 1988).  The streptomycin resistance gene 6’-adenyl transferase (aadE) 
has also been described as part of a gene cluster alongside aphA-3 and streptothricin acetyl 
transferase (sat) on a Campylobacter resistance plasmid (Gibreel, Skold et al. 2004). 
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It has been suggested that the resistance genes on some Campylobacter plasmids may have 
originated in Enterococcus spp.; for example the resistance gene cluster of Campylobacter 
plasmid pCJE8480 is similar to that of an Enterococcus faecalis (Taylor, Garner et al. 1983; 
Taylor and Courvalin 1988; Gibreel, Skold et al. 2004).  
Aminoglycoside–inactivating enzymes (such as aph2 and aadE) encoded on Campylobacter 
plasmids with origins from both Gram positive and Gram negative sources have been 
described elsewhere (Nirdnoy, Mason et al. 2005). 
Although there are numerous Campylobacter plasmids that contain tet(O), it is thought that 
the plasmids share some homology to one another. A well described C. jejuni strain 81-176 
contains two plasmids, pVir a 37kb non-conjugative plasmid encoding a type IV secretion 
system that may be associated with virulence (Bacon, Alm et al. 2000; Bacon, Alm et al. 
2002) and pTet a 45kb, tet(O) containing conjugative plasmid (Bacon, Alm et al. 2000). 
Sequence analysis of pTet and another smaller plasmid pCC31 also containing tet(O) 
revealed that despite both being mosaic in structure (having homologues of genes found in 
different commensal and pathogenic bacteria that inhabit the oral and intestinal tract of 
animals) and being isolated nearly 20 years apart they share a high identity (94.3%) with 
each other and also show similar gene organisation (Figure 1.6) (Batchelor, Pearson et al. 
2004).  
1.3.2 Why study beta-lactam resistance in C. jejuni? 
Erythromycin (a macrolide) and the fluoroquinolones (in particular ciprofloxacin) are the 
drugs of choice for treating campylobacteriosis, not beta-lactams (Aarestrup and Engberg 
2001; Allos 2001; BNF 2009). Nonetheless Campylobacter surveillance schemes have shown 
that ciprofloxacin resistant Campylobacter are widespread. For instance, 45% of isolates 
 
 
Figure 1.6 Genetic map of plasmids pTet and pCC31 showing differences in gene organization 
 
 
 
 
 
 
 Genes are identified by their predicted function as follows: DNA transfer functions, horizontal stripes; Campylobacter mating gene (cmg) 
homologues of T4SS, filled; repA, chequered; restriction modification, vertical stripes; tet(O), diagonal stripes; genes with unknown role, 
open. Genes that are only found in one of the two plasmids are labelled in bold (Batchelor, Pearson et al. 2004). 
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were reported as resistant from EnterNet participating laboratories in Europe between 
2005-2006 to ciprofloxacin (HPA 2006; HPA 2007). The percentage of isolates resistant to 
beta-lactams is also high. Enter-net reported that in 2007 34% of C. jejuni isolated from its 
participating European laboratories, were resistant to ampicillin (HPA 2007). The number of 
ampicillin resistant isolates of C. jejuni  isolated from poultry and clinical isolates has been 
shown to be increasing (Corcoran, Quinn et al. 2006; McGill, Cowley et al. 2006).  
Nonetheless beta-lactams could be used in the treatment of infections with Campylobacter. 
Augmentin, a combination of ampicillin and the beta-lactamase inhibitor clavulanic acid (also 
called co-amoxyclav), could be used as resistance was detected in only 0.4% of C. jejuni 
screened by Enter-Net in 2007 (HPA 2007) and  may become a viable alternative to 
erythromycin and ciprofloxacin. 
1.3.3 Beta-lactamases of C. jejuni 
Beta-lactamases are thought to be the main mechanism of beta-lactam resistance in C. jejuni 
and their production of these enzymes has been noted for over 20 years (Fliegelman, Petrak 
et al. 1985). In 1985 Lucain et al., reported in a conference abstract the presence of four 
antigenically distinct beta-lactamases that had differing pI values, molecular weights and 
activity profiles (Lucain, Goosses et al. 1985). Ninety six percent (22/23) of the isolates 
Lucain studied produced a beta-lactamase; the most prevalent was termed type A and was 
the product of over 78% (18/23) of the beta-lactamase producing isolates. Type A had a pI of 
8.3 and a distinct narrow-spectrum penicillinase profile i.e. only active against penicillin, 
ampicillin, oxacillin and carbenicillin. The type A beta-lactamase had no activity for the 
cephalosporins (cephaloridine, cefuroxime and cefotaxime), but weak activity for 
cephalothin.  
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The presence of beta-lactamases in a high proportion of C. jejuni isolates has been 
documented on several further occasions. In 1985, Fliegelman et al. detected the production 
of a beta-lactamase in 93% (25/27) of the isolates studied (Fliegelman, Petrak et al. 1985), 
Lariviere et al. reported that 89.3% (142/159) of the strains they tested were beta-lactamase 
producers (Lariviere, Gaudreau et al. 1986) and 88% (88/100) of isolates produced a beta-
lactamase in the study described by Tajada et al. in 1996 (Tajada, Gomez-Garces et al. 1996). 
Production of a beta-lactamase was also linked to amoxicillin and ampicillin resistance 
(Fleming, D'Amico et al. 1882; Maia, Rubin et al. 1983). 
In 1991, Lachance et al. partially characterised a beta-lactamase isolated from clinical 
isolates of C. jejuni from the Montreal region of Canada. Again a distinct pattern of activity 
was noted with the penicillins; ampicillin, amoxicillin, penicillin G and cloxacillin being the 
preferred substrate. As with Lucain’s type A beta-lactamase, cephalothin was weakly 
hydrolysed whilst activity against other cephalosporins and imipenem was lacking (Lachance, 
Gaudreau et al. 1991). Clavulanic acid and tazobactam were found to significantly inhibit the 
enzyme (P<0.05 Mann-Whitney U test) and one microgram per millilitre of clavulanic acid 
was shown to cause all beta-lactamase positive strains to become susceptible to both 
amoxicillin and ampicillin (susceptible when MIC 8µg/ml).  
Conflicting reports about the effectiveness of inhibitors on beta-lactamases from C. jejuni 
have been published. Some are in agreement with Lachance et al., (Fleming, D'Amico et al. 
1882; Maia, Rubin et al. 1983) whilst others are in disagreement having found no significant 
effect of inhibitors (Van der Auwera and Scorneaux 1985; Alfredson and Korolik 2005).  
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1.3.3.1 The chromosomally encoded Campylobacter oxacillinases 
A 257 amino acid Ambler class D beta-lactamase was isolated from a human clinical isolate 
of C. jejuni and was assigned the number OXA-61 by the Lahey clinic (Alfredson and Korolik 
2005; Jacoby and Bush 2010). When a non-beta-lactamase producing isolate of C. jejuni was 
transformed with the blaOXA-61 gene (and its conserved 122bp promoter region), a 32 fold 
increase in the MIC of ampicillin, piperacillin and carbenicillin was conferred. When E. coli 
HB101 was transformed with blaOXA-61 , there was a less prominent increase in MIC. 
Alfredson and Korolik hypothesised that this may be due to E. coli only weakly recognising 
the blaOXA-61  promoter (Alfredson and Korolik 2005). OXA-61 was found not to be 
significantly affected by clavulanic acid at a concentration of 2µg/ml. 
The product of the Cj0299 gene of the sequenced Campylobacter jejuni subspecies jejuni 
NCTC11168 was shown to vary from OXA-61 by only one amino acid (Griggs, Peake et al. 
2009). The cj0299 gene was found to be present in 91% of ampicillin resistant 
(MIC≥16µg/ml) poultry isolates (Griggs, Peake et al. 2009). However, unlike Alfredson and 
Korolik, Griggs et. al., found that the beta-lactamase inhibitors clavulanic acid and 
tazobactam had a significant effect on Cj0299, reducing the MIC of amoxicillin by 4-64 and 
16-32 fold respectively. 
1.3.4 A novel beta-lactamase in Campylobacter 
Following the Defra funded studies OZO501 and V02200 between 2000 and 2006 
(Humphrey, Jorgensen et al. 2005; Piddock, Griggs et al. 2008), 1288 veterinary isolates of 
Campylobacter were isolated from chicken flocks in the UK, fifty two percent of which were 
found to be resistant to ampicillin (Griggs, Peake et al. 2009). 
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Twenty six of the isolates that were ampicillin resistant (MIC≥16µg/ml), tested positive (by 
nitrocefin testing) for the presence of a beta-lactamase and did not produce an amplimer 
following PCR designed to amplify the cj0299 gene. From two of these isolates, P843 and 
P854, a novel protein with beta-lactamase activity was isolated (Griggs, Peake et al. 2009); 
this was the first report of more than one beta-lactamase being isolated from C. jejuni since 
the conference abstract of Lucain (Lucain, Goosses et al. 1985). This second beta-lactamase 
(CjBla2) was distinct from OXA-61 and Cj0299 as it had a pI of 9.21 and a molecular mass of 
32.4kDa. Analysis by QTOF-MS and FTICR-MS yielded no homology to known β-lactamases of 
Campylobacter, Helicobacter or Pseudomonas. BLAST searching revealed the closest hit in 
the Campylobacter protein database was with formyltetrahydrofolate deformylase 
(accession number CAB73055), thought to be the product of the purU gene (Cj0790). This 
protein has no predicted β-lactamase activity. 
1.3.5 Non-beta-lactamase mediated beta-lactam resistance in 
Campylobacter 
Resistance to ampicillin and other β-lactams had also been found in isolates that do not 
produce a β-lactamase suggesting that other mechanisms of beta-lactam resistance are 
employed by Campylobacter (Griggs, Peake et al. 2009). 
Intrinsic resistance to some β-lactams may in part be due to the size and charge restrictions 
that outer membrane porins impose on molecules trying to enter the cell, it had been 
suggested that this may be the case with resistance to the cephalosporins (Page, Huyer et al. 
1989). 
Alternatively beta-lactams could be substrates of efflux pumps. Two RND type multi-drug 
efflux pumps, CmeB (encoded by the cmeABC operon) and CmeF (encoded by the cmeDEF 
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operon) have been described in C. jejuni (Lin, Michel et al. 2002; Pumbwe and Piddock 2002; 
Pumbwe, Randall et al. 2004; Pumbwe, Randall et al. 2005). Inactivation of cmeB was shown 
to give a 2-fold increase in susceptibility of NCTC11168 to ampicillin (MIC reduced from 
4µg/ml to 1µg/ml), whilst over expression decreased susceptibility three fold (MIC increased 
from 4µg/ml to 32µg/ml (Pumbwe, Randall et al. 2004). It has also been shown that 
inactivation of cmeF also increases susceptibility to ampicillin, but this time a threefold 
increase in susceptibility was found (MIC reduced from 4µg/ml to 0.5µg/ml) (Pumbwe, 
Randall et al. 2005).  
1.4 Aim 
The aim of this study is to better understand the various mechanisms contributing to beta-
lactam resistance in Campylobacter with particular focus on the role of efflux and both 
genomically and plasmid encoded beta-lactamases.  
1.5 Hypotheses to be investigated during this thesis 
 A second beta-lactamase (Bla2) can confer resistance to beta-lactams in Campylobacter. 
 The purU gene codes for the novel beta-lactamase, Bla2. 
 The cj0299 gene can be present on the genome but not expressed. 
 Beta-lactam resistance can be transmissible between strains of Campylobacter. 
 Beta-lactam resistance can be conferred by the CmeABC and/or the CmeDEF efflux pump(s). 
 Presence of the CmeABC and/or the CmeDEF efflux pump(s) is required for Cj0299 mediated 
resistance to be conferred. 
 Over-expression of cj0299 can confer resistance to all beta-lactams except carbapenems. 
 Cj0299 confers resistance due to altered kinetic properties and not over-production of enzyme.  
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Chapter 2 – Materials and Methods 
2.1 Bacterial strains  
Veterinary Campylobacter isolates from Defra funded studies OZO501 (Griggs, Johnson et al. 
2005; Humphrey, Jorgensen et al. 2005) and VM2200 (Piddock, Griggs et al. 2008) were 
selected for study if they fell in to one of two categories: 
i. No amplimer was produced following PCR for the blaOXA-193  gene (C. jejuni 
NCTC11168 cj0299) and beta-lactamase activity was detectable (Table 2.1) 
ii. An amplimer was produced following PCR for the blaOXA-193 gene and no beta-
lactamase activity was detectable (Table 2.2). 
Details of blaOXA-193 PCR are given in Section 2.4.5.  Other bacterial isolates/strains used in 
this study include those required for investigations into transferrable beta-lactam resistance, 
the role of efflux in beta-lactam resistance and the identification of the novel beta-
lactamase, CjBla2 (Table 2.3). 
2.2 Growth, storage and identification of bacterial strains 
All Campylobacter strains were grown routinely on Mueller-Hinton (MH) agar (Oxoid Ltd., 
Basingstoke, UK, Catalogue No: CM0337B) supplemented with 5% defibrinated horse blood 
(TCS Bioscience Ltd., Buckingham, UK, Cat. No: HB034) with antibiotics where necessary.  On 
occasion Campylobacter agar base (Oxoid Ltd., Basingstoke, UK, Catalogue No: CM0689) with 
5% horse blood (lysed by addition to hot agar) and Preston supplement (which contains the 
antibiotics rifampicin, trimethoprim and cycloheximide to select for the growth of 
Campylobacter) (Oxoid Ltd., Basingstoke, UK, Catalogue No: SR0117) was used in place of 
MH agar to reduce the risk of contamination. Cultures were grown for 48 hours (unless  
 
 
Table 2.1 Isolates selected for study as they do not produce an amplimer following PCR of blaOXA-193 (C. jejuni NCTC11168 cj0299) but 
did produce a beta-lactamase phenotype 
 
ARG Species Defra Study Farm Rx Phase Serotype Phage type blaOXA-193 Nitrocefin Ampicillin MIC (µg/ml) 
P339 C. jejuni OZO501 Farm 1 1 week post HS8 1 - + 128 
P843 C. jejuni OZO501 Farm 4 During HS37 1 - + 32 
P852 C. jejuni OZO501 Farm 4 1 week post UT 1 - + 128 
P853 C. jejuni OZO501 Farm 4 1 week post HS2 UT - + 128 
P854 C. jejuni OZO501 Farm 4 1 week post UT UT - + 128 
P858 C. jejuni OZO501 Farm 4 1 week post HS50 1 - + 128 
P859 C. jejuni OZO501 Farm 4 1 week post UT UT - + 128 
P862 C. jejuni OZO501 Farm 4 1 week post UT UT - + 256 
P888 C. jejuni OZO501 Farm 4 2 week post HS50 1 - + 128 
P891 C. jejuni OZO501 Farm 4 2 week post UT 1 - + 128 
P1007 C. jejuni OZO501 Farm 5 Pre HS3 UT - + 128 
P1052 C. jejuni OZO501 Farm 5 During UT UT - + 128 
P1058 C. jejuni OZO501 Farm 5 During UT UT - + 128 
P1170 C. jejuni OZO501 Farm 4 2 week post HS50 UT - + 64 
P1177 C. jejuni OZO501 Farm 4 2 week post HS50 UT - + 128 
 
(Griggs, Johnson et al. 2005; Humphrey, Jorgensen et al. 2005) 
UT = un-typable  
 
3
9 
 
 
Table 2.2 Isolates selected for study as they do produce an amplimer by PCR of blaOXA-193 but do not produce a beta-lactamase 
phenotype 
 
ARG Code Species Defra Study Farm Treatment Phase Serotype Phage type blaOXA-193 Nitrocefin Ampicillin MIC (µg/ml) 
P323 C. coli OZO501 Farm 1 1 week post HS56 2 + - 8 
P324 C. coli OZO501 Farm 1 1 week post HS48 44 + - 8 
P851 C. jejuni OZO501 Farm 4 1 week post UT UT + - 8 
P1102 C. jejuni OZO501 Farm 6 During HS4 19 + - 8 
P1154 C. jejuni OZO501 Farm 6 4 week post HS42 44 + - 8 
P1197 C. jejuni OZO501 Farm 5 Pre UT 31 + - 8 
P1199 C. jejuni OZO501 Farm 5 2 week post UT 33 + - 8 
 
(Griggs, Johnson et al. 2005; Humphrey, Jorgensen et al. 2005) 
UT = un-typable  
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Table 2.3 All other isolates used in this study 
ARG 
Code 
Species Section of work Description Reference 
P270 C. jejuni Throughout study NCTC11168   
National Collection of Type 
Cultures 
P2252 C. jejuni Efflux (Chapter 3) P270cmeB::Magellan3(aph) This study 
P2253 C. jejuni Efflux (Chapter 3) P270cmeF::Magellan3(cat) This study 
P2224 C. jejuni CjBla2 (Chapter 4) P270purU::Magellan3(cat) This study 
P2247 C. jejuni CjBla2 (Chapter 4) P854purU::Magellan3(cat) This study 
I819 E. coli CjBla2 (Chapter 4) DH5α + pHSG398(P854_1490) This study 
L823 
S. enterica serovar 
Typhimurium 
CjBla2 (Chapter 4) S. enterica serovar Typhimurium SL1344 acrA::aph (Blair, La Ragione et al. 2009) 
P1131 C. coli 
Transferrable beta-lactam 
resistance (Chapter 5) 
Poultry isolate  
(Griggs, Johnson et al. 2005; 
Humphrey, Jorgensen et al. 2005) 
P1931 C. coli 
Transferrable beta-lactam 
resistance (Chapter 5) 
Poultry isolate (Piddock, Griggs et al. 2008) 
P1983 C. jejuni 
Transferrable beta-lactam 
resistance (Chapter 5) 
Kanamycin resistant flaB mutant of NCTC81116 Donated by A.Ridley 
P1984 C. jejuni 
Transferrable beta-lactam 
resistance (Chapter 5) 
NCTC81-176 
National Collection of Type 
Cultures 
P2238 C. jejuni 
Transferrable beta-lactam 
resistance (Chapter 5) 
Transconjugant (P1984 donor, P1983 recipient) This study 
P2241 C. jejuni 
Transferrable beta-lactam 
resistance (Chapter 5) 
Transconjugant (P1131 donor, P1983 recipient) This study 
P2244 C. jejuni 
Transferrable beta-lactam 
resistance (Chapter 5) 
Transconjugant (P1931 donor, P1983 recipient) This study 
  
4
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method required otherwise) in a CO2 incubator (7.5% CO2) at a temperature of 37°C.  For 
some experiments strains were cultured in a microaerophilic atmosphere created using a gas 
generating system (BD Bioscience, Oxford, UK, Catalogue No: 260628) and microaerophilic 
sachets (BD Bioscience, Oxford, UK, Catalogue No: 260680) incubated for 48 hours at 37°C. 
Liquid cultures were prepared in 5 ml of MH broth (Oxoid Ltd., Basingstoke, UK, Catalogue 
No: CM0405) in T25 FalconTM tissue culture flasks (BD Bioscience, Oxford, UK, Catalogue No: 
353108) and were cultured overnight in 7.5% CO2 at 37°C with shaking (80 rpm). 
For long term storage strains were put onto Protect TM beads (Technical Service Consultants 
Ltd., Heywood, UK, Catalogue No: TS70) and kept at -80°C. 
Microscopic examination (at X100 magnification with an oil immersion lens) was performed 
routinely for identification. Colonies were Gram stained (see below) and observed to confirm 
that the curved-spiral Gram negative rods, characteristic of Campylobacter jejuni, were 
present.   
When Gram staining, approximately five large colonies were removed from the surface of an 
agar plate with a sterile loop and emulsified onto a microscope slide with 1 ml of sterile 
distilled water and left to air dry. Once dry, the slide was passed through the flame of a 
Bunsen burner two-to-three times to fix the slide. The slide was flooded; 1. with crystal 
violet for 30 seconds to stain, 2. with Grams iodine for 30 seconds to fix, 3. with alcohol 
decolouriser (methanol and acetone mix) for ten seconds then finally, 4. counter stained 
with safranin for 30 seconds, the slide was rinsed with water between each stage. Reagents 
were purchased together in a Gram staining kit (Fisher Scientific, Loughborough, Catalogue 
No: P/L505/15). 
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2.3 Investigating the role efflux plays in beta-lactam resistance in 
Campylobacter  
2.3.1 PCR amplification of cmeB and cmeF 
PCR primers were designed to amplify the entire cmeB/F gene plus extensive flanking 
sequence, including large parts of upstream and downstream genes using the PRIMER v2.00 
program (Scientific and Educational Software, Cary, USA) (Table 2.4).  Strains to be tested 
were grown for 48 hours on MH agar + 5% horse blood, cells were then harvested and used 
to form a turbid suspension in 200 µl of sterile distilled water. The suspension was heated to 
99°C for five minutes in a heated block to form a crude boiled lysate, and then pulsed in a 
micro-centrifuge to pellet cell debris. The supernatant was used as template DNA.  
PCR reactions contained 45 µl of PCR ReddyMix (containing a Taq polymerase) (Thermo 
Scientific, Waltham, USA, Catalogue No: AB0794), 1 µl of forward primer, 1 µl of reverse 
primer (all primers used in this study were at a working concentration of 25 µM) and 1 µl of 
template DNA. A contamination control that contained primers, master mix and water (in 
place of template DNA) was included in all PCRs undertaken in this study as was a positive 
control strain (in this instance NCTC11168) and negative control strain where applicable. The 
PCR parameters varied depending upon which primers were used (Table 2.4.). 
2.3.1.1 Agarose gel electrophoresis 
PCR amplimers were viewed by agarose gel electrophoresis to check for the expected 
amplimer. Gel electrophoresis was performed using 1% (w/v) agarose gels made by 
combining electrophoresis grade agarose (Invitrogen Ltd., Paisley, UK, Catalogue No: 10975-  
 
 
Table 2.4 cmeB and cmeF primers and PCR parameters for cmeB and cmeF PCR 
Primer Target gene 5’3’ Sequence Product Size Initial denaturation 
PCR Parameters X 30 cycles 
Final extension 
Denaturation Annealing Extension 
297 cmeB AGCTGGAGCTATAGGTCT 
2921 bp 95°C (5 min) 95°C (1 min) 47°C (1 min) 72°C (4 min) 72°C (10 min) 
298 cmeB GTCTTGAAGCACTTCCTG 
291 cmeF AACCGACCTATTACCGT 
2932 bp 95°C (5 min) 95°C (1 min) 47°C (1 min) 72°C (5 min) 72°C (10 min) 
633 cmeF GTGCAGGTACTACGAGTAAG 
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035) with Tris-Boric acid-EDTA (TBE) (Invitrogen Ltd., Paisley, UK, Catalogue No: 15581-028). 
Ten times TBE stock was diluted one in ten to give a working concentration of 0.1 M Tris,  
0.09 M Boric Acid, and 0.001 M EDTA. The agarose was dissolved by heating for 90 seconds 
in 650 W microwave and allowed to cool before ethidium bromide was added to a final 
concentration of 0.1 µg/ml. Molten agarose was poured into a gel tray (to which combs were 
added to create wells) and allowed to set before being immersed in working concentration 
TBE in a gel tank.  Five microlitres of each PCR product were loaded into a well in the gel, 5 µl 
of HyperLadder 1 (BioLine, London, UK, Catalogue No: BIO-33025), ( separation range of 200-
10,000bp), was also loaded into a well so the PCR product sizes could be determined. The gel 
was electrophoresed at 120 V until the dye front was close to the bottom of the gel at which 
time the gel was removed from the gel tray and placed on the viewing platform of a Gene 
genius image analyser (Syngene, Cambridge, UK) which was used to visualise the gel. 
2.3.2 DNA sequencing of cmeB and cmeF PCR amplimers 
PCR amplimers were column purified using Qiagen’s QIAquick PCR Purification Kit (Qiagen, 
Crawley, UK, Catalogue No: 28104) and eluted in 50 µl of the supplied elution buffer. Five 
microlitres was electrophoresed on a 1% (w/v) agarose gel alongside HyperLadder I, and 
GeneTools software (Syngene, Cambridge, UK) was used to quantify the DNA. An image of 
the DNA was captured and the software was used to compare the sample DNA to a known 
standard (the HyperLadder) in order to determine the concentration of DNA in the samples. 
Sequencing was performed at the Functional Genomics department at Birmingham 
University and sequencing reactions were set up according to their protocol (Appendix A). 
The BigDye® Terminator v3.1 Cycle sequencing kit (Applied Biosystems Ltd., Foster City, USA) 
was used to perform the PCR sequencing reaction. Sequence data were compared to 
46 
 
published genome sequences using MEGA 3.1 software (Center for Evolutionary Functional 
Genomics, Tempe, USA). 
2.3.3 Natural transformation 
The method employed was adapted from Wang and Taylor (Wang and Taylor 1990).  The 
insertionally inactivated cmeB or cmeF gene was amplified from P2252 or P2253 
respectively, purified using a QIAquick kit by Qiagen, and then kept at -20°C until needed. 
The strain to be transformed was cultured on four MH agar plates for 16 hours at 37°C in an 
atmosphere of 7.5% CO2. All cells were then harvested and re-suspended in MH broth to an 
OD600 of 0.5 (≈3x10
9 cells/ml); 0.5 ml of the cell suspension was added to a T25 FalconTM 
tissue culture flask, already containing 1 ml of MH broth. The transformation mixture was 
cultured at 37°C in 7.5% CO2 with shaking (80 rpm). After three hours incubation 3 µg of 
purified PCR amplimer (cmeB::aph or cmeF::cat) was added to the mixture which was then 
left to incubate for a further five hours. A control flask was set up to which water was added 
in place of DNA. Following incubation, 100 µl of each transformation mixture was plated out 
onto MH + 5% horse blood plates containing 50 µg/ml of kanamycin or 20 µg/ml of 
chloramphenicol (Table 2.5); the plates were incubated at 37°C in 7.5% CO2 and were 
examined for colonies for up to 5 days. 
2.3.4 Determination of the minimum inhibitory concentrations (MICs) of 
antibiotics 
The agar doubling-dilution method recommended by the NCCLS Campylobacter Working 
Group (McDermott, Bodeis et al. 2004) was followed throughout this study to determine the 
minimum inhibitory concentrations (MICs) of a range of antibiotics (Table 2.5). Strains to be 
 
 
Table 2.5 Antibiotics used in this study 
 
Antibiotic Antibiotic Class Supplier Product Number Solubilised  in 
Ampicillin β-lactam, penicillin Sigma Aldrich, UK A9393 Sodium bicarbonate 
Cefotaxime β-lactam, 3
rd
 generation cephalosporin Sigma Aldrich, UK C7912 Distilled water 
Cefoxitin β-lactam, 2
nd
 generation cephalosporin Sigma Aldrich, UK C4786 Distilled water 
Cephalothin β-lactam, 1
st
 generation cephalosporin Sigma Aldrich, UK C4520 Distilled water 
Chloramphenicol - Sigma Aldrich, UK C-0378 70% Methanol 
Kanamycin Aminoglycoside Sigma Aldrich, UK K1876 Distilled water 
Meropenem β-lactam, carbapenem 
Purchased from Heartlands Hospital pharmacy 
 (distributed by AstraZeneca) 
Distilled water 
Oxacillin β-lactam, penicillin Sigma Aldrich, UK 28221 Distilled water 
Penicillin β-lactam, penicillin Sigma Aldrich, UK P7794 Distilled water 
Tetracycline Tetracycline Sigma Aldrich, UK T8032 Distilled water 
  
4
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tested were grown on MH agar + 5% horse blood plates for 48 hours in a microaerophilic 
atmosphere at 37°C. Colonies were harvested and emulsified in 5 ml of MH broth to give 
turbidity equal to a 0.5 McFarland standard (measured spectrophotometrically as an 
absorbance of 0.13 at OD600).  
Antibiotic stocks (10,000 µg/ml, 1,000 µg/ml and 100 µg/ml) were made up on the day of 
the experiment. Appropriate volumes of antibiotic stock solutions to create a doubling 
dilution series (Appendix B) were aseptically pipetted into sterile universal tubes to which 20 
ml of molten MH agar (containing 5% horse blood) was dispensed using a peristaltic pump 
dispenser (Jencons Scientific Ltd., UK). The antibiotic and agar were mixed and poured into 
sterile tri-vented Petri dishes and allowed to set. Plates were dried in a 50°C oven for 15 
minutes before being inoculated. Two plates that contained 20 ml of MH agar + 5% horse 
blood but did not contain any antibiotics were created and inoculated at the start of replica 
plating to create a ‘start plate’ and  at the finish of replicator plating to create a ‘finish plate’. 
Two hundred microlitres of each bacterial suspension was added to the wells of a multi-
point inoculator template and then replica plated with a multi-point inoculator (that 
delivered approximately 1 µl of culture) onto the test and control plates. NCTC11168 whose 
antimicrobial resistance profile is well documented was included as a control. The test plates 
and the start and finish plates were incubated for 48 hours at 37°C in an atmosphere of 7.5%  
CO2. After 48 hours test plates were compared to the start and finish plates, the MIC of an 
agent was defined as the concentration at which an approximately 90% reduction in growth 
of the organisms could be seen when compared to the start/finish plate.  
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2.4 Identification of novel Campylobacter beta-lactamases 
2.4.1 PCR amplification of purU (C. jejuni NCTC11168 cj0790) 
A C. jejuni mutant in which the purU gene had been disrupted by a Magellan3 -Himar based 
transposon containing a chloramphenicol acetyl transferase (cat) gene was obtained from Dr 
A Grant (Table 2.3) and given the laboratory code P2224.  
PCR reactions were performed using 12.5 µl of Extensor PCR master mix (containing 
ThermoPrime® Taq and a proof reading enzyme) (Thermo Scientific, Waltham, USA, 
Catalogue No: AB-0794), 2 µl of the supernatant of boiled cell lysate, 5 µl of UltraPure™ 
DEPC-Treated water (Invitrogen Ltd., Paisley, UK, Catalogue No: 750023) and 1 µl each of the 
forward and reverse primers. Primers were designed to amplify the entire cmeB/F gene plus 
extensive flanking sequence, including large parts of upstream and downstream genes. 
Cycles were modified for the use of Extensor PCR master mix (Table 2.6).  
2.4.2 DNA sequencing of the cj0790 PCR amplimer 
Performed as described previously (Section 2.3.2) but with purU primers (Table 2.6). 
2.4.3 Transformation of P854 with purU::cat 
Method performed as described previously (Section 2.3.3) using the insertionally inactivated 
purU::cat (which was amplified from P2224) (Section 2.4.1) to transform P854. 
Chloramphenicol was used to select transformants.  
 
 
Table 2.6 purU primers and PCR parameters for purU PCR 
 
Primer Target gene 5’3’ Sequence Product Size Initial denaturation 
PCR Parameters X 30 cycles 
Final extension 
Denaturation Annealing Extension 
665 purU GAAGGAATGGCTTGGACT 
1192 bp 95°C (5 min) 95°C (1 min) 47°C (1 min) 72°C (4 min) 72°C (10 min) 
666 purU CTGGATGTGCTTGTGCTG 
 
  
5
0 
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2.4.4 Detection of beta-lactamase activity 
2.4.4.1 Nitrocefin spot test  
Strains to be tested were grown on MH agar then harvested after 48 hours and added to 1 
ml of sterile water to form a turbid suspension. An MSE Soniprep 150 microprobe (Sanyo 
Biomedical, Loughborough, UK) was used to lyse the suspensions by sonicating (on ice) for a  
total of 2 minutes (4 X 30 second pulses with 3 X 30 second pauses).   When large numbers 
of samples needed to be processed simultaneously a sonicating waterbath was used in place 
of a sonicating probe to allow batch processing. In order to ensure that these different 
methods of sonicating did not affect the outcome of the assay, positive (P854) and negative 
(NCTC1168) control strains were processed using each method to ensure the outcomes were 
consistent between the two methods of sonicating (Figure 2.1). 
 Fifty microlitres of sonicate was added to a well in a 96 well microtitre tray. Ten microlitres 
of freshly made nitrocefin (500 µg/ml) (Fisher Scientific, Loughborough, UK, Catalogue No: 
SR112C) was added to the sonicate (to a final concentration of 83 µg/ml) then observed. A 
colour change from yellow to red within 5 minutes denoted a beta-lactamase positive strain 
(Figure 2.1). Isolates that had previously had their beta-lactamase profiles characterised in 
this laboratory by nitrocefin testing were used as positive (P843, P854) and negative 
(NCTC11168) controls (Griggs, Peake et al. 2009).  
2.4.4.2 Development of a quantitative nitrocefin assay  
A method was developed using a spectrophotometer in order to quantify beta-lactamase 
activity with nitrocefin. Test isolates were grown for 48 hours on MH agar as described 
previously (Section 2.2). Cells were harvested and emulsified in 1 ml distilled water to an  
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Figure 2.1Detecting beta-lactamase production by nitrocefin spot test 
 
 
1. C. jejuni NCTC11168 (sonication achieved using sonicating waterbath) + nitrocefin 
2. C. jejuni NCTC11168 (sonication achieved using microprobe) + nitrocefin 
3. C. jejuni P854 (sonication achieved using sonicating waterbath) + nitrocefin 
4. C. jejuni P854 (sonication achieved using microprobe) + nitrocefin 
 
Following the addition of 10 µl of nitrocefin (500 µg/ml) to 50 µl of sonicated bacterial cells 
(sonication achieved using either a microprobe or sonicating waterbath) a colour change 
from yellow to red can be observed if the bacteria are beta-lactamase positive.  
Shown above is the colour change seen after five minutes for C. jejuni NCTC11168, a strain 
that does not produce a beta-lactamase (nitrocefin negative) and C. jejuni P854, a strain that 
does produce a beta-lactamase (nitrocefin positive).  
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OD600 of 0.6. Cells were then sonicated as described in section 2.3.3. Two hundred and fifty 
microlitres of sonicate was added to a cuvette (Fisher Scientific, Loughborough, UK, 
Catalogue No: 14-955-125). Fifty microlitres of freshly made nitrocefin (500 µg/ml) (Fisher 
Scientific, Loughborough, UK, Catalogue No: SR112C) was added to the sonicate (to a final 
concentration of 83 µg/ml). The change in optical density at OD486 for each isolate 
(compared to a blank containing water in place of sonicate) was recorded every five minutes 
for half an hour. A positive control (P843 or P854) and negative control (NCTC11168) was 
always included and the test performed in duplicate or triplicate. 
Automation of this nitrocefin assay using a FLUOstar Optima (BMG Labtech, Aylesbury, UK) 
with a 485 nm filter was also investigated. Fifty microlitres of sonicate was added in 
triplicate to the wells in a 96 well plate (Sterilin, Aberdeen, UK, Catalogue No: 611U96) and 
then loaded in to a FLUOstar Optima which was programmed to record the absorbance at 
OD485 every five minutes for one hour. The FLUOstar was programmed to inject ten 
microlitres of working concentration nitrocefin into each well at T = 10 minutes.  
2.4.5 PCR amplification of blaOXA-193 and flanking sequences 
PCR reactions were set up as described previously (section 2.3.1) but primers and cycle 
conditions were varied (Figure 2.2 and Table 2.7). PCR primers were designed that amplified 
the entire gene plus extensive flanking sequence, including large parts of upstream and 
downstream genes; primers that bound internally were also designed. 
2.4.6 Sequencing of blaOXA-193 PCR amplimers 
Sequencing reactions were performed as described previously (Section 2.3.2) but with 
blaOXA-193 primers (Figure 2.2 and Table 2.7). 
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Figure 2.2 blaOXA-193 primers  
 
AATCAATTTAATCTTACTTGCGATTTCTATACCCCCTTCCACTTTTACCCCATTTGCGTGGCTTTCTTTGAT
AAATCTTGAGGCATTTAAGATAGCGTCACGATCTGAACTTTGATAAGACATAAAAGGCATATCAGCAAGTAC
GAAAGACTTTTTAGCTCCGCGAGAAACAGCTTTGGTAAAAATCAACATTTCATCCATAGTAACACTTAAAGT
ATCTTGCATACCAAGTACCGTCATGGCTAATGAATCTCCAACCAATATAATATCTATATCGCTATTGTCTAA
AATTCTTGCACTATGATAATCATACGCACTTACCATGGTTATTTTTTCATTTTTGGCCTTTTTTTCCAAAAA
ACTAATCATACTTTTTCTCATtttgcatacctcaatttttagctataaaataataagcaaaaaactagcata
taatttttcataaatagtaaatgaatgataaagtaagttatatttaatcgatggattgctttaatggttaca
attttagaaaatttcagttcatgttaaaggatatttaaagaaaataaagctttaaaaagtattttgtttaaa
attatttaaatagaaagatattttATGAAAAAAATAACTTTATTTTTACTTTTCTTAAATTTAGTGTTTGGG
CAAGATAAGATATTAAATAATTGGTTTAAAGAGTATAATACAAGCGGCACTTTTGTTTTTTATGATGGAAAA
ACTTGGGCGAGTAACGACTTTTCAAGGGCTATGGAGACTTTCTCTCCCGCTTCCACTTTTAAAATTTTTAAT
GCTCTAATTGCACTTGATAGTGGTGTGATAAAAACTAAAAAAGAAATTTTTTATCACTATAGAGGTGAAAAA
GTATTTTTATCTTCTTGGGCGCAAGATATGAATTTAAGTTCAGCTATAAAATATTCTAATGTTCTTGCTTTT
AAAGAAGTGGCAAGAAGAATTGGTATCAAAACTATGCAAGAATATTTAAACAAGCTTCATTATGGTAATGCT
AAAATTTCCAAGATCGATACTTTTTGGCTTGACAACTCACTAAAAATAAGCGCTAAAGAACAAGCAATTTTG
CTTTTTAGACTTTCACAAAATAGCTTACCTTTTTCTCAAGAAGCAATGAATAGTGTTAAGGAAATGATTTAT
TTAAAAAATATGGAAAATTTAGAGCTTTTTGGAAAAACAGGTTTTAATGATGAGCAAAAAATTGCTTGGATT
GTAGGTTTTGTGTATTTAAAAGATGAAAATAAATATAAGGCTTTCGCGCTAAATTTAGATATTGATAAATTT
GAAGATTTATATAAAAGAGAAAAAATTTTAGAAAAATATTTAGATGAACTTGTAAAAAAAGTTAAAAATGAT
GGCTAGtgagtatttcgtaaaatgcaaaaatacttaattgtatgatttgcgtacacttaaagtactcattaa
aaaattaaatttttgctcTTATTTATCAAGTTTTCCTACGATGATAGGGTTAAAGGCTTTTATGGATAGCAA
AAGCGTATCGCCGATTTTTACATCTTGATAAGCTTTTAGAAATTCCTCTTCACTAAGAGTGATTTTAATAAT
ATCTTGATTTAAAAGCAAGGTTAAAACCACTAAAATATCACTTTTTTTAATTTCTAGCAAAGTTGCACTTAA
GCGTAATTTTGCGCTGATATTTGAATGAGTAAAAAATTCATTTTTAGGAAAATCTTTAATAATTTTTCCGTT
TTTAAGCTCTAAAATTCTATGACTTAACTTATAAATTTCAGCTAGATCATGACTTACCAATAAAGTACTTAT
TTTAAAATACTCTAAAATCTTGGTTAATTCATCTTGTAAATTGGCACGCATTTTAAAATCCAAAGCACTCAA
AGGTTCATCTAAAAGCAAGATTTTTGGTTCTCTTGCTAAAGCTCTTGCTAAAGCTACTCTTTGTGCCTGCCC
CCCACTTAAATGTTTAGGATAAATTTTAGC     
 
Primer Number 5’3’ Sequence Co-ordinates on  NCTC11168 genome 
821 GATAGCGTCACGATCTGAAC 272811.272830 
467 ATACGCACTTACCATGG 273029.273679 
469 GAGTATAATACAAGCGGCAC 273399.273418 
470 CCAATTCTTCTTGCCACTTC 273660.273679 
468 ATCGGCGATACGCTTTT 274231. 274247 
822 GGCACAAAGAGTAGCTTTAG 274640.274659 
 
The sequence of blaOXA-193 (cj0299) Campylobacter jejuni subsp. jejuni NCTC 11168 (position 273321..274094) and 600 bp of 
sequence both upstream and downstream is shown  above. Coding sequence is shown in uppercase text whereas non-
coding intergenic regions are shown in lowercase text, genes are labeled on the right of the diagram. 
Primers used in this study are highlighted in various colours and detailed in the above table. Primer direction is indicated by 
the arrows above the primer sequence in the main diagram. blaOXA-193 start and stop codons are boxed. 
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Table 2.7 blaOXA-193 primers and PCR parameters for blaOXA-193 PCR 
 
Primer 
1 
Primer 
2 
Expected 
product 
size 
Initial 
denaturation 
PCR parameters X 30 cycles 
Final 
extension Denaturation Annealing Extension 
821 822 1849bp 95°C (5 min) 95°C (30 sec) 45°C (45 sec) 72°C (2 min) 72°C (10 min) 
467 468 1218bp 95°C (5 min) 95°C (30 sec) 45°C (45 sec) 72°C (90 sec) 72°C (10 min) 
469 470 281bp 95°C (5 min) 95°C (30 sec) 45°C (45 sec) 72°C (30 sec) 72°C (10 min) 
467 470 650bp 95°C (5 min) 95°C (30 sec) 45°C (45 sec) 72°C (45 sec) 72°C (10 min) 
469 468 849bp 95°C (5 min) 95°C (30 sec) 45°C (45 sec) 72°C (1 min) 72°C (10 min) 
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2.4.7 Southern blotting for blaOXA-193  
There was no information in the literature regarding Southern blotting for blaOXA-193 
therefore this protocol was developed. Many of the conditions were varied during 
optimisation and are detailed in this section. 
2.4.7.1 Genomic DNA extraction and quantification 
Test strains were cultured on MH agar for 48 hours. All the colonies on the plate were 
harvested and used to make a suspension in 1 ml of sterile distilled water. A Wizard  
Genomic DNA Purification Kit (Promega, Madison, USA, Catalogue No: A1120) was used and 
the manufacturer’s instructions for extracting genomic DNA from Gram negative bacteria 
were followed. Re-hydration of DNA was at 65°C for 1 hour. Five microlitres of sample was 
run on a 1% (w/v) gel alongside HyperLadder I (BioLine, London, UK, Catalogue No: BIO-
33025) and the gel was visualised using a Gene genius image analyser (Syngene, Cambridge, 
UK). DNA concentrations were determined by pipetting 1 µl of sample onto a Nano DropTM 
spectrophotometer (Thermo Scientific, Waltham, USA). 
2.4.7.2 Restriction enzyme digestion of genomic DNA 
During method development the restriction endonucleases ClaI (Promega, Madison, USA, 
Catalogue No: R6551) and HindIII (Promega, Madison, USA, Catalogue No: R6045) were 
tested at concentrations of 5 U, 10 U and 30 U/µg of DNA with digestion times of 1, 2, 3 and 
4 hours.  
Following these experiments the restriction endonuclease HindIII was used to digest 
genomic DNA. Reactions contained 2-3 µg of genomic DNA, 30 U of enzyme, bovine serum 
albumin (BSA) to a final concentration of 0.1 µg/ml and 10 x Buffer E (Promega, Madison, 
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USA, Catalogue No: R6045); sterile distilled water was used to create a final reaction volume 
of 50 µl. Reactions were incubated at 37°C for 4 hours. The enzyme was inactivated by 
heating to 65°C for 20 minutes. Negative (contamination) controls containing no restriction 
endonuclease (difference in volume made up with sterile distilled water) were included in 
each experiment. Controls and digests were loaded onto a 0.8% (w/v) agarose gel and 
electrophoresed at 60 V for 4 hours and viewed with a Gene genius image analyser 
(Syngene, Cambridge, UK) for visual confirmation of digestion.  
2.4.7.3 Transfer of DNA to blotting membrane 
DNA was transferred from the agarose gel to a HybondTM H+ membrane (GE Healthcare, 
Little Chalfont, UK, Catalogue No: RPN303B) under vacuum at 80 mbar for 2 hours using a 
VacuGene vacuum blotting system (GE Healthcare, Little Chalfont, UK, Catalogue No: 80-
1266-24). The unit was assembled by placing the gel supporting screen onto the base unit 
with the shiny side facing upwards, the support was wetted with distilled water and a piece 
of Hybond H+ membrane (2 cm larger than the gel in length and width) was placed onto the 
support screen.  A mask was placed over the support screen and membrane ensuring that 
the cut-out in the mask was over the membrane. The lid of the apparatus was added and 
clasped down and the apparatus was connected to a vacuum tap with silicone tubing. 
After the agarose gel was visualised to confirm digestion, it was placed onto the VacuGene 
Unit and was first flooded with depurination solution (0.125 M HCl) for 10-20 minutes, then 
washed with sterile distilled water. Two further 10-20 minute washes followed, one with a 
denaturing solution (0.5M NaOH 1.5M NaCl) and then a neutralising solution (1.5M NaCl, 
0.5M Tris,  1mM EDTA, pH7.2) with washes of distilled water in between. Finally, the blot 
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was flooded with 20 x SSC (3 M sodium chloride, 0.3 M sodium citrate, pH 7.0) for 1-1.5 
hours. Recipes for all solutions are listed in Appendix C. 
Following transfer the gel was visualised using the Gene Genius Image Analyser to ensure all 
DNA has been transferred. The apparatus was dismantled and the location of the gel lanes 
was marked onto the membrane with a blunt pencil so that the top side of the membrane 
could be identified. The membrane was removed with either blunt ended forceps or gloved 
hands. DNA was then fixed to the membrane by placing the membrane in a UV cross linker 
(Stratagene, California, USA) and irradiating with 12000 Joules of UV light for 45 seconds. 
2.4.7.4 Hybridisation buffer 
The agarose gel was measured to determine its area and 0.25ml of hybridisation buffer 
(containing 4%w/v blocking reagent and NaCl to a final concentration of 0.5M) was used per 
cm2 of blot.  
2.4.7.5 Generating a labelled probe for blaOXA-193  
A 281 bp fragment of blaOXA-193 was amplified by PCR from NCTC11168 (primers 467 and 468, 
Table 2.7) and labelled to use as a Southern blotting probe. The ‘Gene Images AlkPhos Direct 
Labelling and Detection System’ (GE Healthcare, Little Chalfont, UK, Catalogue No: RPN3690) 
was used to create an alkaline phosphatase labelled probe. For every millilitre of 
hybridisation buffer 5-10 ng of DNA was used to create labelled probe. Twenty microlitres of 
cross-linker solution (supplied with kit) was diluted with 80 µl of sterile water to give the 
working concentration. Probe DNA was diluted with sterile water to a concentration of 5-10 
ng/ml. Ten microlitres of diluted DNA was denatured by heating for 10 minutes in a boiling 
water bath following which the DNA was immediately placed on ice for five minutes. Ten 
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microlitres of reaction buffer (supplied with kit) was added to the cooled DNA and mixed by 
gentle pipetting followed by 2 µl of labelling reagent (supplied with kit) which was mixed by 
gentle pipetting. Finally, 10µl of cross linker working solution was added to the DNA, mixed 
thoroughly by pipetting then the reaction was heated to 37°C for 30 minutes. Probe DNA 
was kept on ice and always used within 2 hours.  
2.4.7.6 Hybridisation 
The blot was pre-hybridised with the hybridisation buffer in a hybridisation oven at 50-65°C 
before probe labelled with alkaline phosphatase was added to a concentration of 5-10 ng/µl 
of hybridisation buffer. The probe was left to hybridise to the blot for 28-36 hours at 50-60°C 
in a rotisserie hybridisation oven. 
Following hybridisation the blot was washed with both primary and secondary wash buffers. 
The first wash was for 10 minutes with 5ml/cm2 of primary wash buffer (pre-heated to 55°C) 
with gentle agitation, this was repeated with fresh primary wash buffer for a further 10 
minutes. The next wash was with sufficient secondary wash buffer (Appendix C) to cover the 
blot, for 5 minutes, at room temperature, again with gentle agitation. This wash was also 
repeated with fresh secondary wash buffer under the same conditions.  
2.4.7.7 Signal detection 
After being placed on Saran WrapTM (SC Johnson, Racine, USA) 40 µl/cm2 of detection 
reagent (GE Healthcare, Little Chalfont, UK) was pipetted onto the blot and left for five 
minutes. The blot was then covered in a clean piece of saran wrap and placed DNA side up in 
a light proof film cassette. A sheet of HyperfilmTM (GE Healthcare, Little Chalfont, UK, 
Catalogue No: 28-9068-37) was placed over the blot in a dark room and the film was locked 
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into the cassette and left to develop for 45 minutes initially and repeated with a longer time 
if necessary. Film was developed in a darkroom with Kodak GBX Developer and Fixer (Sigma, 
Gillingham, UK, Catalogue No: P7402-1GA and P7167-1GA). The film was removed from the 
cassette in the darkroom and placed in a tray of photographic developer; the tray was 
agitated for 90 seconds then the film was removed and rinsed with water. The film was then 
placed in a tray of photographic fixer and agitated for 30 seconds then removed and rinsed. 
The film was then viewed by eye and photographed. 
2.4.8 flaA SVR (short variable region) typing 
2.4.8.1 PCR amplification of flaA 
PCR reactions were set up as described previously (section 2.3.1) but primers and cycle 
conditions were varied (Table 2.8). 
2.4.9 Sequencing of flaA 
Sequencing reactions were performed as described previously (Section 2.3.2) but with flaA 
primers (Table 2.8). 
2.4.9.1 Determination of flaA type 
Sequencing data was aligned to representative flaA SVR types downloaded from the 
Campylobacter online flaA database (http://pubmlst.org/campylobacter/) using MEGA 3.1 
software (Center for Evolutionary Functional Genomics, Tempe, USA). Once identified the 
flaA region of each test isolate was queried against the Campylobacter online flaA database 
to determine its flaA SVR sequence type. 
  
 
 
Table 2.8 flaA primers and PCR parameters for flaA PCR 
 
Primer 
Target 
gene 
5’3’ Sequence 
Product 
Size 
Initial 
denaturation 
PCR Parameters X 30 cycles Final 
extension Denaturation Annealing Extension 
985 flaA GGATTTCGTATTAACACAAATGGTGC 
1713 bp 95°C (5 min) 95°C (30 sec) 45°C (45 sec) 72°C (1 min 45 sec) 72°C (5 min) 
986 flaA CTGTAGTAATCTTAAAACATTTTG 
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2.4.10 Whole genome DNA sequencing and analysis of C. jejuni P854 
2.4.10.1 Isolation of genomic DNA 
P854 genomic DNA was isolated and quantified as described previously (Section 2.4.7.1). 
2.4.10.2 SOLEXA sequencing of P854 genomic DNA 
Genomic DNA was sent for Illumina - SOLEXA Sequencing at the School of Biological Sciences 
Sequencing Service, University of Edinburgh. 
2.4.10.3 Assembly and annotation of SOLEXA sequencing reads 
Sequencing data was uploaded to ‘my xBASE’ (http://ng.xbase.ac.uk/my/) and was 
assembled into 621 contigs comprising of 83 scaffolds using the SOAP de novo program 
(http://soap.genomics.org.cn/soapdenovo.html) with assistance from Dr Nick Loman.  
Several randomly selected segments of P854 nucleotide sequence (selected by Nick Loman) 
were used to interrogate sequenced Campylobacter genomes using the Basic Local 
Alignment Search Tool, BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi), and these searches 
revealed Campylobacter jejuni RM1221 to be the most similar to P854. The P854 assembled 
contigs were then run through the xBASE annotation pipeline using C. jejuni RM1221 as a 
reference genome. 
2.4.10.4 Identification of putative beta-lactamase genes 
The Artemis Comparison Tool, ACT, (http://www.sanger.ac.uk/resources/software/artemis/) 
was used to view the annotated P854 genome and compare it to the C. jejuni RM1221 
genome. The P854 genome was then queried for genes that had been annotated as putative 
beta-lactamase genes. The DNA and amino acid sequences of any putative beta-lactamase 
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genes identified were queried against known beta-lactamase genes/proteins in GenBank 
using BLAST. The product of the P854_1490 gene was identified as a putative novel 
oxacillinase, the sequence of this protein was submitted to the Lahey clinic 
(http://www.lahey.org/studies/)  who confirmed it to be a novel and assigned it the unique 
oxacillinase number, OXA-184. From here on the gene P854_1490 is described as blaOXA-184 
and the product of this gene is described as OXA-184.  
2.4.11 Screening isolates for the presence of blaOXA-184 
2.4.11.1  PCR amplification of blaOXA-184  
PCR reactions were set up as described previously (Section 2.3.1) but primers and cycle 
conditions were varied (Figure 2.3 and Table 2.9). Primers that bound within the genes up 
and downstream of the target gene (to amplify the whole blaOXA-184) and that bound within 
the target gene itself were designed. 
2.4.11.2 Sequencing of blaOXA-184 PCR amplimers 
Sequencing reactions were performed as described previously (Section 2.3.2) but with 
blaOXA-184 primers (Table 2.9). 
2.4.11.3 Analysis of blaOXA-184 screening results 
Sequence data were compared to blaOXA-184 using MEGA 3.1 software (Center for 
Evolutionary Functional Genomics, Tempe, USA). Six isolates contained an oxacillinase gene 
which produced a protein with one amino acid difference to OXA-184. The sequence of this 
protein was submitted to the Lahey clinic (http://www.lahey.org/studies/) who confirmed it 
to be a novel and assigned it the unique oxacillinase number, OXA-185. From here on any 
genes encoding the OXA-185 protein are described as blaOXA-185. 
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Figure 2.3 blaOXA-184 primers  
TTGATAAGAAAGCTTGATATAAAAGATTTAGCTTCTTGTATCAAGCTTTGTAAGCAAAACGTATTCACTC
TTTGTAAAAATGATTACACAAAAGAACAAATTCATGCTTGGATTAATATAAACCAAAAAACTTGAgaaga
aaaatttcaaaatcaactaggctttgtttatgaagaaaaaggccaaatcatatattttataagtataaat
attagaagaaaaaacactcgatctttgctttattcatgcaaactatgctcatcaaggtttattaaagctt
taattgttataatagaccaataagaattaaaaaatttcttcatgaaaaaggaaataaaTTGAAAAAAATA
CTTTTACTTTTTAGTCTTTTTTACTCTTTTGCTTTGGCAAATGATAAATTAAAAGATTTTTTTAAAGACT
ACAATACAAGCGGAGTTTTTATAACTTTTGATGGAAAACATTATGCAAGTAATAATTTTAAAAGAGCTAA
AGAACCTTTTTCTCCTGCTTCGACTTTTAAAATTTTTAATGCTTTAATTGCGCTTGATAATGGTGTAGTT
AAAGATACAAAGGAAATTTTTTATCATTATAAGGGTGAAAAAGTATTTTTGCCCTCTTGGAAACAAGATG
CTAGTTTAAGCTCAGCCATAAAACGCTCTCAAGTGCCTGCTTTTAAAGAATTGGCAAGAAAAATAGGACT
TAAAACCATGCAAGAAAGCTTAAATAAACTTTCCTATGGAAATACAAAAATTTCAAAAATCGATACCTTT
TGGTTGGATAATTCTTTACAAATTTCTGCAAAAAATCAAGCTGATTTGCTTTTTAAACTTTCACAAAATT
CTTTACCTTTTTCCAAGAAAAGTCAAGAAGAAGTTAAAAAAATTATTCTTTTTAAAGAAGATAAAATCCA
AAAAATTTATGCTAAAACAGGTTTTAATGATGGTATAAATTTGGCTTGGATTGTTGGATTTATAGAGAGT
AAAAACAAAATTTTATCTTTTGCCTTAAATGTTGATATAAAGAACATTAAAAATCTTAAAATAAGAGAAG
AATTGCTAGAAAAATATATTTATTCTTTAAACTAAttaagcttttataagaaattgtttaatgatcaaaa
tatcgcaatataatagtttttaagaaaaatagatataaaatactgattatattaaatttatttaagagaa
atgttagatgtccatggtaacttatgctttttagcacttgccttggttttgttgtcttttaataaaatta
aaacagcttatttattttttataattagtgtattttttgcttattattttaagataattaatatcacttt
tatagtaattaatattattgcatttgggTTGGCTTTATATTATAGATATAAAAAATCACTTATTTTAGAA
TTGATATTGTTTGTTTTTTGTATAGGCTTATTTTTACATTTTATACCAGGAATTAATAATATAAAAGTTT
TAGATAAGGTTTATGCAAGTGAAAATAGTGCACCATTTACTTTATACTTTAATTTTGATAAACCTATAGG
TGTATTTATATTGTTTTTATTGTTACCTGCTTTATTTACAAATAAAAATTATGTAAAAGCTTCATTACTC
AAATGGATTTTATTAATTTTAAGTCCTTTATTTTTATTATCTATACCTTGGTATTTTAATGTTTTGAAAT
TTGAATTTAGCTTACCTTGGTGGTTACCCTATTTTTTATTTTCTAATGTTTTATTGGTAGCTTTGGTTGA
AGAAGTGTATTTTAGAGGTTATCTTCAACAAAGACTCTCTCAAATTTTAAATCCAAATTTTGCTTTATTG
ATAGCAAGTATAGCTTTTGGATTGATTCATTATAGAAGTGGAATTTTAATGATTATTTTTGCGAGTTTAG
CTGGAATTATATATGGATTAGCATATAAATATAACAAAAGTTTATGGATAAGTGTATTATTTCATTGTGG
ATTAAATTTAATTCATTTGATATTTTTTACTTATCCTTTTTATTTAAAATCATAA 
 
Primer Number 5’3’ Sequence Product 
1008 AAGAACCTTTTTCTCCTGCTTCGACTT 
183bp 
1009 AAGCAGGCACTTGAGAGCGTTT 
1010 TCAAGCTTTGTAAGCAAAACG 
1670bp 
1010 AGGGTAACCACCAAGGTAAGC 
The sequence of blaOXA-184 Campylobacter jejuni P854 sequence both upstream and downstream is shown above. Coding 
sequence is shown in uppercase text where as non-coding intergenic regions are shown in lowercase text, genes are labeled 
on the right of the diagram. Primers used in this study are highlighted in various colours and detailed in the above table. 
Primer direction is indicated by the arrows above the primer sequence in the main diagram. blaOXA-184 start and stop codons 
are boxed. 
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Table 2.9 blaOXA-184 primers and PCR parameters for blaOXA-184 PCR 
 
Primer 
1 
Primer 
2 
Expected 
product 
size 
Initial 
denaturation 
PCR parameters X 30 cycles 
Final 
extension Denaturation Annealing Extension 
1008 1009 183 bp 95°C (5 min) 95°C (30 sec) 50°C (30 sec) 72°C (20 sec) 72°C (10 min) 
1010 1011 1670 bp 94°C (2 min) 94°C (10 sec) 42°C (30 sec) 68°C (1 min) 68°C (7 min) 
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2.4.12 Cloning blaOXA-184 into E. coli (α-Select) 
2.4.12.1 Cloning strategy (including selection of a suitable cloning vector) 
A vector required for cloning that was suitable for expression in E. coli, had a multiple 
cloning site and a selective marker other than ampicillin resistance. The pHSG398 plasmid 
(Takara Biosciences, Product number 3398), which is a pUC18 based vector with a 
chloramphenicol resistance marker was selected for use as it met all requirements (Figure 
2.4). The intention was to clone the coding sequence of blaOXA-184 only (i.e. no Campylobacter 
expression signals) into the multiple cloning site of the plasmid, allowing the gene to be 
controlled by the lacZ promoter and ribosome binding site. 
2.4.12.2 Creation of a blaOXA-184 PCR amplimer suitable for cloning 
PCR primers were designed to amplify the blaOXA-184 gene (excluding expression signals) and 
to introduce an EcoRI restriction site at the start of the amplimer and an XbaI restriction site 
to the end of the amplimer (Table 2.10). The PCR reactions were set up as described 
previously (Section 2.3.1) but primers and cycle conditions were varied (Table 2.10). 
2.4.12.3 Cloning into vector pHSG398 
The blaOXA-184 PCR amplimer with EcoRI/XbaI ends (Table 2.10) and pHSG398 DNA were both 
digested with EcoRI high fidelity restriction enzyme (New England Biolabs, Product number 
R3101S) and XbaI restriction enzyme (New England Biolabs, Product number R0145S) (Table 
2.11). Digests and controls (lacking any restriction enzymes) were incubated at 37°C for 1 
hour then heat inactivated at 65°C for 20 minutes. 
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2.4.12.4 Transformation of E. coli with pHSG398 (blaOXA-184) 
One 200 µl aliquot of BioLine bronze efficiency α-Select competent cells (Product number 
BIO-85025) was thawed on ice then split into four 50 µl aliquots in pre-chilled eppendorfs. 
Two microlitres of pHSG398(blaOXA-184) was added to the first two eppendorfs containing α- 
Figure 2.4 The pHSG398 cloning vector 
 
 
 
 
 
Image modified from product information sheet (Takara Biosciences). 
 
  
 
 
Table 2.10 blaOXA-184 cloning primers and PCR parameters for blaOXA-184 cloning PCR 
 
Primer 
Target 
gene 
5’3’ Sequence 
Product 
Size 
Initial 
denaturation 
PCR Parameters X 20 cycles 
Final extension 
Denaturation Annealing Extension 
1012 blaOXA-184  GCGGAATTCTTGAAAAAAATACTTTTACT 
879 bp 94°C (2 min) 94°C (10 sec) 45°C (30 sec) 68°C (1 min) 68°C (7 min) 
1014 blaOXA-184  GCGTCTAGAATCTAACATTTCTCTTAAAT 
 
TTG = Start codon 
GAATTC = EcoRI restriction site 
TCTAGA = XbaI restriction site  
6
8 
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Table 2.11 Restriction enzyme digestion of blaOXA-184 cloning PCR amplimer and pHSG398 
 
Digestion of the blaOXA-184 (EcoRI/XbaI) PCR amplimer 
 Digestion Control reaction 
DNA 30 µl 15 µl 
NEBuffer 4* 5 µl 2.5 µl 
EcoRI-HF restriction enzyme** 5 µl 0 µl 
XbaI restriction enzyme*** 5 µl 0 µl 
Bovine serum albumin** 1 µl 0.7 µl 
Water 4 µl 7 µl 
TOTAL 50 µl 25 µl 
Digestion of pHSG398 DNA 
 Digestion Control reaction 
DNA 2 µl 1 µl 
NEBuffer 4* 2 µl 1 µl 
EcoRI-HF restriction enzyme** 5 µl 0 µl 
XbaI restriction enzyme*** 5 µl 0 µl 
Bovine serum albumin**** 1 µl 0.5 µl 
Water 5 µl 7.5 µl 
TOTAL 20 µl 10 µl 
 
* NEBuffer 4 (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM Magnesium acetate, 1 
mM DTT, pH 7.9 at 25°C) 
**20,000 U/ml 
***20,000 U/ml 
****BSA (200 µg/ml) 
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Select cells, 2µl of pHSG398 was added to the third tube and 2µl of water to the fourth and 
final tube. Reactions were incubated on ice for 30 minutes. Cells were then heat-shocked by 
heating the eppendorfs to 42°C for 30 seconds then returning to incubation on ice for a 
further two minutes. Reactions were diluted with 950µl of SOC (Appendix D), transferred to 
a Universal tube and incubated at 37°C with shaking for one hour. Seventy five microlitres of 
each of the reactions was transferred to the surface of eight LB (Luria-Bertani) (Oxoid, UK, 
Product No: CM1021) agar plates containing 0.5 mM IPTG (Isopropyl β-D-1-
thiogalactopyranoside), 80 µg/ml X-gal (5-bromo-4- chloro-3-indolyl- beta-D-
galactopyranoside) and 35 µg/ml chloramphenicol. Plates were incubated overnight at 37°C 
then examined for the presence of transformants (white colonies). Candidate colonies were 
streaked onto fresh LB plates (containing the same concentrations of IPTG, X-gal and 
chloramphenicol). Putative mutants were stored at -80°C on ProtectTM beads (Service 
Consultants Ltd., Heywood, UK, Catalogue No: TS70).   
2.4.13 Characterisation of α-Select pHSG298 (blaOXA-184) mutants 
2.4.13.1 PCR amplification of blaOXA-184  
All putative α-Select pHSG298 (blaOXA-184) mutants were screened for the presence of blaOXA-
184 using the PCR described previously (Section 2.4.12.2). 
2.4.13.2 Sequencing of blaOXA-184 PCR amplimers  
Sequencing reactions were performed as described previously (Section 2.3.2) but with 
blaOXA-184 primers (Table 2.9). 
2.4.13.3 Detection of beta-lactamase activity  
Beta-lactamase production was determined as described previously (Section 2.4.4). 
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2.4.13.4 Determination of the MICs of antibiotics  
MICs of antibiotics were determined as previously described (Section 2.3.4) with the 
addition of 0.5 mM IPTG to each agar plate. 
2.4.13.5 RNA isolation  
RNA was isolated from three technical replicates of each isolate, on three separate 
occasions. Single colonies of isolates to be tested were inoculated into 10 ml LB broths which 
incubated at 37°C, overnight with shaking. One millilitre of each overnight culture was 
inoculated into 24 ml of fresh LB broth and incubated at 37°C with shaking until mid-
logarithmic phase was achieved (OD600 of 0.6). Five millilitres of each culture was added to 1 
ml of a 95% ethanol, 5% phenol mixture and incubated on ice for 30 minutes. Samples were 
centrifuged at 2250 x g at 4°C for 10 minutes and the supernatants were discarded. Pellets 
were re-suspended in 100 µl of TE buffer containing 50 µg/ml lysozyme and incubated for 5 
minutes at room temperature. The Promega SV Total RNA purification kit (Promega, UK, 
Catalogue No: Z3100) was then used, according to manufacturer’s instructions. Isolated RNA 
was viewed by gel electrophoresis as described previously (Section 2.3.1.1). RNA 
concentrations were determined by pipetting 1 µl of sample onto a Nano DropTM 
spectrophotometer (Thermo Scientific, Waltham, USA). 
2.4.13.6 cDNA synthesis 
Superscript III Reverse transcriptase (Invitrogen, UK) was used to synthesise cDNA. First 
strand DNA synthesis was achieved as follows; 1µg of RNA was combined with 1µl of 50 
ng/µl random length primers, 1 µl dNTP mix and was made up to 10 µl with RNase free 
sterile water in microcentrifuge tubes. The reaction was incubated at 65°C for five minutes 
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followed by one minute of incubation on ice. Ten microlitres of the first strand synthesis mix 
was combined with 2 µl of first strand buffer, 4 µl of 25mM MgCl2, 2 µl 0.1M STT, 1 µl 40 
U/µl RNase Out and 1 µl of 100 U/µl Superscript III Reverse Transcriptase. The reaction was 
incubated at 25°C for 10 minutes then at 50°C for 50 minutes. The reaction was terminated 
by an inactivation step of heating to 85°C for 5 minutes. 
2.4.13.7 RT-PCR 
PCRs for blaOXA-184 and 16S were performed using cDNA as a template. PCR amplification of 
blaOXA-184 has been described previously (Section 2.4.11.1). PCR amplification of 16S was 
performed as described previously (Section 2.3.1) but primers and cycle conditions were 
varied (Table 2.12). 
2.4.14 Inactivation of blaOXA-184 in C. jejuni P854 
2.4.14.1 Using PCR to create blaOXA-184::aph 
An inactivation strategy was devised based on part of the Datsenko and Wanner method of 
gene inactivation (Datsenko and Wanner 2000) but employing the natural competency of 
Campylobacter (Figure 2.5). In the Dasenko and Wanner method an antibiotic resistance 
genes flanked by an FRT (FLP recognition target) is amplified with primers that have 5’ 
homology (30-50 nucleotides) to genes adjacent to the target; this PCR amplimer is used in 
transformation with a λ Red recombinase to inactivate the target gene. The resistance 
cassette can then be removed using a FLP expression plasmid (Datsenko and Wanner 2000).  
PCR amplification of aph was performed as described previously (Section 2.3.1) but primers 
and cycle conditions were varied (Table 2.13). The Salmonella strain L823 (acrA::aph) (Table 
2.3) was used as a source of template DNA. 
 
 
Table 2.12 16S primers and PCR parameters for 16S PCR 
 
Primer 
Target 
gene 
5’3’ Sequence 
Product 
Size 
Initial 
denaturation 
PCR Parameters X 30 cycles Final 
extension Denaturation Annealing Extension 
147 16s GGTGCAAGCGTTAATCGGAA 
541 bp 95°C (5 min) 95°C (30 sec) 50°C (30 sec) 72°C (20 sec) 72°C (10 min) 
148 16s TCGTCAGCTCGTGTTGTGAA 
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Figure 2.5 Strategy for inactivation of blaOXA-184 
 
 
 
 
A modified Datsenko and Wanner method employing natural transformation (Datsenko and 
Wanner 2000). 
 
 
 
Table 2.13 aph+ blaOXA-184 cloning primers and PCR parameters for aph+ blaOXA-184 cloning PCR 
 
Primer Target gene 5’3’ Sequence Product Size 
Initial 
denaturation 
PCR Parameters X 30 cycles 
Final extension 
Denaturation Annealing Extension 
1051 
aph + 40bp of 
blaOXA-184  
ATACTTTTACTTTTTAGTCTTT
TTTACTCTTTTGCTTTGGGTGT
AGGCTGGAGCTGCTTC 
1574 bp 95°C (5 min) 95°C (30 sec) 45°C (30 sec) 72°C (1 min 45 sec) 72°C (10 min) 
1052 
aph + 40bp of 
blaOXA-184 
ATGGACCATGGCTAATTCCCG
CTTGGATTGTTGGATTTATAG
AGAGTAAAAACAAAATTT 
 
GAATTC = homology to blaOXA-184 
TCTAGA = homology to aph 
  
7
5 
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2.4.14.2 Natural transformation of P854 with blaOXA-184::aph 
Natural transformation of P854 was performed as described previously (Section 2.3.3) using 
the blaOXA-184::aph amplimer produced above to inactivate the blaOXA-184 gene. Transformants 
were selected on MH agar plates containing 50 µg/ml of kanamycin. 
2.5 Conjugal transfer of beta-lactam resistance in Campylobacter 
2.5.1 Conjugation 
Conjugation reactions were set up between previously characterised tetracycline resistant, 
kanamycin sensitive donor strains P1131, P1931, and P1984 (conjugation positive control) 
and a tetracycline sensitive, kanamycin resistant recipient strain P1983 (Table2.3) to 
determine whether beta-lactam resistance could be transferred conjugatively alongside 
tetracycline resistance. The method that was followed is based on a published method 
(Taylor, Gradis et al. 1981).  
Donor and recipient strains were cultured as described previously on MH agar for 48 hours. 
Two methods of conjugation were followed, one in liquid and the other on agar. 
2.5.1.1 Liquid conjugation 
Bacterial cells were harvested and a suspension was made in MH broth to an OD600 of 0.1. 
Five hundred microlitres of the donor solution was mixed with 1 ml of the recipient solution 
and added to a T25 FalconTM tissue culture flask already containing 1 ml of fresh MH broth. 
After overnight incubation at 37°C in 7.5% CO2 cultures were serially diluted and 100 µl of 
the un-diluted, 10-1, 10-2 and 10-3 dilutions were plated out onto MH agar containing 10 
µg/ml of tetracycline and 50 µg/ml of kanamycin, and incubated for up to 5 days at 37°C in 
7.5% CO2.  
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2.5.1.2 Agar conjugation 
Bacterial cells were harvested and a suspension was made in phosphate buffer (Sigma, 
Gillingham, UK, Catalogue No: D8537) to an OD600 of 0.1. One hundred and fifty microlitres 
of the donor solution was mixed with 150 µl of the recipient solution. The mating mixture 
was spread onto MH agar and cultured overnight at 37°C in CO2. After overnight incubation 
the bacterial cells were harvested from the surface of the agar plate by flooding with 2 ml of 
phosphate buffer. The suspension was serially diluted and 100 µl each of the un-diluted, 10-
1, 10-2 and 10-3 dilutions were plated out onto MH agar containing 10 µg/ml of tetracycline 
and 50 µg/ml of kanamycin, and incubated for up to 5 days at 37°C in CO2.  
2.5.2 Plasmid Isolation 
Various protocols were used so as to isolate a good quantity of high quality plasmids. 
2.5.2.1 Mini-preparations  
Qiagen’s QIAprep Miniprep kit (Qiagen, Crawley, UK, Product No: 27104) and Promega’s 
PureYield™ Plasmid Miniprep System (Promega, Southampton, UK, Product Number: A1221) 
were tested, in both instances the manufacturer’s instructions were followed including 
modifications for large, low copy number plasmids.  
2.5.2.2 Other (non-kit based) plasmid preparations 
A modified Kado and Liu alkaline lysis  (Kado and Liu 1981)  method was carried out. 
Bacterial cultures were grown on MH agar for 48 hours in a CO2 incubator (7.5% CO2) at a 
temperature of 42°C.  Cultures were Gram stained for purity before a loop-full of cells was 
used to inoculate 10 ml of MH broth. Cultures of P2241 and P2244 also contained 40 µg/ml 
of ampicillin. Broth cultures were incubated overnight at 37°C in 7.5% CO2 with shaking. The 
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following morning 1.5 ml aliquots were centrifuged at 12,000 x g (in a Mistral centrifuge) for 
three minutes and the pellet re-suspended in 150 µl of suspension buffer (40 mM Tris, 2 mM 
Sodium EDTA pH7.9) followed by 300 µl of lysis buffer (100 mM SDS, 50 mM Tris pH 12.6). 
Tubes were mixed by gentle inversion until the suspension became clear. Following 
incubation at 60°C in a water bath for one hour 600 µl of phenol chloroform (Sigma, 
Gillingham, UK, Product No: P3803) was added; the tubes were then gently inverted and 
then kept on ice for 20 minutes.  The upper phase from each tube were removed gently with 
a pipette (being careful not to disturb the interface) and 600 µl aliquots were transferred to 
clean microcentrifuge tubes. Twenty microlitres of 3 M potassium acetate was added to 
each 600 µl aliquot followed by 450 µl of 100% ethanol, the mixture was then left at -20°C 
overnight. Following overnight incubation tubes were centrifuged at 12,100 x g in a 
microcentrifuge for five minutes. The supernatant was discarded and the precipitate washed 
three times in 70% ethanol in water. The pellet was left to air dry for two hours then was re-
suspended in 50 µl of water. 
Another protocol, the Birnboim and Doly maxi-preparation method with modifications by 
Smith and Thomas (Birnboim and Doly 1979; Smith and Thomas 1983), was also followed. 
Bacterial cultures were grown on MH agar for 48 hours in a CO2 incubator (7.5% CO2) at a 
temperature of 37°C.  Cultures were Gram stained for purity before a loop-full of cells was 
used to inoculate 400 ml of MH broth. Cultures of P2241 and P2244 also contained 40 µg/ml 
of ampicillin.  
Cultures were incubated overnight at 37°C in 7.5% CO2 with shaking (80 rpm). Bacterial cells 
were pelleted by centrifugation at 2,250 x g for 15 minutes (in a Mistral centrifuge), pellets 
were then re-suspended in 25 ml of ice cold Lysis Solution 1 (25 mM Tris-pH 8.5, 10 mM 
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EDTA-pH 8, 50 mM glucose). Fifty microlitres of Lysis Solution 2 (0.2 M NaOH, 1% SDS) was 
then added and the tube inverted several times to ensure complete lysis. Following 
incubation on ice for five minutes 37.5 ml of neutralising solution 3 (3 M Sodium acetate-pH 
5) was added and the contents mixed by carefully inverting. Preparations were centrifuged 
for 15 minutes at 2,250xg (in a Mistral centrifuge) at 4°C to pellet cell debris. The 
supernatant was filtered using filter paper and a funnel to remove any remaining debris. 
Plasmid DNA was precipitated by adding 100 ml of isopropanol and pelleted by 
centrifugation at 2,250 x g for minutes at room temperature. The supernatant was discarded 
and the pellet re-suspended in 3 ml of TNE buffer (100 mM Tris-pH 8, 50 mM NaCl, 5 mM 
EDTA-pH 8). 
2.5.2.3 Caesium chloride density gradient centrifugation 
The 3 ml plasmid preparation from the modified Birnboim and Doly maxi-preparation was 
purified by density gradient centrifugation. First, 4.72 g of caesium chloride (CsCl) was 
accurately weighed out into a glass tube and the 3 ml of plasmid preparation was added. The 
volume was made up to 4.5 ml with TNE buffer (100 mM Tris-pH 8, 50 mM NaCl, 5 mM 
EDTA) and the solution was gently inverted until all the CsCl dissolved. Five hundred 
microlitres of 10 mg/ml ethidium bromide (EtBr) was then added. The sample was split 
equally between two Beckman 3.5 ml centrifugation tubes (Beckman Coulter, High 
Wycombe, Product No. 349621) using a Pasteur pipette, the tubes were weighed to ensure 
they were within 0.1 g of each other then the tubes were topped-up to the bottom of the 
neck of the tube with TNE. Tubes were then heat sealed with a QuickSeal® tube topper 
(Beckman Coulter, High Wycombe, UK, Product No: 360976) and centrifuged overnight at 
801,920 x g in an ultra centrifuge (Beckman Coulter, Hugh Wycombe, Product No. TL-100) at 
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20°C using a Type 100 Ti rotor (Beckman Coulter, High Wycombe, Product No: 363013) with 
spacer (Beckman Coulter, High Wycombe, UK, Product No: 360270). Following centrifugation 
sealed caps were removed with scissors to prevent tubes collapsing when liquid was 
removed with a needle. Tubes were then visualised under UV light and fluorescent DNA 
bands were extracted and transferred to a clean tube with a needle and syringe.  
Isopropanol saturated with CsCl/H20 was added to the extracted plasmid with a Pasteur 
pipette and was gently agitated until the bottom layer became clear and the top layer pink-
red.  The isopropanol and EtBr (top layer) was removed with a pipette and discarded. This 
process was repeated three times to ensure all EtBr was removed from the plasmid DNA. 
Four hundred microlitre aliquots were transferred to microcentrifuge tubes; 500 µl of 
nuclease free water and 100 µl of 3M sodium acetate were added to each tube, followed by 
530 µl of isopropanol. Tubes were centrifuged in a microcentrifuge for 45 minutes at 12,100 
x g. The supernatant was gently removed and the pellet re-suspended in 200 µl of TNE. 
Twenty five microlitres of 3 M sodium acetate and 500 µl of 70% ethanol were added before 
centrifuging for 10 minutes in a microcentrifuge at 12,100 x g to pellet DNA. Supernatant 
was gently removed and the pellet washed with 70% ethanol. The pellet was air-dried for 
one hour then re-hydrated in 50 µl of TNE. Five microlitres of each plasmid preparation and 
5 µl of HyperLadder 1 were electrophoresed on a 0.8% (w/v) agarose gel at 70 V for four 
hours. 
2.5.2.4 Maxi Preparations 
The QIAGEN Large Construct Kit (Qiagen, Crawley, UK, Product No:12462) was tested and 
the manufacturer’s instructions were followed. A Beckman JA25.50 rotor (Beckman Coulter, 
London, UK, Catalogue No: 363058) was used for centrifugation of volumes of 50-250 ml and 
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a JLA16.250 rotor (Beckman Coulter, London, UK, Catalogue No: 363930) was used for 
centrifugation of volumes up to 50 ml. 
2.5.3 Restriction enzyme digestion of plasmid DNA 
The restriction endonuclease HindIII (Promega, Madison, USA, Catalogue No: R6045) was 
selected to digest plasmid DNA as a literature search revealed this enzyme had been used 
previously with Campylobacter plasmids (Jesse, Pittenger-Alley et al. 2006). Reactions 
contained approximately 0.5 µg of plasmid DNA, 40 U of enzyme, BSA to a final 
concentration of 0.1 µg/ml and 10 x Buffer E (Promega, Madison, USA, Catalogue No: 
R6045), sterile distilled water was used to create a final reaction volume of 40 µl. Reactions 
were incubated at 37°C for one and a half hours then the enzyme was inactivated by heating 
to 65°C for 20 minutes. Negative controls containing no restriction endonuclease (difference 
in volume made up with sterile distilled water) were included in each experiment. Controls 
and digests were loaded onto a 0.8% (w/v) agarose gel at 60 \V for 4 hours and viewed with 
a Gene genius image analyser (Syngene, Cambridge, UK) for visual confirmation of digestion.  
2.5.4 Growth kinetics 
Campylobacter isolates were grown at the University of Bristol on MH agar for 48 hours at 
37°C in a microaerobic atmosphere (5% O2, 10% CO2 2% H2 in a balance of N2). Several 
colonies were used to inoculate 10 ml of MH broth and incubated overnight at 37°C in a 
microaerobic atmosphere. One millilitre of overnight culture was diluted to an OD600 of 0.05. 
Twenty microlitres of this diluted culture was added to a 100-well honeycomb plate (Thermo 
labsystems, UK) and diluted with a further 200 µl of MH broth. The plates were sealed inside 
a variable atmosphere cabinet (Don Whitley Scientific Ltd, UK, Product: MAC 10000) after 
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being incubated there for one hour in a microaerobic atmosphere. Plates were incubated at 
37°C using a Bioscreen C plate reader (Thermo scientific, UK) and the absorbance (at OD600) 
was measured every hour after shaking for 48 hours. 
2.6 The oxacillinases of Campylobacter 
2.6.1 Comparison of oxacillinases 
The amino acid sequences of oxacillinases proteins were aligned and dendograms were 
produced based on the Neighbour-Joining method using MEGA 3.1 software (Center for 
Evolutionary Functional Genomics, Tempe, USA). The genomic context of the genes encoding 
these oxacillinases was compared using xBASE (http://www.xbase.ac.uk/).  
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Chapter 3 – Results and Discussion 
What contribution does efflux make towards beta-lactam 
resistance in Campylobacter? 
3.1 Background 
Efflux has previously been shown to play a role in innate antibiotic resistance in 
Campylobacter jejuni, including resistance to the beta-lactam ampicillin (Lin, Michel et al. 
2002; Pumbwe and Piddock 2002; Pumbwe, Randall et al. 2005). Campylobacter are also 
innately resistant to cephalosporin type beta-lactams and previous studies have suggested 
that low permeability of the Campylobacter cell wall and/or poor binding affinity of the 
antibiotics to the bacterial penicillin binding proteins may be the cause (Lachance, Gaudreau 
et al. 1991). 
3.2 Aims and Hypothesis 
The hypothesis to be investigated was that: “the efflux pumps CmeB and/or CmeF are 
responsible for the innate resistant to cephalosporins in Campylobacter jejuni”. 
The aims of the experiments in this section were to: 
 Confirm the insertional inactivation of cmeB and cmeF in C. jejuni NCTC11168 mutants 
 Determine the MICs of a range of beta-lactam antibiotics for the mutants in which 
cmeB and cmeF were inactivated. 
3.3 Confirmation of inactivation of cmeB and cmeF  
Mutants previously created in C. jejuni NCTC11168 by Vito Ricci (unpublished data) were 
given the laboratory codes P2252 (cmeB::aph) and P2253 (cmeF::cat) respectively. The cmeB 
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mutant (NCTC11168 cmeB::aph) was created by natural transformation using cmeB::aph 
DNA supplied by Professor X. Zhang (Lin, Michel et al. 2002) and the cmeF mutant 
(NCTC11168 cmeF::cat) was created in the same way using cmeF::cat DNA supplied by Dr A. 
Grant (Grant, Coward et al. 2005). 
PCR was used to confirm the cmeB/F gene(s) had been disrupted. The cmeB gene was 
amplified using primers 297 and 298 (Materials and Methods, Table 2.4) and produced a 
2.9Kb amplimer when the parental strain (NCTC 11168) was used as the DNA template. An 
amplimer of approximately 4.5Kb was predicted when cmeB was inactivated by mutational 
insertion of the aph gene (which encodes aminoglycoside phosphotransferase conferring 
kanamycin resistance). P2252 was shown to have an insertionally inactivated cmeB gene as it 
produced an amplimer of approximately 4.5Kb during PCR (Figure 3.1). 
The primers 291 and 633 (Materials and Methods, Table 2.4) were used to amplify cmeF; this 
primer pair produces a 2.3Kb amplimer when the parental strain (NCTC11168) was used as 
the DNA template. An amplimer of approximately 4.5Kb was predicted when cmeF had been 
successfully inactivated by mutational insertion of the cat gene (encoding chloramphenicol 
acetyl transferase which confers chloramphenicol resistance). P2253 was shown to have an 
insertionally inactivated cmeF gene as PCR with the primers 291 and 633 produced an 
amplimer of approximately 4.5Kb (Figure 3.2).  
Both the P2252 cmeB amplimer and the P2253 cmeF amplimer were sequenced using their 
respective primers. Sequencing confirmed that the cmeB gene of P2252 contained the aph 
gene and that the cmeF gene of P2253 contained the cat gene. 
  
 
 
Figure 3.1 PCR amplification of cmeB  
 
 
HL1 = HyperLadder 1 
Following PCR amplification with primers 297 and 298 (Materials and Methods, Table 2.4) 5µl of each PCR reaction was loaded on to a 1% 
(w/v) agarose gel and electrophoresed at 100 V for approximately 45 minutes. The amplimer obtained for P270 (NCTC11168) is 
approximately 2.9 Kb in size, amplimers from P2252 are approximately 4.5 Kb. The ten P2252 PCR replicates were combined and used as 
a source of DNA to inactivate cmeB (by natural transformation) in other isolates. 
8
5 
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Figure 3.2 PCR amplification of cmeF 
 
 
 
 
HL1 = HyperLadder 1 
Following PCR amplification with primers 291 and 633 (Materials and Methods, Table 2.4) 5 
µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and electrophoresed at 100 
V for approximately 45 minutes. The amplimer obtained for P270 (NCTC11168) is 
approximately 2.3 Kb in size, amplimers from P2253 are approximately 4.5 Kb. The four 
P2253 PCR replicates were combined and used as a source of DNA to inactivate cmeF (by 
natural transformation) in other isolates. 
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3.4 The effect of efflux pump inactivation on resistance to beta-lactams 
The agar doubling-dilution method recommended by the CLSI Campylobacter Working 
Group (McDermott, Bodeis et al. 2004) was used to determine the minimum inhibitory 
concentration (MIC) of a range of beta-lactam antibiotics for the cmeB and cmeF 
insertionally inactivated mutants (Table 3.1).  
Inactivation of cmeB led to a significant decrease (≥ two doubling dilutions) in the MIC of 
oxacillin, cephalothin, cefuroxime, cefotaxime, cefoxitin and Aztreonam. The MIC values 
decreased between five and nine doubling dilutions. The MIC of penicillin and ampicillin also 
decreased upon inactivation of cmeB but only by one doubling dilution. Inactivation of cmeF 
caused no significant change in the MIC of any of the beta-lactam antibiotics tested. 
3.5 Inactivation of cmeB in ampicillin resistant C. jejuni isolates 
On six occasions attempts were made to inactivate cmeB in two ampicillin resistant, beta-
lactamase producing isolates (P854 and P305) by natural transformation with a cmeB::aph 
PCR amplimer created using primers 297 and 298, and using kanamycin to select for 
insertionally inactivated mutants (Materials and Methods, Table 2.1 and Table 2.4). 
However, despite repeating this experiment numerous times and varying conditions (such as 
the quantity of DNA used in the transformation and recovery time), no transformants could 
be obtained.  
3.6 Discussion 
The efflux mutants P2252 and P2253 were shown by both PCR and sequencing as having 
cmeB and cmeF, respectively, inactivated. 
 
 
Table 3.1 Minimum inhibitory concentrations (MICs) of a panel of beta-lactam antibiotics for C. jejuni NCTC 11168 in 
which cmeB or cmeF had been inactivated 
 
 
 
Minimum Inhibitory Concentration (µg/ml) 
 
Penicillin Ampicillin Oxacillin Cephalothin Cefuroxime Cefotaxime Cefoxitin Aztreonam 
P270 (NCTC11168) 8 4 64 128 64 2 64 64 
P2252 (NCTC11168 
cmeB::aph) 
4 (1) 2 (1) 2 (6) 4 (5) 0.12 (9) 0.03 (6) 0.5 (7) 0.5 (7) 
P2253 (NCTC11168 
cmeF::cat) 
8 4 64 256 64 2 64 64 
 
 
MICs are the mode value of at least three biological repeats using the agar doubling-dilution method recommended by the CLSI 
Campylobacter Working Group (McDermott, Bodeis et al. 2004). Values in bold text indicate a decrease in MIC when compared to that 
for the parental strain, bold red text indicates a significant decrease in MIC when compared to the parental strain (≥ two doubling 
dilutions). Numbers in parentheses represent change (in doubling dilutions) in MIC compared with that for the parental strain. 
  
8
8 
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Inactivation of cmeB resulted in a small, but reproducible, reduction in the MIC of penicillin 
and ampicillin. The relatively low MIC of penicillin and ampicillin in the parental strain could 
be responsible for this effect; a small decrease in MIC may always be produced but the error 
of the method used does not allow this decrease to be deemed significant. Others have 
shown inactivation of cmeB in C. jejuni NCTC11168 to cause a similar decrease in the MIC of 
ampicillin, a two-fold doubling dilution reduction compared to the one doubling dilution 
reduction found in this study (Pumbwe and Piddock 2002; Guo, Lin et al. 2010). Inactivation 
of cmeB appears to confer a host-dependent effect in C. jejuni for instance; inactivation of 
cmeB in C. jejuni 81-176 has been shown to cause a reduction of five doubling dilutions in 
the MIC of ampicillin, whereas inactivation of the same gene in C. jejuni 211190 caused no 
change in the MIC of ampicillin (Lin, Michel et al. 2002).  
Inactivation of cmeB resulted in a decrease of five to nine doubling dilutions in MIC of a 
range of cephalosporins plus aztreonam. The innate resistance of Campylobacter to 
cephalosporins has previously been thought to be associated with low uptake into the 
Campylobacter cell and/or poor binding affinity of the antibiotics to the bacterial penicillin 
binding proteins (Lachance, Gaudreau et al. 1991). However, data from this study suggests 
that the efflux pump CmeABC confers the innate resistance of Campylobacter to this class of 
drugs. 
Interestingly, it was also noted throughout this study that the cmeB mutant, P2252, was 
unable to grow on agar containing Preston supplement (Oxoid Ltd., Basingstoke, UK, 
Catalogue No: SR0117) which is used for the selective culture of Campylobacter in clinical 
microbiology laboratories. Preston supplement contains polymyxin B, rifampicin, 
trimethoprim, and cycloheximide; all agents to which Campylobacter are usually innately 
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resistant. This study suggests that the innate resistance of Campylobacter to one or more of 
these compounds is due to efflux by the CmeABC efflux pump.  
Following the completion of these experiments in parallel another group published similar 
findings (Guo, Lin et al. 2010), suggesting that CmeABC is involved in the efflux of 
cephalosporins in several Campylobacter species. They also note that the MIC of rifampicin 
(one of the components of Preston supplement) decreased when the CmeABC efflux pump 
was inactivated (Guo, Lin et al. 2010).  
Data presented herein suggested that the efflux pump CmeDEF does not play a role in 
resistance to beta-lactam antibiotics in C. jejuni NCTC 11168 as the MIC of all beta-lactams 
tested were unchanged in the cmeF mutant when compared to the parental strain. 
In Salmonella it has been shown that an intact RND MDR efflux pump (homologous to 
cmeABC) is required for resistant bacteria to be selected (Ricci, Tzakas et al. 2006; Ricci and 
Piddock 2009). In addition, in several bacterial species, an intact RND MDR efflux pump is 
required for “full” resistance to be observed (Li and Nikaido 2009). To determine whether 
the same is true for beta-lactam resistance in Campylobacter an attempt was made to 
inactivate the cmeB gene in multiple ampicillin resistant, beta-lactamase producing isolates  
(it had previously been shown for one beta-lactamase producing Campylobacter isolate that 
inactivation of cmeB did not cause a reduction in the MIC of ampicillin) (Lin, Michel et al. 
2002). However, no cmeB mutants could be selected from beta-lactamase producing strains. 
Currently it cannot be determined whether mutants could not be selected due to (i) the 
isolates used not being naturally competent or having low-levels of competency or (ii) 
because inactivating cmeB in these isolates was a lethal event. Further experiments to 
determine whether other genes in these bacteria can be inactivated by natural 
91 
 
transformation may determine the cause of the inability to produce cmeB mutants. It cannot 
be determined whether the efflux pump CmeABC is required for ampicillin resistance despite 
the presence of a beta-lactamase. 
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Chapter 4 – Results and Discussion 
Do some Campylobacter isolates encode a novel beta-lactamase? 
4.1 Background 
Campylobacter jejuni is known to encode a Class D beta-lactamase OXA-61 and C. jejuni  
NCTC11168 has been shown to encode a beta-lactamase (the product of the Cj0299 gene) 
with just one amino acid difference to OXA-61 (Alfredson and Korolik 2005; Griggs, Peake et 
al. 2009). Although the product of the cj0299 gene had been referred to as OXA-61 in the 
past (Griggs, Peake et al. 2009), due to its similarity to the oxacillinase, it is not OXA-61 and 
so for clarity another OXA number was requested from the Lahey clinic 
(http://www.lahey.org/studies/) during the course of this study. The Lahey clinic assigned 
the number OXA-193 to the product of cj0299 and so from here on the oxacillinase gene of 
C. jejuni NCTC11168 (previously known as cj0299) will be referred to as blaOXA-193. 
 In the prior work pertaining to this thesis it was observed that two ampicillin resistant 
veterinary isolates of Campylobacter, P843 and P854 (Materials and methods, Table 2.1), 
produced no amplimer from a PCR for blaOXA-193 but produced a beta-lactamase as 
determined by the nitrocefin test (Griggs, Peake et al. 2009). The beta-lactamases from P843 
and P854 had an isoelectric point of 9.21 and a molecular mass of 32.4kDa. The mass and 
isoelectric point of this protein were different to that of OXA-61 and OXA-193 so the novel 
beta-lactamase was termed CjBla2. Analysis by QTOF-MS and FTICR-MS yielded no homology 
to known β-lactamases of Campylobacter, Helicobacter or Pseudomonas. BLAST searching 
revealed no homology to any known beta-lactamases and the most protein with the highest 
identity in the Campylobacter protein database was with formyltetrahydrofolate 
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deformylase (accession number CAB73055), thought to be the product of the purU gene 
(cj0790) (Griggs, Peake et al. 2009). This protein has no predicted β-lactamase activity. 
4.2 Aims and Hypotheses 
There were three hypotheses: 
1. The PurU protein (Cj0790) is CjBla2. 
2. CjBla2 is the product of a mutated blaOXA-193 gene. 
3. CjBla2 is a novel beta-lactamase encoded by a novel gene. 
The aims of the experiments in this section were to: 
1. Determine whether cj0790 encodes CjBla2. 
2. Determine whether CjBla2 is the product of a mutated blaOXA-193 gene. 
3. Ascertain how many veterinary Campylobacter isolates have the CjBla2 phenotype 
(blaOXA-193 negative, beta-lactamase producing and ampicillin resistant). 
4. If CjBla2 is not the product of cj0790 or a mutated blaOXA-193 gene, to identify the 
gene responsible. 
4.3 Does purU (cj0790) encode the novel beta-lactamase CjBla2? 
4.3.1 Creation of an insertionally inactivated purU mutant 
A purU mutant, NCTC11168 purU::Magellan3(cat), was donated by Dr A. Grant (Grant, 
Coward et al. 2005) and given the laboratory code of P2224. The presence of the cat 
(chloramphenicol acetyl transferase) gene within P2224 allowed the strain to be selectively 
cultured on MH agar plus five percent horse blood plates containing 15 µg/ml of 
chloramphenicol.  
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PCR using primers 665 and 666 that bind upstream and downstream of the purU gene 
(Materials and Methods, Table 2.6) was used to confirm that the gene was disrupted. When 
the purU gene was amplified from NCTC 11168 an 1192bp amplimer was detected whereas 
when the same region is amplified from P2224 the amplimer was approximately 3 Kb in size 
(Figure 4.1) confirming that the region has been disrupted. 
Having confirmed that P2224 contains purU::Magellan3(cat) the amplimer from the purU 
PCR of P2224 was used to naturally transform P854 in order to inactivate purU.  
Transformants were selected on MH agar plus 5% horse blood plates containing 15 µg/ml of 
chloramphenicol.  
4.3.2 Characterisation of P854 purU::Magellan3(cat) 
PCR with external gene primers 665 and 666 was used to confirm that four representative 
P854 transformants (assigned laboratory codes: P2247, P2248, P2249, P2250) contained 
disrupted purU genes (Figure 4.1). The PCR amplimer of one transformant, P2250, was 
sequenced using primers 665 and 666. The disruption of purU in P2250 was confirmed as the 
mariner inverted repeat sequence of the transposon was identified in the sequencing read 
(Figure 4.2). 
Nitrocefin, a chromogenic cephalosporin, was used to test for beta-lactamase activity in the 
P854 purU::cat (P2250 and the other three) insertionally inactivated candidates. All mutants 
retained their beta-lactamase activity (Figure 4.3). 
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Figure 4.1 PCR amplification of purU using external gene primers 
 
 
 
HL1 = HyperLadder1  
1. NCTC11168 
2. P2224  NCTC11168 purU::Magellan3(cat) 
3. P2247   P854 purU::Magellan3(cat)   candidate 1 
4. P2248   P854 purU::Magellan3(cat)   candidate 2 
5. P2249   P854 purU::Magellan3(cat)   candidate 3 
6. P2250   P854 purU::Magellan3(cat)   candidate 4 
7. Negative control 
 
Following PCR amplification of purU using the external gene primers 665 and 666, 5 µl of each PCR reaction was 
loaded on to a 1% (w/v) agarose gel and electrophoresed at 100 V for approximately 45 minutes. The amplimer 
obtained for NCTC11168 is approximately 1.2 Kb in size, amplimers from all other reactions are approximately 
3 Kb. 
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Figure 4.2 DNA sequencing of the purU region of P2250 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Black text, published purU gene (Parkhill, Wren et al. 2000); black bold underlined text,  purU external gene 
primers; red text, P2250 sequence read; red, bold, underlined text, Mariner inverted repeat . 
  
 gaaggaatggcttggactttggagtaaaaagcgtattgagcaagctaaaagattagggctt 
------------------------------------------------------------- 
 
tatgagaataagtttgaaagtaaaattttagcaaaagatttcataaatgctggattttgtg 
-atgagaataagtttgaaagtaaaattttagcaaaagatttcataaatgctggattttgtg 
 
gtaaaattcttggtttaaagcttcaagaagcaagagagaatgaattaaaagaatatataaa 
gtaaaattcttggtttaaagcttcaagaagcaagagagaatgaattaaaagaatatataaa 
 
aggtttagctaaATGATTTCTGTATTAAAAATTTGCACCAAAGATCAAAAAGGTTTAATTT 
aggtttagctaaATGATTTCTGTATTAAAAATTTGCACCAAAGATCAAAAAGGTTTAATTT 
 
ATAGAATTTCTGATGTTATTTTTAAATATCATATCAATATAGTAAAAAACGATGAATTTGT 
ATAGAATTTCTGATGTTATTTTTAAATATCATATCAATATAGTAAAAAACGATGAATTTGT 
 
AGGTGAAGGAATGTTTTTTTTTCGTGCTCTTTTAGAAGGTGAGTTTGATAAAGAAGCTTTT 
AGGTGAAGGAATGTTTTTTTTTCGTGCTCTTTTAGAAGGTGAGTTTGATAAAGAAGCTTTT 
 
ATAGGAACGCTTGAGGCTATGCTTGGACAAGAAGCCTTGATAGAGCTTTGCGAGAAGAGAA 
ATAGGAACGCTTGAGGCTATGCTTGGACAAGAAGCCTTGATAGAGCTTTGCGAGAAGAGAA 
 
AAAAAGATATTGTTGTTTTTGCTACTAAAGAAAGTCATTGTTTGGGAGATTTGCTAATAAA 
AAAAAGATATTGTTGTTTTTGCTACTAAAGAAAGTCATTGTTTGGGAGATTTGCTAATAAA 
 
GCATTA---------------------------- 
GCATTAAACAGGTTGGCTGATAAGTCCCCGGTCT 
 
 
TAGTAACGAACTTGAAGCAAATATCAAAGCTGTGATTTCAAATCACAACTCTTTA 
----AACGAACTTGAAGCAAATATCAAAGCTGTGATTTCAAATCACAACTCTTTA 
 
AAGGATTTAGTTGAGAAATTTGAAATTCCTTATCATTTTATCAGCGCTGAAAATTTAGATC 
AAGGATTTAGTTGAGAAATTTGAAATTCCTTATCATTTTATCAGCGCTGAAAATTTAGATC 
 
GTAAAGAGCAAGAAAATCAGATTTTAAAATGTCTTGAACAATATAAATTTGATTATTTGGT 
GTAAAGAGCAAGAAAATCAGATTTTAAAATGTCTTGAACAATATAAATTTGATTATTTGGT 
 
TTTGGCAAAATATATGAGAATTTTATCTCCTGATTTTGTTAGGCATTTTGAAGGCAAGATT 
TTTGGCAAAATATATGAGAATTTTATCTCCTGATTTTGTTAGGCATTTTGAAGGCAAGATT 
 
ATAAATATTCACCATTCTTTCTTACCTGCATTTATAGGAGCAAATCCTTATAAACAAGCCT 
ATAAATATTCACCATTCTTTCTTACCTGCATTTATAGGAGCAAATCCTTATAAACAAGCCT 
 
TTGAAAGAGGGGTTAAAATAATTGGAGCTACGGCACATTTTGTAAATAATAATCTTGATGA 
TTGAAAGAGGGGTTAAAATAATTGGAGCTACGGCACATTTTGTAAATAATAATCTTGATGA 
 
AGGTCCTATTATCACTCAAGCTGTTTCGCCTGTAAACCATGAATTTACTTGGCAAGATATG 
AGGTCCTATTATCACTCAAGCTGTTTCGCCTGTAAACCATGAATTTACTTGGCAAGATATG 
 
CAACAAGCAGGTAGAAATATAGAAAAAGATGTTCTTTCAAAAGCACTTGATTTGGCTTTTG 
CAACAAGCAGGTAGAAATATAGAAAAAGATGTTCTTTCAAAAGCACTTGATTTGGCTTTTG 
 
AAGATAGAATTTTTATACATAATAATAAAACTATAATATTTTAAtgcgataattttactat 
AAGATAGAATTTTTATACATAATAATAAAACTATAATATTTTAAtgcgataattttactat 
 
agttttatttaaagcattaaaaaaataatcaatatcctctttttcatgcgtataatgcaag 
agttttatttaaagcattaaaaaaataatcaatatcctctttttcatgcgtataatgcaag 
 
cttattcttaaccaacctggttttgttttaagtttttgattatcttttaagcctagcaaat 
cttattcttaaccaacctggttttgttttaagtttttga---------------------- 
 
catgaccataaggcccagcacaagcacatccag 
--------------------------------- 
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Figure 4.3 Determining whether insertionally inactivated purU mutants have beta-
lactamase activity (detectable by nitrocefin) 
 
 
 
Yellow = Nitrocefin negative, no beta-lactamase activity detectable 
Red = Nitrocefin positive, detectable beta-lactamase activity   
 
Number Strain 
Beta-lactamase 
activity 
1 NCTC11168 Reference strain Not detectable 
2 P843 CjBla2 producer Detectable 
3 P854 CjBla2 producer Detectable 
4 P2224 NCTC11168purU::Magellan3(cat) Not detectable 
5 P2247 P854 purU::Magellan3(cat) Detectable 
6 P2248 P854 purU::Magellan3(cat) Detectable 
7 P2249 P854 purU::Magellan3(cat) Detectable 
8 P2250 P854 purU::Magellan3(cat) Detectable 
 
 
Bacterial cultures were sonicated for two minutes then centrifuged to pellet cell debris, 50 µl of the 
supernatant was transferred to a well in a 96 well microtitre tray and 10 µl of nitrocefin was added to each 
sample. A colour change from yellow to red is a positive nitrocefin reaction indicating the presence of beta-
lactamase activity.  
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4.4 Is CjBla2 the product of a mutated blaOXA-193 gene? 
4.4.1 PCR of blaOXA-193  
Previously both P843 and P854 had been identified as giving no amplimer during PCR of the 
blaOXA-193 gene (Table 2.7). In order to confirm these findings PCRs were repeated using 
primers both internal and external to the gene in case mutations in one or more of the 
primer binding sites had led to the previous lack of amplimers. None of the primer 
combinations yielded amplimers following PCR of blaOXA-193 in either isolate (Figure 4.4). 
4.4.2 Southern blotting of blaOXA-193  
Southern blotting was carried out to determine whether P843 and P854 contained a 
mutated beta-lactamase gene that was sufficiently different from cj0299 to prevent primer 
binding and subsequent PCR amplification but still shared enough homology to cj0299 to be 
considered a variant form.  
A search of the literature revealed that HindIII and ClaI are commonly used to digest 
Campylobacter genomic DNA (Korolik, Moorthy et al. 1995; Ahmed, Manning et al. 2002). A 
281 bp probe was designed that spanned the active site of the OXA-193 enzyme (Figure 4.5). 
Both enzymes were tested at a range of concentrations and incubation times (Figure 4.6) to 
determine the optimal digest conditions. A four hour incubation with HindIII at a 
concentration 30 U/µg gave the clearest digest pattern so was used for all blots. 
Blotting was initially performed following the manufacturers protocol, however when 
following this method the resulting blots were unreadable as they contained too much 
background signal (Figure 4.7a). Various changes were made to the protocol in order to 
decrease background signal and increase signal from the probe (Table 4.1). These changes  
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Figure 4.4 PCR amplification of blaOXA-193 from NCTC11168, P843 and P854 
 
 
 
 
 
PCR of blaOXA-193 with primers 
467 and 468 
PCR of blaOXA-193 with primers 
469 and 468 
PCR ofblaOXA-193 with primers 
467 and 470 
1. NCTC 11168 5. NCTC 11168 9.   NCTC 11168 
2. P843 6. P843 10. P843 
3. P854 7. P854 11. P854 
4. Negative control (water) 8. Negative control (water) 12. Negative control (water) 
 
 
 
White + or -, presence or absence of amplimer. HL1, HyperLadder1. 
 
Following PCR amplification of blaOXA-193 with three combinations of blaOXA-193 primers (Materials and 
Methods, Table 2.7), 5 µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and 
electrophoresed at 100V for approximately 45 minutes. Amplimers were obtained for NCTC11168 from PCR 
with all three primer combinations. P843 and P854 did not produce amplimers for any of the PCRs. 
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Figure 4.5 Southern blotting probe 
 
gagtataatacaagcggcacttttgttttttatgatggaaaaacttgggcgagtaacgac 
 
 E  Y  N  T  S  G  T  F  V  F  Y  D  G  K  T  W  A  S  N  D  
 
Ttttcaagggctatggagactttctctcccgcttccacttttaaaatttttaatgctcta 
 
 F  S  R  A  M  E  T  F  S  P  A  S  T  F  K  I  F  N  A  L  
 
Attgcacttgatagtggtgtgataaaaactaaaaaagaaattttttatcactatagaggt 
 
 I  A  L  D  S  G  V  I  K  T  K  K  E  I  F  Y  H  Y  R  G  
 
Gaaaaagtatttttatcttcttgggcgcaagatatgaatttaagttcagctataaaatat 
 
 E  K  V  F  L  S  S  W  A  Q  D  M  N  L  S  S  A  I  K  Y  
 
tctaatgttcttgcttttaaagaagtggcaagaagaattgg 
 
 S  N  V  L  A  F  K  E  V  A  R  R  I     
 
 
The DNA and amino acid sequence of the 281bp Southern blotting probe, boxed text indicates the active 
site tetrad STFK and the Amino Acid sequence coding for it. 
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Figure 4.6 Optimisation of restriction enzyme digestion of NCTC11168 genomic DNA 
 
 
 
 
Lane 
Restriction 
Enzyme 
Enzyme 
Concentration 
Digestion 
Time 
Lane 
Restriction 
Enzyme 
Enzyme 
Concentration 
Digestion 
Time 
1 None* - - 17 None* - - 
2 ClaI 5 U/µg DNA 1 hour 18 HindIII 5 U/µg DNA 1 hour 
3 ClaI 10 U/µg DNA 1 hour 19 HindIII 10 U/µg DNA 1 hour 
4 ClaI 30 U/µg DNA 1 hour 20 HindIII 30 U/µg DNA 1 hour 
5 None* - - 21 None* - - 
6 ClaI 5 U/µg DNA 2 hours 22 HindIII 5 U/µg DNA 2 hours 
7 ClaI 10 U/µg DNA 2 hours 23 HindIII 10 U/µg DNA 2 hours 
8 ClaI 30 U/µg DNA 2 hours 24 HindIII 30 U/µg DNA 2 hours 
9 None* - - 25 None* - - 
10 ClaI 5 U/µg DNA 3 hours 26 HindIII 5 U/µg DNA 3 hours 
11 ClaI 10 U/µg DNA 3 hours 27 HindIII 10 U/µg DNA 3 hours 
12 ClaI 30 U/µg DNA 3 hours 28 HindIII 30 U/µg DNA 3 hours 
13 None* - - 29 None* - - 
14 ClaI 5 U/µg DNA 4 hours 30 HindIII 5 U/µg DNA 4 hours 
15 ClaI 10 U/µg DNA 4 hours 31 HindIII 10 U/µg DNA 4 hours 
16 ClaI 30 U/µg DNA 4 hours 32 HindIII 30 U/µg DNA 4 hours 
*Un-digested DNA control 
Lane 32 is the clearest digest. 
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Figure 4.7 Examples of Southern blots during development   
  
  
               a               b 
 
 
Southern-blot hybridisation of HindIII digested genomic DNA from C. jejuni NCTC11168, P843 and P854 probed 
with blaOXA-61 gene.  
a.   Too much background to determine whether or not there are any signals. 
b.  Blot is completely blank; no signal has been produced even for the blaOXA-61 positive control (NCTC 11168 
digested genomic DNA). Blot was left for 1 hour 30 minutes before the film was developed. 
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Table 4.1 Steps taken to optimise Southern blot 
 
Problem Adjustment Reason 
Too much 
background 
Use new photographic 
developer/fixer 
In case the developer/fixer were contaminated. 
 Increase hybridisation temperature At a higher temperature the stringency is increased, 
this should help to eliminate none-specific binding of 
the probe. 
 Decrease development time Leaving the film in photographic developer for too 
long increases the amount of background. 
 Filter the detection reagent Filtering detection reagent through a 0.2 micron filter 
removes any contamination (step recommended by 
manufacturer). 
 Increase concentration of probe DNA Concentration of DNA used to make probe was 
increased from 10ng/microlitre to 40ng/microlitre. 
No signal Lower hybridisation temperature At a lower temperature the stringency is decreased, 
this should increase binding of the probe. 
 Increase ratio of probe:hybridisation 
buffer 
To increase the signal generated by the probe. 
 
 Increase the amount of target DNA 
loaded onto gel. 
The amount of genomic DNA that was digested and 
loaded onto gel was increased from 2µg to 3µg in 
order to increase the amount of target DNA available 
for the probe to bind to. 
 Increase the length of each transfer 
stage. 
The time taken to perform each wash during transfer 
of DNA from gel to membrane was increased to allow 
maximum transfer. 
  
104 
 
were implemented incrementally and were successful in removing non-specific signal (Figure 
4.7b).  Once background signal had been eradicated it became clear that the positive control 
(NCTC11168) did not generate a signal (Figure 4.7b). Further modifications were made to the 
protocol (Table 4.1) to enhance the probe signal. 
Once the Southern blot for blaOXA-193 was sufficiently optimised it was used to test for the 
presence of blaOXA-193 in P843 and P854. Genomic DNA from NCTC11168 (positive control), 
P843 and P854 was digested with HindIII and electrophoresed through a 0.8% agarose gel 
(Figure 4.8a).  
Southern blotting was performed using the modified protocol. The 281bp blaOXA-193 probe 
hybridised to NCTC11168 DNA (positive control) but did not hybridise to the DNA of either 
P843 or P854 (Figure 4.8b). 
4.5 Do any other veterinary isolates of Campylobacter posses the ‘CjBla2 
phenotype’? 
Prior to this project only two veterinary isolates had been identified that were ampicillin 
resistant, had beta-lactamase activity detectable by nitrocefin and did not produce 
amplimers during blaOXA-193 PCR.  
Initial screening data relating to veterinary isolates of Campylobacter collected during two 
Defra funded studies VM0220 and OZ0501 (Griggs, Johnson et al. 2005; Humphrey, 
Jorgensen et al. 2005; Piddock, Griggs et al. 2008) was queried to produce a list of potential 
isolates with the ‘CjBla2 phenotype’.  
These isolates were then checked to determine whether they  
1. produced amplimers during blaOXA-193 PCR 
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Figure 4.8 Southern blot hybridization for blaOXA-193  
 
        
 a              b 
                      
Southern-blot hybridisation of HindIII digested genomic DNA from C. jejuni NCTC11168, P843 and P854 probed 
with blaOXA-61 gene.  
a. Digested genomic DNA of 1. NCTC11168, 2. P843 and 3. P854.  
b. Probe was able to bind to NCTC11168 genomic DNA (arrow on diagram), the blaOXA-193 probe was unable to 
bind to either P843 or P854 genomic DNA. 
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2. hydrolysed nitrocefin 
3. were resistant to ampicillin (MIC≥ 16µg/ml) 
Thirteen isolates were identified in addition to the initial two, P843 and P854, from the 
collection as non-replicate isolates (Materials and Methods, Table 2.1). The flaA type of each 
isolate was determined (Table 4.2). All isolates were shown to not produce amplimers during 
blaOXA-193 PCR (Figure 4.9), were able to hydrolyse nitrocefin (Figure 4.10) and were resistant 
to ampicillin (MIC of ampicillin ranged from 128-256 μg/ml) (Table 4.3). 
Four isolates from the CjBla2 panel were subjected to a Southern hybridisation with a 281bp 
probe for blaOXA-193. The probe was unable to bind to the DNA of any of these isolates (Figure 
4.11). 
4.6 Sequence analysis of the P854 genome 
DNA was isolated from a culture of P854 that had its blaOXA-193  negative status checked by 
PCR and had also been shown to have beta-lactamase activity. DNA was then sent to The 
Gene Pool (University of Edinburgh) to be sequenced using an Illumina GA II (SOLEXA) 
platform. 
With the help of Dr Nick Loman of the University of Birmingham, the sequencing data 
received was assembled into 621 contigs which made up 83 scaffolds. The P854 genome was 
run through an annotation pipeline using Campylobacter jejuni RM1221 as the reference 
strain as preliminary BLAST searching had revealed that this was the most closely related 
fully annotated Campylobacter genome. It is important to note that although C. jejuni 
RM1221 is not identical to NCTC11168 (the reference strain used in other aspects of this 
work), RM1221 and NCTC11168 have similar genomic organisation in the 
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Table 4.2 flaA types of putative CjBla2 producers 
 
Laboratory 
code 
flaA 
type 
P339 flaA100 
P843 flaA21 
P852 flaA617 
P853 flaA18 
P854 flaA18 
P858 flaA616 
P859 flaA18 
P862 flaA18 
P888 flaA18 
P891 flaA617 
P1007 flaA34 
P1052 flaA34 
P1058 flaA616 
P1170 flaA34 
P1177 flaA350 
 
Previously characterised isolates (P843 and P854) are illustrated in bold text.  
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Figure 4.9 PCR amplification of blaOXA-193 from potential CjBla2 producers 
 
 
 
 
HL1 = HyperLadder1  
1. NCTC11168 7. P858 13. P1052 
2. P339 8. P859 14. P1058 
3. P843 9. P862 15. P1170 
4. P852 10. P888 16. P1177 
5. P853 11. P891 17. Water (negative) 
6. P854 12. P1007  
 
Following PCR amplification of blaOXA-193 using the internal gene primers 467 and 468 (Materials and Methods, 
Table 2.7) 5 µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and electrophoresed at 100 V for 
approximately 45 minutes. The amplimer obtained for NCTC11168 is the correct size (281bp), no amplimers 
were obtained for any of the CjBla2 panel. 
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Figure 4.10 Detection of beta-lactamase activity in CjBla2 producers  
 
 
 
 
Number Isolate 
Beta-lactamase 
activity 
Number Isolate 
Beta-lactamase 
activity 
1 Water Not detectable 10 P862 Detectable 
2 NCTC11168 Not detectable 11 P888 Detectable 
3 P339 Detectable 12 P891 Detectable 
4 P843 Detectable 13 P1007 Detectable 
5 P852 Detectable 14 P1052 Detectable 
6 P853 Detectable 15 P1058 Detectable 
7 P854 Detectable 16 P1170 Detectable 
8 P858 Detectable 17 P1177 Detectable 
9 P859 Detectable    
 
 
Bacterial cultures were sonicated for two minutes then centrifuged to pellet cell debris, 50 µl of the 
supernatant was transferred to a well in a 96 well micro titre tray and 10 µl of nitrocefin was added to each 
sample. A colour change from yellow to red is a positive nitrocefin reaction indicating the presence of beta-
lactamase activity. 
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Table 4.3 MIC of a range of beta-lactams for putative CjBla2 producers 
 
Isolate 
Minimum Inhibitory Concentration (MIC) (µg/ml) 
PEN AMP  OXA CEF CFX CTX FOX 
P339 128 256 256 512 128 4 256 
P843 64 64 512 1024 256 16 256 
P852 256 256 256 512 128 16 256 
P853 256 128 512 1024 128 16 256 
P854 >256 >256 512 1024 256 16 256 
P858 >256 256 512 1024 128 16 256 
P859 128 128 256 256 128 4 128 
P862 256 256 256 512 128 4 128 
P888 256 128 128 256 128 4 128 
P891 256 256 256 512 128 16 256 
P1007 >256 256 512 512 128 8 256 
P1052 128 128 256 256 64 8 128 
P1058 128 128 128 256 64 4 128 
P1170 256 128 128 256 64 4 128 
P1177 >256 256 512 256 128 16 256 
 
MICs are the modal value of at least three biological repeats. 
PEN, penicillin; AMP, ampicillin; OXA, oxacillin; CEF, cephalothin; CFX, cefuroxime; CTX, cefotaxime; FOX, 
cefoxitin. 
  
 
 
Figure 4.11 Southern blot hybridization for blaOXA-193  
  
           a        b 
+ Positive control (known to contain blaOXA-193 ). 
a. Digested genomic DNA. b. blaOXA-193 probe was only able to bind to the DNA of the two positive controls, arrow on diagram. 
 
1. NCTC11168 blaOXA-193  positive 5. P339 blaOXA-193  negative 
2. P843 blaOXA-193  negative 6. P859 blaOXA-193  negative 
3.P854 blaOXA-193  negative 7. P1007 blaOXA-193  negative 
4. P305  blaOXA-193  positive 8. P1052 blaOXA-193  negative 
1
1
1 
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region surrounding the beta-lactamase gene blaOXA-193 of NCTC11168 and cje0344 of RM1221 
(Figure 4.12). 
An alignment of P854 with RM1221 was created using the Artemis Comparison Tool (Figure 
4.13) allowing the P854 genome to be interrogated. 
4.7 Identification of putative beta-lactamases 
Four P854 genes were annotated as being putative beta-lactamase genes (Table 4.4). Three 
of these (P854_0720, P854_0903 and P854_1029) were annotated as metallo beta-
lactamases and had homologues within RM1221. The remaining gene, P854_1490, was 
simply annotated as a ‘beta-lactamase’ and there were no significantly homologous genes in 
RM1221 (Table 4.4). 
4.8 In silico analysis of P854_1490 
4.8.1 The genomic context of P854_1490 
When the area containing P854_1490 was aligned with the corresponding region of RM1221 
despite some similarities there are also some clear differences (Figure 4.14).  
When considering P854_1490, the most noteworthy point is that it is in a similar position to 
the cje0344 gene of RM1221. However, protein-protein BLAST searching revealed that the 
P854_1490 protein shares only 64% identity with Cje0344 and 65% identity with OXA-193. 
Downstream of P854_1490 the genomic arrangement is typical of Campylobacter jejuni as 
the mod operon is present. The mod genes encode an ABC transport system that transports 
molybdenum and to a lesser extent, tungsten; both of these metals co-factors for enzymes 
involved in the Campylobacter respiratory chain (Taveirne, Sikes et al. 2009). The Artemis 
Comparison Tool did not identify the mod operon as being homologous to the same  
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Figure 4.12 Area surrounding blaOXA-193 in NTC11168 compared to that same region in 
Campylobacter jejuni RM1221 
 
 
 
 
 
Campylobacter jejuni RM1221 contains a blaOXA-193 homologue cje0344, RM1221 also contains the pan operon 
upstream and the mod operon downstream of the beat-lactamase as does NCTC11168. 
 
Genomes are aligned based on their nucleotide (A) or amino acid (B) sequence. Homologous regions of 
nucleotide (A) and amino acid (B) sequence are connected with red lines.  
 
Figure was produced using the nucmer and promer tools on Xbasse (http://xbase.bham.ac.uk/campydb/). 
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Figure 4.13 Alignment of P854 with Campylobacter jejuni RM1221produced using the 
Artemis Comparison Tool 
 
 
 
 
 
 
Homologous genes are connected by red lines; blue lines represent genes that are inverted in P854 when 
compared to the reference strain RM1221. Areas that are not connected represent genes that are unique to 
the strain. 
 
 
 
Table 4.4 Putative beta-lactamase genes in the P854 genome 
 
Gene Annotation Protein sequence 
Homologue in 
RM1221? 
Protein sequence of RM1221 homologue 
P854_0720 
Metallo-beta-
lactamase family 
MQIIKQACGAYETNCYILFSEHGEIIIDPGFDALNFIKKHVKNPLAILNTH
GHYDHVWDNEKVKQAYQIPIYIHKNDAFMLEDPFNQGFMPSKADYLI
DDENIISIGGLDFKFHFLPGHTPGCTMIEIVGKNIMFSGDFLFYRSIGRW
DFPYSDANLMKQSLEKVMTYKEDFKLLPGHGQETTLKEEQVHLPSWLR
YF 
Yes, homology 
to cje0900 
MQIIKQACGAYETNCYILFGEHGEIIIDPGFDALNFIKKHVKNPLAILNTH
GHYDHVWDNEKVKQAYQIPIYIHKNDTFMLEDPFNQGFMPSKANYLI
DDENIISIGGLDFKFHFLPGHTPGCTMIEIVGKNIMFSGDFLFYRSIGRW
DFPYSDANLMKQSLEKVMTYKEDFKLLPGHGQETTLKEEQVHLPSWLR
YF 
P854_0903 
Metallo-beta-
lactamase domain-
containing protein  
MFNFITTLLKTNLYFLEEKTTSKNSNQTHIISLKQSDDEFLNLLFSFLVPQS
DEDKNFIGKTRTKIKRNEHNIALIKNPNFNALIDTGFLDTIDTLKEKLHIHK
TDFKDITHIILTHAHPDHIGALMSEENLFPKAQILIDKKEYDFWIKSDRQEI
KNTLLKLKNIEFIDHSKDLIFQNSGIKAIPAYGHTPGQNAIIIDDKIVFWGD
LLHLYDIQIPKPKIAIKFDIDQNEAIQTREKLLKEFKERKLKVIGTHVPFIKPK
FLD 
Yes, homology 
to cje1761 
MSEENLFPKAQILIDKKEYDFWIKSDRQEIKNTLLKLKNIEFINHSKDLIFQ
NSGIKAIPAYGHTPGQNAIIIDDKIVFWGDLLHLYDIQIPKPKIAIKFDIDQ
NEAIQTREKLLKEFKERKLKVIGTHVPFIKPKFLD 
P854_1029 
Metallo-beta-
lactamase family  
MDENKEINKNEQNPNSNLKNNKRYKYKNRRKKLADSLQNENDTPKID
QNSNKEISENSENKTEKKKKKNRNLPSKLTGNEDQIALAECIEANRVSHE
NRLHPLKYNNSSEHKIRITPLGGLGEIGGNISVFETNKDAIIVDIGMSFPD
GTMHGVDIIIPDFDYVRKIKDKIRGIVITHAHEDHIGAVPYFFKEFQFPIYA
TPLALGMISNKFEEHGLKAERKWFRPVEKRRVYEIGEFDIEWIHITHSIID
ASALAIKTKAGTIIHTGDFKIDQTPIDGYPTDLGRLAHYGEEGVLCLLSDS
TNSYKEGYTKSESSVGPTFDQIFSRTKGRVIMSTFSSNIHRVYQAITYGLK
YGRKVCVIGRSMERNLYTTMELGYIKLDRKIFIDADEVSKYKDNEVLIVTT
GSQGETMSALYRMATDEHKFIKIKPTDQVIISAKAIPGNEASVSAVLDYL
LKAGAKVAYQEFSEIHVSGHASIEEQKLMLTLTKPKFFLPVHGEYNHITK
HKETAMKCGIPERNIYLMSDGDQVELCQKYVKRIKTVKTGKVFVDNQI
NKQIADDVVIDRQKLADSGIVVIIAQIDKTTKTLINKPRVFSYGLVADKHD
HAFSKDMAEVLGQFFINVKDEVLNDPRFLENQIRQVLRKHIFRKIKKYPT
IVPTIFVM 
Yes, homology 
to cje1879 
MDENKEINKNEQNPNSNSKNNKRYKYKNRRKKLADSLQNENDTPKID
QNSNKENSENSENKTEKKKKKNRNLPSKLTGNEDWQIALAECIEANRIS
HENRLHPLKYNNSSEHKIRITPLGGLGEIGGNISVFETNKDAIIVDIGMSF
PDGTMHGVDIIIPDFDYVRKIKDKIRGIVITHAHEDHIGAVPYFFKEFQFP
IYATPLALGMISNKFEEHGLKAERKWFRPVEKRRVYEIGEFDIEWIHITHS
IIDASALAIKTKAGTIIHTGDFKIDQTPIDGYPTDLGRLAYYGEEGVLCLLS
DSTNSYKEGYTKSESSVGLTFDQIFARTKGRVIMSTFSSNIHRVYQAITYG
LKYGRKVCVIGRSMERNLYTTMELGYIKLDRKIFIDADEVSKYKDNEVLIV
TTGSQGETMSALYRMATDEHKFIKIKPTDQVIISAKAIPGNEASVSAVLD
YLLKAGAKVAYQEFSEIHVSGHASIEEQKLMLTLTKPKFFLPVHGEYNHIT
KHKETAMKCGIPERNIYLMSDGDQVELCQKYVKRIKTVKTGKVFVDNQI
NKQIADDVVIDRQKLADSGIVVIIAQIDKATKTLINKPRVFSYGLVADKH
DHAFSKDMAEVLGQFFINVKDEVLNDPRFLENQIRQVLRKHIFRKIKKYP
TIVPTIFVM 
P854_1490 Beta-lactamase 
LKKILLLFSLFYSFALANDKLKDFFKDYNTSGVFITFDGKHYASNNFKRAK
EPFSPASTFKIFNALIALDNGVVKDTKEIFYHYKGEKVFLPSWKQDASLSS
AIKRSQVPAFKELARKIGLKTMQESLNKLSYGNTKISKIDTFWLDNSLQIS
AKNQADLLFKLSQNSLPFSKKSQEEVKKIILFKEDKIQKIYAKTGFNDGINL
AWIVGFIESKNKILSFALNVDIKNIKNLKIREELLEKYIYSLN 
No 
 
1
1
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Figure 4.14 Alignment of the region surrounding P854_1490 with the corresponding 
region in Campylobacter jejuni RM1221 (produced using the Artemis Comparison Tool) 
  
 
 
 
Homologous genes are connected by red lines. Areas that are not connected represent genes that are unique 
to the strain. The genes in the P854 and RM1221 mod operons share only 82% identity (at the amino acid level) 
with one another. 
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operon in RM1221. This is not surprising as the sequence of the mod genes vary between 
Campylobacter species. 
Upstream of P854_1490 there were clear differences between P854 and RM1221. Upstream 
of the oxacillinase gene of RM1221 is the pan operon which contains the pantothenate 
biosynthesis genes panD, panC and panB. In higher organisms pantothenic acid is a 
precursor of coenzyme A that is required for fatty acid biosynthesis although its role in 
bacteria is less well defined (Pearson, Pin et al. 2003). The PanD protein has also been shown 
to be involved in amino acid catabolism (production of alanine from aspartate) (Fouts, 
Mongodin et al. 2005). The pan operon is completely lacking in P854. The putative beta-
lactamase gene P854_1490 is flanked by two genes that are not found in this position in any 
other sequenced Campylobacter jejuni isolates. The gene upstream, P854_1491, may be a 
pseudogene, or a gene encoding a truncated form of the ThiF (thiamine biosynthesis) 
protein encoded by the gene that is usually between the pan operon and the surE gene 
upstream. The protein product of the P854_1491 gene is 44 amino acids in length and shares 
55% identity with ThiF (Cj0295) protein of C. jejuni NCTC11168. 
The protein product of P854_1489 shows little similarity to any Campylobacter protein, 
protein BLAST revealed a maximum of 27% identity with Campylobacter proteins. Using a 
blastn search one gene was similar, the cla0303 gene (a metal dependent membrane 
permease) of Campylobacter lari RM2100. When this gene is viewed in context in C. lari 
RM2100, it can be seen downstream of a putative beta-lactamase gene, cla0304 (Figure 
4.15). 
4.8.2 The OXA-184 (P854_1490) protein 
The P854_1490 gene has a GC content of 25.7% and encodes a protein of 248aa in length. 
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Figure 4.15 The region of Campylobacter jejuni RM1221 corresponding to the P854_1490 
containing region of P854 (produced using the Artemis Comparison Tool) 
 
 
 
 
 
Diagram produced using CampyDB (http://xbase.bham.ac.uk/campydb/). 
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Protein BLAST searches reveal that the P854_1490 protein is most similar to class D beta-
lactamases, also known as Oxacillinases (OXAs). The amino acid sequence of P854_1490 was 
submitted to the Lahey clinic who confirmed it to be a novel oxacillinase sequence and 
assigned it the number OXA-184. From here on the gene encoding OXA-184 (previously 
referred to as P854-1490) will be referred to as blaOXA-184. 
When OXA-184 is aligned with other class D beta-lactamases including representatives of the 
OXA sub groups and the Campylobacter jejuni beta-lactamase OXA-61, it can be seen to fit 
within the expected patterns and contains all the conserved regions of an OXA including the 
active site tetrad STFK (Figure 4.16). 
Analysis in the form of a neighbour-joining tree (Figure 4.17) illustrates that the closest 
relative of OXA-184 is OXA-61 and that the beta-lactamase of C. lari RM2100 also clusters 
with them to form a group of Campylobacter beta-lactamases. 
4.9 Screening the CjBla2 panel for blaOXA-184  
One pair of primers was designed to amplify an 183bp fragment of the blaOXA-184  gene, 
another pair was designed to amplify a 1670bp product that included the whole blaOXA-193  
gene. The forward primer was within the gene upstream (P854_1491) and the reverse 
primer was within the gene downstream (P854_1489) (Materials and Methods, Figure 2.3). 
The internal primer pair may not be specific to OXA-184 and may amplify other Class D beta-
lactamase genes due to sequence similarity. The external primer pair which bind in the 
genes up and downstream will be able to identify isolates which have this unusual 
arrangement of genes in the OXA region. During PCR using the internal primer pair, all 
thirteen isolates in the ‘CjBla2 panel’ produced amplimers of the expected size (Figure 4.18).  
 
 
Figure 4.16 Amino acid alignments of thirteen representative class D β-lactamases from the different subgroups with OXA-61 and the 
novel β-lactamase from P854, OXA-184 
 
OXA-02  ------MAIR IFAILFSIFS LATFAHAQEG TL-------- ----ERSDWR KFFSEFQAKG TIVVADERQA DRAMLVFDPV RSKKRYSPAS TFKIPHTLFA LDAGAVRDEF 
OXA-20  ------MIIR FLALLFSAVV LVSLGHAQEK TH-------- ----ESSNWG KYFSDFNAKG TIVVVDERTN GNSTSVYNES RAQQRYSPAS TFKIPHTLFA LDAGAVRDEF 
OXA-10  --------MK TFAAYVIIAC LSSTALAGSI TE-------- ----NTS-WN KEFSAEAVNG VFVLCKS--S SKSCATNDLA RASKEYLPAS TFKIPNAIIG LETGVIKNEH 
OXA-48  -----MRVLA LSAVFLVASI IGMPAVAKEW QE-------- ----NKS-WN AHFTEHKSQG VVVLWNE--N KQQGFTNNLK RANQAFLPAS TFKIPNSLIA LDLGVVKDEH 
OXA-40  ----MKKFIL PIFSISILVS LSACSSIKTK SEDNFHIS-S QQ--HEKAIK SYFDEAQTQG VIIIKEG--K NLSTYGNALA RANKEYVPAS TFKMLNALIG LEN-HKATTN 
OXA-51  ----MN--IK TLLLITSAIF ISACSPYIVT ANPNHSASKS DE--KAEKIK NLFNEVHTTG VLVIQQG--Q TQQSYGNDLA RASTEYVPAS TFKMLNALIG LEH-HKATTT 
OXA-23  ----MN--KY FTCYVVASLF LSGCTVQHNL IN-ETPSQIV QG--HNQVIH QYFDEKNTSG VLVIQTD--K KINLYGNALS RANTEYVPAS TFKMLNALIG LEN-QKTDIN 
OXA-58  ----MK-LLK ILSLVCLSIS IGACAEHSMS RAKTSTIPQV NNSIIDQNVQ ALFNEISADA VFVTYDG--Q NIKKYGTHLD RAKTAYIPAS TFKIANALIG LEN-HKATST 
OXA-50  ----MR---- -PLLFSALLL LSGHTQASEW ND-------- -----SQAVD KLFGAAGVKG TFVLYDV--Q RQRYVGHDRE RAETRFVPAS TYKVANSLIG LSTGAVRSAD 
OXA-63  ----MS--KK NFILIFIFVI LISCKNTEKI SN-------- ----ETTLID NIFTNSNAEG TLVIYNL--N DDKYIIHNKE RAEQRFYPAS TFKIYNSLIG LNEKAVKDVD 
OXA-18  MQRSLSMSGK RHFIFAVSFV ISTVCLTFSP AN-------- ----AAQKLS CTLVIDEASG DLLHREGS-- ---------- -CDKAFAPMS TFKLPLAIMG YDADILLDAT 
OXA-42  MKFRHALSS- -------AFV L----LGCIA AS-------- ----AHAKTI CTAIADAGTG KLLVQDGD-- ---------- -CGRRASPAS TFKIAISLMG YDAGFLRNEH 
OXA-30  MKNTIHINF- -----AIFLI IANIIYSSAS AS-------- ----TDISTV ASPLFEGTEG CFLLYDASTN AEI-AQFNKA KCATQMAPDS TFKIALSLMA FDAEIIDQKT 
OXA-61  ----MK--KI TLFLLFLNLV FGQDK----- ---------- -------ILN NWFKEYNTSG TFVFY----D GKTWASNDFS RAMETFSPAS TFKIFNALIA LDSGVIKTKK 
OXA-184 ----LKK-IL LLFSLFYSFA LANDK----- ---------- --------LK DFFKDYNTSG VFITF----D GKHYASNNFK RAKEPFSPAS TFKIFNALIA LDNGVVKDTK 
 
OXA-02  QIFR-WDGV- -NRGFAGHNQ DQDLRSAMRN STVWVYELFA KEIGDDKARR YLKKIDYGNA DPST------ SNGDYWIEGS LAISAQEQIA FLRKLYRNEL PFRVEHQRLV 
OXA-20  HVFR-WDGA- -KRSFAGHNQ DQNLRSAMRN STVWVYQLFA KEIGENKARS YLEKLNYGNA DPST------ KSGDYWIDGN LAISANEQIS ILKKLYRNEL PFRVEHQRLV 
OXA-10  QVFK-WDGK- -PRAMKQWER DLTLRGAIQV SAVPVFQQIA REVGEVRMQK YLKKFSYGNQ NISG------ GIDKFWLEGQ LRISAVNQVE FLESLYLNKL SASKENQLIV 
OXA-48  QVFK-WDGQ- -TRDIATWNR DHNLITAMKY SVVPVYQEFA RQIGEARMSK MLHAFDYGNE DISG------ NVDSFWLDGG IRISATEQIS FLRKLYHNKL HVSERSQRIV 
OXA-40  EIFK-WDGK- -KRTYPMWEK DMTLGEAMAL SAVPVYQELA RRTGLELMQK EVKRVNFGNT NIGT------ QVDNFWLVGP LKITPVQEVN FADDLAHNRL PFKLETQEEV 
OXA-51  EVFK-WDGQ- -KRLFPEWEK DMTLGDAMKA SAIPVYQDLA RRIGLELMSK EVKRVGYGNA DIGT------ QVDNFWLVGP LKITPQQEAQ FAYKLANKTL PFSPKVQDEV 
OXA-23  EIFK-WKGE- -KRSFTAWEK DMTLGEAMKL SAVPVYQELA RRIGLDLMQK EVKRIGFGNA EIGQ------ QVDNFWLVGP LKVTPIQEVE FVSQLAHTQL PFSEKVQANV 
OXA-58  EIFK-WDGK- -PRFFKAWDK DFTLGEAMQA STVPVYQELA RRIGPSLMQS ELQRIGYGNM QIGT------ EVDQFWLKGP LTITPIQEVK FVYDLAQGQL PFKPEVQQQV 
OXA-50  EVLP-YGGK- -PQRFKAWEH DMSLRDAIKA SNVPVYQELA RRIGLERMRA NVSRLGYGNA EIGQ------ VVDNFWLVGP LKISAMEQTR FLLRLAQGEL PFPAPVQSTV 
OXA-63  EVFYKLMA-- -KSFLESWAK DSNLRYAIKN SQVPAYKELA RRIGIKKMKE NIEKLDFGNK SIGD------ SVDTFWLEGP LEISAMEQVK LLTKLAQNEL QYPIEIQKAI 
OXA-18  TPRWDYKPEF NGY--KSQQK PTDPTIWLKD SIVWYSQELT RRLGESRFSD YVQRFDYGNK DVSGDPGKHN GLTHAWLASS LKISPEEQVR FLRRFLRGEL PVSEDALEMT 
OXA-42  DPVLPYRDSY IAWGGEAWKQ PTDPTRWLKY SVVWYSQQVA HHLGAQRFAQ YAKAFGYGNA DVSGDPGQNN GLDRAWIGSS LQISPLEQLE FLGKMLNRKL PVSPTAVDMT 
OXA-30  IFKWDKTP-- --KGMEIWNS NHTPKTWMQF SVVWVSQEIT QKIGLNKIKN YLKDFDYGNQ DFSGDKERNN GLTEAWLESS LKISPEEQIQ FLRKIINHNL PVKNSAIENT 
OXA-61  EIFYHYRGE- -KVFLSSWAQ DMNLSSAIKY SNVLAFKEVA RRIGIKTMQE YLNKLHYGNA KIS------- KIDTFWLDNS LKISAKEQAI LLFRLSQNSL PFSQEAMNSV 
OXA-184 EIFYHYKGE- -KVFLPSWKQ DASLSSAIKR SQVPAFKELA RKIGLKTMQE SLNKLSYGNT KIS------- KIDTFWLDNS LQISAKNQAD LLFKLSQNSL PFSKKSQEEV 
 
OXA-02  KDLMIVEAGR N-WILRAKTG WEG------- -----RMGWW VG--WVEWPT GSVFFALNID TPNRMDDLFK REAIVRAILR SIEALPPNPA VNSDAAR 
OXA-20  KDLMIVEAKR D-WILRAKTG WDG------- -----QMGWW VG--WVEWPT GPVFFALNID TPNRMEDLHK REAIARAILQ SVNALPPN-- ------- 
OXA-10  KEALVTEAAP E-YLVHSKTG FSGVG----- TESNPGVAWW VG--WVEKET EVYFFAFNMD IDN-ESKLPL RKSIPTKIME SEGIIGG--- ------- 
OXA-48  KQAMLTEANG D-YIIRAKTG YS-------- TRIEPKIGWW VG--WVELDD NVWFFAMNMD MPT-SDGLGL RQAITKEVLK QEKIIP---- ------- 
OXA-40  KKMLLIKEVN G-SKIYAKSG WGMG------ --VTPQVGWL TG-WVEQANG KKIPFSLNLE MKEG-MSGSI RNEITYKSLE NLGII----- ------- 
OXA-51  QSMLFIEEKN G-NKIYAKSG WGWD------ --VDPQVGWL TG-WVVQPQG NIVAFSLNLE MKKG-IPSSV RKEITYKSLE QLGIL----- ------- 
OXA-23  KNMLLLEESN G-YKIFGKTG WAMD------ --IKPQVGWL TG-WVEQPDG KIVAFALNME MRSE-MPASI RNELLMKSLK QLNII----- ------- 
OXA-58  KEMLYVERRG E-NRLYAKSG WGMA------ --VDPQVGWY VG-FVEKADG QVVAFALNMQ MKAG-DDIAL RKQLSLDVLD KLGVFHYL-- ------- 
OXA-50  RAMTLLESGP G-WELHGKTG WCFD------ --CTPELGWW VG-WVKR-NE RLYGFALNID MPGGEADIGK RVELGKASLK ALGILP---- ------- 
OXA-63  SDITITRANL H-ITLHGKTG LADSK----- NMTTEPIGWF VG--WLEEND NIYVFALNID NINS-DDLAK RINIVKESLK ALN-LLK--- ------- 
OXA-18  KAVVPHFEAG D-WDVQGKTG TGS--LSDAK GGKAP-IGWF IG-WATR-DD RRVVFAR-LT VGARKGEQPA GPAARDEFLN TLPALSENF- ------- 
OXA-42  ERIVESTTLA DGTVVHGKTG VSYPLLADGT RDWARGSGWF VG-WIVR-GN QTLVFAR-LT QDERKQPVSA GIRTREAFLR DLPRLLAAR- ------- 
OXA-30  IENMYLQDLD NSTKLYGKTG AGF------T ANRTLQNGWF EG-FIISKSG HKYVFVS-AL TGNLGSNLTS SIKAKKNAIT ILNTLNL--- ------- 
OXA-61  KEMIYLKNME N-LELFGKTG FNDG------ ----QKIAWI VGFVYLKDEN KYKAFALNLD IDKF-EDLYK REKILEKYLD ELVKKVKNDG ------- 
OXA-184 KKIILFK-ED KIQKIYAKTG FNDGIN---- ------LAWI VGFIESK--N KILSFALNVD IKNI-KNLKI REELLEKYIY SLN------- ------- 
Yellow highlighting -identical amongst all the amino acid sequences; green highlighting - conserved (even if variable) among all class D β-lactamases.  
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Figure 4.17 Neighbour joining tree of thirteen representative class D β-lactamases from 
all the different subgroups with OXA-61, the beta-lactamase of C. lari RM2100 (CLA0304)  
and the novel β-lactamase from P854 (OXA-184) 
 
 
 
 
 
 
 
The putative beta-lactamase of P854 is outlined in red (OXA-184). The Campylobacter beta-lactamase group is 
also illustrated. Diagram produced using MEGA 4.1. 
  
122 
 
Figure 4.18 PCR amplification of a 183bp fragment of blaOXA-184 from potential CjBla2 
producers using internal primers 1008 and 1009 
 
 
 
 
 
 
HL1, HyperLadder 1. 
Following PCR amplification of blaOXA-184 using the internal gene primers 1008 and 1009 (Materials and 
Methods, Table 2.9) 5 µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and electrophoresed at 
100 V for approximately 45 minutes. The amplimer obtained for P854 and all thirteen members of the CjBla2 
panel is 183bp in size; the amplimers from P270 (NCTC11168) were the same size but did not amplify as well. 
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As expected the primer pair was also able to amplify the blaOXA-193  gene from NCTC11168, 
although the amplification was less efficient due to mismatch primer binding.  
Two of the isolates, P1170 and P1177 did not produce an amplimer during PCR with the 
external primer pair (Figure 4.19). The remaining eleven isolates produced amplimers of the 
expected size. P843 a previously characterised ‘CjBla2 producer’ produced a slightly larger 
amplimer than expected.  
The amplimers produced (by the twelve strains) during PCR amplification with external 
primers were sent for DNA sequencing. These data revealed that the isolates can be divided 
into three distinct groups (Figure 4.20). ‘Group 1’ consisted of five isolates (P339, P853, 
P859, P862 and P1007) which contained blaOXA-184 in the same genomic context as P854. 
‘Group 2’ contained only P843, this isolate had a 108bp insertion in the non-coding region 
upstream of blaOXA-184 and a C  G point mutation in the non-coding region downstream of 
blaOXA-184. Six isolates (P852, P858, P888, P891, P1052 and P1058) made up ‘Group 3’. These 
isolates contained a C A point mutation in blaOXA-184 which resulted in an amino acid 
change from leucine to isoleucine at amino acid position 233/248. Isolates in this group also 
contained a point mutation in the non-coding region downstream of blaOXA-184 and seven 
point mutations in P854_1489. As this oxacillinase was distinct from OXA-184, its amino acid 
sequence was also submitted to the Lahey clinic and was assigned the number OXA-185.  
As the amplimer for isolates P1170 and P1177 could not be classified into any of these 
groups they could perhaps be considered to be a fourth group. DNA sequencing of the 
183bp internal PCR amplimer showed the sequence to be identical to blaOXA-184 but as this 
amplimer does not cover the region containing the CA (LeuIle) point mutation present  
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Figure 4.19 PCR amplification of a1670bp fragment including blaOXA-184 and the region up 
and downstream from potential CjBla2 producers using external primers 1010 and 1011 
 
 
 
 
 
 
HL1, HyperLadder 1. 
Following PCR amplification of blaOXA-184 using the external gene primers 1010 and 1011 (Materials and 
methods, Table 2.9) 5µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and electrophoresed at 
100 V for approximately 45 minutes. The amplimer obtained for P854 and isolates P339 to P1058  is 1670 bp in 
size; P843 produced an amplimer that was slightly larger than the expected 1670bp and P1170, P1177 and the 
negative control P270 (NCTC11168) did not produce any amplimers. 
  
 
 
Figure 4.20 Genetic variation of blaOXA-193  and the surrounding region in the CjBla2 panel isolates 
 
TTGATAAGAAAGCTTGATATAAAAGATTTAGCTTCTTGTATCAAGCTTTGTAAGCAAAACGTATTCACTCTTTGTAAAAATGATTACACAAAAGAACAAATTCATGCTTGGATTAATATAAACC
tttgtttatgaagaaaaaggccaaatcatatattttataagtataaatattagaagaaaaaacactcgatctttgctttattcatgcaaactatgctcatcaaggtttattaaagctttaTTGG
AATTTACTCTTAAAAGCTATCCTTATAGTGAAATTTACGCTTTTGCTAGTTTTAGTGTTAAAAATTTCTTTTTAAAAGCAGGATTTAAAATCATCAAAGAAAACattgttataatagaccaata
agaattaaaaaatttcttcatgaaaaaggaaataaaTTGAAAAAAATACTTTTACTTTTTAGTCTTTTTTACTCTTTTGCTTTGGCAAATGATAAATTAAAAGATTTTTTTAAAGACTACAATA
CAAGCGGAGTTTTTATAACTTTTGATGGAAAACATTATGCAAGTAATAATTTTAAAAGAGCTAAAGAACCTTTTTCTCCTGCTTCGACTTTTAAAATTTTTAATGCTTTAATTGCGCTTGATAA
TGGTGTAGTTAAAGATACAAAGGAAATTTTTTATCATTATAAGGGTGAAAAAGTATTTTTGCCCTCTTGGAAACAAGATGCTAGTTTAAGCTCAGCCATAAAACGCTCTCAAGTGCCTGCTTTT
AAAGAATTGGCAAGAAAAATAGGACTTAAAACCATGCAAGAAAGCTTAAATAAACTTTCCTATGGAAATACAAAAATTTCAAAAATCGATACCTTTTGGTTGGATAATTCTTTACAAATTTCTG
CAAAAAATCAAGCTGATTTGCTTTTTAAACTTTCACAAAATTCTTTACCTTTTTCCAAGAAAAGTCAAGAAGAAGTTAAAAAAATTATTCTTTTTAAAGAAGATAAAATCCAAAAAATTTATGC
TAAAACAGGTTTTAATGATGGTATAAATTTGGCTTGGATTGTTGGATTTATAGAGAGTAAAAACAAAATTTTATCTTTTGCCTTAAATGTTGATATAAAGAACATTAAAAATCTTAAAATAAGA
GAAGAATTGCTAGAAAAATATATTTATTCTTTAAACTAAttaagcttttataagaaattgtttaatgatcaaaatatcgcaatataatagtttttaagaaaaatagatataaaatactgattat
attaaatttatttaagagaaatgttagatgtccatggtaacttatgctttttagcacttgccttggttttgttgtcttttaataaaattaaaacagcttatttattttttataattagtgtatt
ttttgcttattattttaagataattaatatcacttttatagtaattaatattattgcatttgggTTGGCTTTATATTATAGATATAAAAAATCACTTATTTTAGAATTGATATTGTTTGTTTTT
TGTATAGGCTTATTTTTACATTTTATACCAGGAATTAATAATATAAAAGTTTTAGATAAGGTTTATGCAAGTGAAAATAGTGCACCATTTACTTTATACTTTAATTTTGATAAACCTATAGGTG
TATTTATATTGTTTTTATTGTTACCTGCTTTATTTACAAATAAAAATTATGTAAAAGCTTCATTACTCAAATGGATTTTATTAATTTTAAGTCCTTTATTTTTATTATCTATACCTTGGTATT
TTAATGTTTTGAAATTTGAATTTAGCTTACCTTGGTGGTTACCCTATTTTTTATTTTCTAATGTTTTATTGGTAGCTTTGGTTGAAGAAGTGTATTTTAGAGGTTATCTTCAACAAAGACTCTC
TCAAATTTTAAATCCAAATTTTGCTTTATTGATAGCAAGTATAGCTTTTGGATTGATTCATTATAGAAGTGGAATTTTAATGATTATTTTTGCGAGTTTAGCTGGAATTATATATGGATTAGCA
TATAAATATAACAAAAGTTTATGGATAAGTGTATTATTTCATTGTGGATTAAATTTAATTCATTTGATATTTTTTACTTATCCTTTTTATTTAAAATCATAA 
Group Isolates Description Point Mutations 
 1:P854 - like P854, P339, P853, P859, P862, 
P1007 
Identical to P854. None 
2: P843 P843 Has a 108bp insertion in the intergenic region upstream of P854_1490 
and a point mutation in the intergenic region downstream of 
P854_1490. 
1. CG 
3: P854_1490 Leu Ile 
variants 
P852, P858, P888, P891, P1052, 
P1058 
Has a point mutation in P854_1490 that leads to a coding change from 
Leucine to Isoleucine, has a point mutation in the intergenic region 
downstream of P854_1490 and seven point mutations in P854_1489. 
2.CA         3.TC         4.CT        
5.CT         6.AG        7.GA      
8.AG             9.GA         10.AG  
Lowercase text indicates non-coding intergenic regions of sequence; uppercase text represents coding sequence (with the exception of the labeled ‘insertion’ highlighted in green).
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in Group 3 isolates it is not possible to determine whether they will contain blaOXA-184 or 
blaOXA-185. 
The three groups are unlikely to be the result of clonal expansion as examples of both 
Group 1 and Group 3 were found on two separate farms and were of at least three 
different flaA types (Figure 4.21). As there has only been members of Group 2 identified 
such conclusions cannot be drawn. 
4.10 Cloning the blaOXA-184  gene 
In order to determine whether blaOXA-184 encodes a functional beta-lactamase, the gene 
was cloned into a plasmid vector which was transformed into Escherichia coli α-Select 
cells (a type of DH5α cells purchased from BioLine) in order to allow expression of the 
gene in a susceptible host background. This strategy was chosen as Campylobacter have 
been shown to be naturally resistant to some beta-lactams (in particular the 
cephalosporins) and so the full substrate profile of beta-lactamase cannot be determined 
within this background (Pumbwe and Piddock 2002; Pumbwe, Randall et al. 2004; Guo, 
Lin et al. 2010).  
The blaOXA-184 gene was amplified using primers designed to insert an EcoRI restriction site 
before the start codon of the gene and an XbaI restriction site downstream of the blaOXA-
184 gene (Figure 4.22).  
The PCR amplimer was digested with EcoRI and XbaI to create ‘sticky ends’ for cloning 
(Figure 4.23). A suitable pUC based vector, pHSG396, with a chloramphenicol resistance 
marker (cat) was selected for use and linearised with EcoRI and XbaI (Figure 4.23). The  
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Figure 4.21 Neighbour joining tree of CjBla2 producers based on their flaA gene 
 
 
 
 
 
 
Red circles, Group 1 (OXA-184). Yellow circles, Group 3 (OXA-185). Green circle, Group 2 (OXA-184, but 
contains a 108 bp insertion upstream of blaOXA-184). Blue circle, Group 4 (amplimer produced during internal 
blaOXA-184, no amplimer produced during external blaOXA-184 PCR). 
Number in parentheses relates to the isolate’s flaA type. 
Farm number represents the farm from which the bacteria were originally isolated.  
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Figure 4.22 Gradient PCR amplification of an 879bp fragment covering blaOXA-184 and 
introducing an EcoRI restriction site upstream of the start codon and an XbaI 
restriction site downstream of the gene 
 
 
 
 
 
HL1, HyperLadder 1. 
Following gradient PCR amplification of blaOXA-184  using the cloning primers 1014 and 1014 (Materials and 
Methods, Table2.10) 5µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and electrophoresed 
at 100V for approximately 45 minutes. Annealing temperatures of 42°C to 50°C produced good amplimers 
of the expected size (879bp). Annealing temperatures of 53°C or higher yielded little to no amplimer.  
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Figure 4.23 Restriction enzyme digestion of PCR amplimer and pHSG398 vector in 
preparation for ligation and cloning 
 
 
Lane Description 
1 PCR amplimer digested with EcoRI and XbaI 
2 Undigested PCR product (control) 
3 Linearised vector pHSG398 digested with EcoRI and XbaI 
4 Undigested vector pHSG398 (control) 
 
The 879bp amplimer of blaOXA-184 (produced by PCR amplification with cloning primers 1012 and 1014) was 
digested with EcoRI and XbaI for one hour, 5 µl of digested amplimer and 5 µl of the undigested control 
were loaded onto a 1% agarose gel and electrophoresed at 100V for approximately 45 minutes. 
Simultaneously the vector pHSG298 was also digested for 1 hour with EcoRI and XbaI, 5 µl of digested 
plasmid and 5 µl of the undigested control were loaded onto a 1% agarose gel and electrophoresed at 100V 
for approximately 45 minutes. Both digested and un-digested amplimer are approximately 879bp. Digested 
plasmid has been linearised and is approximately 2.227Kb in size, undigested plasmid not linearised and is 
running in two circular forms, one at approximately 3.5 Kb in size (open circular form), one at just less than 
1.5 Kb (covalently closed circular form).  
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blaOXA-184 insert was ligated into the vector which was then transformed into α-Select 
cells.  
When the previously characterised blaOXA-193 was expressed in E. coli cells it was noted by 
the authors that the Campylobacter promoter sequence was poorly recognised resulting 
in weak transcription (Alfredson and Korolik 2005). To avoid the problem of poor 
transcription only the blaOXA-184 gene was cloned not the promoter region or ribosome 
binding site, in order to allow the gene to be under the control of the lacZ promoter and 
ribosome binding site on the plasmid.  
Blue-white screening was used to identify candidate colonies containing inserted DNA. 
Nine white colonies were sub-cultured and then subjected to PCR amplification for blaOXA-
184, all nine produced amplimers of the expected size (Figure 4.24). 
Plasmids were isolated from three candidate colonies and were shown to be larger than 
the original pHSG398 (Figure 4.25).  
4.11 Checking the putative α-Select pHSG398 (blaOXA-184) mutants  
The MICs of a range of beta-lactams in E. coli α-Select cells and in three candidate α-
Select pHSG398(blaOXA-184) mutants were obtained. When the MIC values obtained for the 
mutant containing pHSG398(blaOXA-184) were compared to those obtained for the parental 
strain (α-Select) there was no significant difference between them (Table 4.5). 
RNA was isolated from E. coli α-Select cells and from a putative α-Select pHSG398(blaOXA-
184) mutant and used to create cDNA. A control rtPCR for 16S (a gene that should be 
ubiquitously expressed) and a PCR for blaOXA-184 were performed using cDNA as template.  
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Figure 4.24 PCR amplification of an 879bp fragment covering blaOXA-184 from candidate 
colonies which may contain pHSG398 plus the blaOXA-184 insert 
 
 
 
 
HL1, HyperLaddder1; C1-C9, candidate 1-9 
Following PCR amplification of blaOXA-184  using the cloning primers 1012 and 1014 (Materials and methods, 
Table 2.10) 5 µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and electrophoresed at 100 V 
for approximately 45 minutes. The amplimer obtained for P854 and all nine candidate colonies is 879bp  in 
size; the negative controls DH5α and DH5α + pHSG398 did not produce any amplimers. 
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Figure 4.25 Plasmid isolation from three colonies which may contain pHSG398(blaOXA-
184 ) 
 
 
 
 
Lane Description 
1 Plasmid isolated form candidate 1 
2 Plasmid isolated form candidate 2 
3 Plasmid isolated form candidate 7 
4 No plasmid isolated from DH5α cells 
5 Plasmid isolated from DH5α cells containing pHSG398 
 
HL1, HyperLadder1 
Following isolation of plasmid DNA, 5 µl of each plasmid preparation was loaded on to a 1% (w/v) agarose 
gel and electrophoresed at 100V for approximately 45 minutes. The plasmid obtained for the three 
candidate colonies is running in three forms ( approximately 10Kb, 3Kb and 2Kb) as is the plasmid obtained 
from DH5α cells + pHSG398 (approximately 10Kb, 4Kb and 1.5Kb). As the plasmids have not been linearised 
their sizes cannot be accurately estimated although the plasmid isolated from the candidates is clearly 
different from the pHSG398. 
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Table 4.5 Minimum inhibitory concentration of a range of beta-lactams for putative 
CjBla2 producers 
 
Strain 
Minimum Inhibitory Concentration (MIC) (µg/ml) 
PEN AMP  OXA CEF CFX CTX FOX 
α-Select 16 1 256 4 4 0.125 16 
Candidate 1 16 2 256 4 4 0.125 8 
Candidate 1 16 1 256 4 4 0.125 16 
Candidate 7 16 1 256 4 4 0.125 16 
 
 
 
PEN, penicillin; AMP, ampicillin; OXA, oxacillin; CEF, cephalothin; CFX, cefuroxime; CTX, cefotaxime; FOX, 
cefoxitin. 
MICs are the modal value of at least three biological repeats. MIC values obtained for the parental strain (α-
Select) are shown in bold. Candidates 1, 2 and 7 are all putative α-Select pHSG398(blaOXA-184 ) mutants. 
No MIC values obtained for the candidates are significantly different (≥ two doubling dilutions) to those 
obtained for the parental strain. 
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Amplimers from the 16S PCR were obtained from all three replicates of α-Select cells and 
from all three replicates of a putative α-Select pHSG398(blaOXA-184) mutant, therefore  
validating the RNA extraction and cDNA synthesis procedures (Figure 4.26). Amplimers 
were also obtained following blaOXA-184 PCR from all three replicates of α-Select cells and 
from all three replicates of a putative α-Select pHSG398(blaOXA-184) mutant (Figure 4.27). 
4.12 Inactivation of blaOXA-184 in P854 
A strategy was devised to inactivate the blaOXA-184 gene in P854 based on a modified 
Datsenko and Wanner protocol (Datsenko and Wanner 2000). The aph gene was 
amplified by PCR using primers that inserted a 40 bp region of homology to blaOXA-184 
both up and downstream of aph (Figure 4.28). This PCR amplimer was then used to 
insertionally inactivate blaOXA-184 in P854 by natural transformation and homologous 
recombination. No blaOXA-184 mutants were obtained during preliminary experiments. 
4.13 Discussion 
The oxacillinase of C. jejuni NCTC11168 (product of the cj0299 gene) was submitted to 
the Lahey clinic and was assigned the number OXA-193, this has helped in the 
clarification of Campylobacter oxacillinases. 
Work in this laboratory identified two poultry isolates of C. jejuni, P843 and P854, that 
produced no amplimers for blaOXA-193 but produced a beta-lactamase that has a different 
isoelectric point and molecular mass to that of the previously characterised OXA-61 and 
OXA-193 oxacillinases (Alfredson and Korolik 2005; Griggs, Peake et al. 2009). The novel 
beta-lactamase was termed CjBla2 and preliminary mass spectrometry experiments to 
identify the protein suggested that PurU (annotated as a formyltetrahydrofolate  
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Figure 4.26 rtPCR of 16S from α-Select cDNA and cDNA obtained from a putative α-
Select pHSG398(blaOXA-193 ) mutant 
 
 
 
 
 
 
HL1, HyperLaddder1 
1. α-select cDNA 5. putative α-select pHSG398(blaOXA-184 ) mutant cDNA 
2. α-select cDNA 6. putative α-select pHSG398(blaOXA-184 ) mutant cDNA 
3. α-select cDNA 7. Positive control (α-select DNA) 
4. putative α-select pHSG398(blaOXA-184) mutant cDNA 8. Negative control (water) 
 
Following PCR amplification of 16s, 5 µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and 
electrophoresed at 100 V for approximately 45 minutes. Correct sized amplimers (541 bp) were obtained 
for all samples and the positive control. The negative control did not produce any amplimers. 
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Figure 4.27 rtPCR of blaOXA-184 from α-Select cDNA and cDNA obtained from a putative 
α-Select pHSG398(blaOXA-193) mutant 
 
 
 
 
 
 
HL1, HyperLaddder1 
 
1. putative α-select pHSG398(blaOXA-184 ) mutant cDNA 6. α-select cDNA 
2. putative α-select pHSG398(blaOXA-184 ) mutant cDNA 7. Positive control (P854  DNA) 
3. putative α-select pHSG398(blaOXA-184 ) mutant cDNA 8. Negative control (α-Select DNA) 
4. α-select cDNA 9. Negative control (water) 
5. α-select cDNA  
 
Following PCR amplification of blaOXA-184, 5 µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel 
and electrophoresed at 100 V for approximately 45 minutes. Correct sized amplimers (183 bp) were 
obtained for all replicates of a putative α-select pHSG398(blaOXA-184) mutant and the positive control. The 
negative controls and the three replicates of α-select cDNA did not produce any amplimers. 
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Figure 4.28 Gradient PCR amplification of aph with primers that introduce 40bp of 
homology to blaOXA-184 at either end of the amplimer 
 
 
 
 
 
HL1, HyperLadder 1. 
Following gradient PCR amplification of blaOXA-184  using the cloning primers 1051 and 1052 (Materials and 
Methods, Table2.13) 5 µl of each PCR reaction was loaded on to a 1% (w/v) agarose gel and electrophoresed at 
100V for approximately 45 minutes. Annealing temperatures of 42°C to 53°C produced good amplimers of the 
expected size (1.574 Kb).   
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deformylase), the product of the cj0790 gene of C. jejuni NCTC11168, was the most similar 
to CjBla2 (Griggs, Peake et al. 2009). A PurU mutant was constructed but when tested for 
beta-lactamase production, it was found to have detectable beta-lactamase activity 
comparable to that of the parental strain P854, suggesting that cj0790 does not encode 
CjBla2. Confirmation that CjBla2 of P843 and P854 was unlikely to be the product of a 
mutated blaOXA-193  gene was obtained as PCR with combinations of four blaOXA-193 primers, 
gave no amplimers and  a labelled blaOXA-193  DNA probe was unable to hybridise to digested 
genomic DNA from P843 and P854 during Southern blotting.   
DNA sequencing of the P854 genome and subsequent assembly and annotation resulted in 
the identification of four putative beta-lactamase genes. P854_1490 was identified as the 
most probable candidate gene to encode CjBla2 given that (unlike the other three genes) no 
homologues could be found in other sequenced Campylobacter genome. When BLAST 
searching the closest hit with the predicted P854_1490 protein was with OXA-193. However, 
the two proteins are not very closely related as they share only 64% identity with one 
another (just one amino acid substitution denotes a novel oxacillinase). The putative 
P854_1490 is likely to be an oxacillinase (Ambler Class D beta-lactamase) as it contains all 
the highly conserved and identically conserved motifs typical of an oxacillinase (Poirel, Naas 
et al. 2010) and clusters with other oxacillinases (forming a group with oxacillinases of 
Campylobacter origin). The amino acid sequence of P854_1490 was accepted by the Lahey 
clinic to be a novel beta-lactamase and was assigned the number OXA-184. 
Interestingly, blaOXA-184 was demonstrated to be in a very similar genomic context to blaOXA-
193. A mod operon (encoding a molybdenum transport system) was present downstream of 
the gene, as is the case with blaOXA-193 in C. jejuni NCTC11168. Upstream however, the pan 
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operon (involved in pantothenate biosynthesis), is present in NCTC11168, but not present 
upstream of blaOXA-184 in P854. As P854 lacks both the pan operon and blaOXA-193 this is why 
blaOXA-193 PCR with primers from panB and blaOXA-193 failed to produce amplimers for P854. 
As the genes flanking blaOXA-184 (including a pseudo-gene immediately upstream) are not 
present in other sequenced genomes of C. jejuni it is possible that these genes were 
acquired at the same time as the blaOXA-184 gene. Indeed, a similarity can be drawn between 
the genomic context of blaOXA-184 and that of the CLA0304 putative beta-lactamase gene of C. 
lari RM2100 as both are followed downstream by a metal dependent membrane permease, 
suggesting that perhaps this region was acquired by P854 from an unknown C. lari genome.  
The ‘CjBla2’ phenotype, (i.e. ampicillin resistance, lacking amplimers following blaOXA-193 PCR, 
inability of genomic DNA to hybridise to a blaOXA-193 labelled probe and beta-lactamase 
detection) was found for 13 other Campylobacter poultry isolates. As the fifteen isolates 
were collected from three separate farms during 2001-2002 and represent seven flaA types 
the gene(s) responsible for CjBla2 are disseminated in the Campylobacter population. 
Seven of the 15 isolates in the ‘CjBla2’ group (including P854) contained identical genes to 
blaOXA-184 although one, P843, contained a 108bp insertion in the upstream intergenic region. 
Six of the other further isolates contained a putative oxacillinase with a single amino acid 
substitution (LeuIle) difference to that encoded by blaOXA-184. All six of these isolates also 
contained numerous conserved point mutations up and down stream of the oxacillinase 
gene when compared to the P854 genome. The remaining two isolates from the 15 isolate 
‘CjBla2’ group produced an amplimer during blaOXA-184 PCR with internal gene primers, but 
upon PCR with primers external to the oxacillinase gene did not produce an amplimer. As the 
internal PCR did not cover the site encoding the LeuIle variation, it is unclear whether 
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these two isolates encode (i) a protein identical to OXA-184, (ii) a protein identical to OXA-
185 or (iii) another oxacillinase. When a dendogram was produced based on the flaA type of 
the isolates of the group they do not cluster according to which oxacillinase they encode, 
suggesting that these genotypes are not simply the result of clonal expansion.  
Campylobacter have innate resistance to cephalosporin type beta-lactamases, and some 
resistance to penicillin type beta-lactamases due to the CmeABC efflux pump (Chapter 3) 
(Guo, Lin et al. 2010). In order to assess the full substrate profile of the OXA-184 oxacillinase 
the blaOXA-184 gene was cloned into a fully susceptible E. coli background (α-Select) using a 
plasmid vector suitable for expression under the control of the lac promoter. The MICs of a 
range of beta-lactams for the E. coli transformants were then determined, when compared 
to those of the parental strain no significant difference could be seen. RNA was extracted 
from an E. coli blaOXA-184 containing mutant and used to generate cDNA which was the 
template for both a 16S rtPCR and a blaOXA-184 rtPCR. Amplimers were produced during 16S 
rtPCR confirming that RNA isolation and cDNA synthesis were successful. Amplimers were 
also obtained following blaOXA-184 rtPCR confirming that the E. coli mutant is transcribing the 
blaOXA-184 gene. The blaOXA-184 gene which in the mutants is under the control of the inducible 
lacZ promoter has been shown to be transcribed. As the Campylobacter ribosome binding 
site has not been cloned with the coding sequence of the gene, expression will rely on the 
lacZ ribosome binding site and so if the gene has been inserted out of frame with the lacZ 
gene no functional protein may be being translated. It is also possible that a LacZ-OXA-184 
fusion protein is being generated however the possible production of a fusion protein may 
not eliminate the potential beta-lactamase activity of the protein as there are instances 
reported where functional beta-lactamase fusion proteins have been created successfully 
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(Lattemann, Maurer et al. 2000). Further experiments will need to be undertaken to 
determine whether the lack of beta-lactam resistance in the E. coli mutant is due to the 
mutant not translating a functional OXA-184 or whether the blaOXA-184 does not encode a 
functional oxacillinase. 
An attempt was made to inactivate blaOXA-184 in P854 using natural transformation but 
preliminary experiments were not successful as blaOXA-184 mutants were not obtained. It is 
possible that the 40bp of homology the transforming DNA had with the target gene was 
insufficient to allow homologous recombination despite being within the range suggested by 
Datsenko and Wanner (Datsenko and Wanner 2000). Techniques that have successfully 
allowed homologous recombination in Campylobacter in the past (such as allelic 
replacement) have much longer stretches of homologous DNA (in excess of 200bp) 
(Karlyshev and Wren 2005). The method developed here could be improved by using primers 
that create much longer stretches of homologous DNA during PCR. 
Two novel, putative oxacillinases have been identified from Campylobacter and have been 
shown to be disseminated in Campylobacter isolated from poultry, further work needs to be 
performed to characterise these enzymes phenotypically. 
4.14 Further Work 
 Inactivate the blaOXA-184/5 gene in P854/P852 and characterise the mutant phenotype 
MICs of beta-lactam antibiotics and express both blaOXA-184 and blaOXA-185 in a beta-
lactam susceptible background to determine the activity of the oxacillinases. 
 Characterise the OXA-184 and OXA-185 enzymes in terms of their molecular mass and 
isoelectric points. 
 Screen further isolates for the blaOXA-184 and blaOXA-185  genes. 
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Chapter 5 – Results and Discussion 
Is beta-lactam resistance transferrable between Campylobacter 
isolates? 
5.1 Background 
The most important mechanism of beta-lactam resistance in Gram negative bacteria is the 
production of beta-lactamases, enzymes that are capable of hydrolysing the beta-lactam ring 
of beta-lactam antibiotics rendering them ineffective (Medeiros 1997; Bush and Mobashery 
1998; Bush 2001). Following the introduction of penicillin in the 1960s, plasmid mediated 
beta-lactam resistance became a problem; by 1968 17% of surgical patients in a London 
hospital had ampicillin resistant enterococci in their faeces and conjugation experiments 
using E. coli K12 revealed that the majority of isolates could transfer resistance (Datta 1969).  
Although Campylobacter containing plasmids have been described containing resistance 
genes to tetracycline, chloramphenicol, kanamycin and streptomycin (Taylor, Gradis et al. 
1981; Tenover and Elvrum 1988; Wang and Taylor 1990; Gibreel, Skold et al. 2004), plasmid 
encoded beta-lactam resistance in Campylobacter have not been described. 
5.2 Aims and Hypotheses 
It was hypothesised that resistance to ampicillin is transferred alongside tetracycline 
resistance between Campylobacter isolates.  
The aims of this work were to:  
a) Determine whether beta-lactam resistance could be transferred between isolates of 
Campylobacter jejuni and/or the closely related Campylobacter coli. 
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b) If transfer does occur, determine the gene(s) responsible and the mechanism of 
transfer. 
5.3 Creation and selection of ampicillin resistant transconjugant 
Campylobacter 
During a study on poultry isolates by this laboratory (Piddock, Griggs et al. 2008) data from 
unpublished experiments suggested that during conjugation resistance to ampicillin could be 
co-transferred with tetracycline resistance. In this PhD project these experiments were 
repeated to confirm these data.  
Two isolates of C. coli, P1131 and P1931 were selected for use as ‘donor’ strains in these 
experiments. These isolates were resistant to tetracycline (MIC = 256 µg/ml and 128 µg/ml 
respectively) and ampicillin (MIC = 128 µg/ml and 256 µg/ml respectively), were susceptible 
to kanamycin (MIC = 16 µg/ml) (see Table 5.1a) and had previously been shown to contain 
transferrable tetracycline resistance. Although the two isolates of C. coli had the same 
phenotype, they were isolated from different farms, during different Defra funded studies 
and were isolated three years apart (see Table 5.1b). 
P1131 and P1931 were conjugated with an ampicillin, tetracycline susceptible strain of 
NCTC11828 which had been manipulated to contain a chromosomal aph cassette making it 
resistant to kanamycin (P1983). Transconjugants were selected by plating the conjugation 
mixture onto Mueller Hinton agar containing 10μg/ml tetracycline and 50μg/ml of 
kanamycin. A control was set up using the same recipient strain (P1983) but with the well 
characterised Campylobacter strain 81-176 (P1984) that is ampicillin and kanamycin 
sensitive and contains the transferable pTet plasmid (Batchelor, Pearson et al. 2004).   
 
 
Table 5.1a Known minimum inhibitory concentrations of antibiotics for isolates P1131 and P1931  
 
  
 
 
Table 5.1b Information about isolates P1131 and P1931  
 
Isolate Species Defra Study Date Isolated Origin Treatment Phase Sample type flaA type Reference 
P1131 C. coli OZO501 11/11/2002 Farm 6 
2 weeks post-treatment 
with a fluoroquinolone 
Chicken 
faeces 
flaA18 
(Humphrey, Jorgensen et 
al. 2005) 
P1931 C. coli VM0220 02/11/2005 Lang 012 
4 weeks post-treatment 
with chlortetracycline 
Chicken 
faeces 
flaA66 
(Piddock, Griggs et al. 
2008) 
  
Isolate 
Minimum Inhibitory Concentration (µg/ml) 
Ampicillin Tetracycline Kanamycin Ciprofloxacin Nalidixic Acid Trimethoprim Chloramphenicol Erythromycin 
P1131 128 256 16 32 128 512 4 8 
P1931 256 128 16 0.25 16 512 2 4 
1
4
4 
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Putative transconjugants were achieved from all experiments. Conjugation frequencies were 
calculated to be 1.2x10-8 for the conjugation of P1131 X P1983 and 4.03x10-7 for the 
conjugation of P1931 X P1983. Once confirmed to be Campylobacter by microscopy and 
culture a representative isolate from each experiment was assigned a laboratory number; 
P1131 X P1983 = P2241; P1931 X P1983 = P2244 and P1984 X P1983 = P2238 (Materials and 
Methods Table 2.3) and retained for further study. 
5.4 Characterisation of transconjugants 
5.4.1 Presence of plasmid DNA 
The donors and transconjugants contained plasmids of a similar size which can be estimated 
to be approximately 45kb as the sequenced pTet plasmid (present in P1984 and P2238) is 
45.2Kb in size (Batchelor, Pearson et al. 2004); the recipient contained no plasmids (Figure 
5.1). As plasmid isolation with the QIAprep kit yielded low concentrations of plasmid DNA 
(approximately 20ng/µl) and the DNA was contaminated with genomic DNA (Figure 5.1), 
other methods of plasmid isolation were explored in order to obtain higher quantities of 
pure plasmid DNA for further experimentation.  
Promega’s PureYield™ Plasmid Miniprep System (Figure 5.2), the alkaline lysis method of 
Kado and Liu (Kado and Liu 1981) (Figure 5.3), and alkaline lysis by the method of Birnboim 
and Doly (Birnboim and Doly 1979) followed by purification by caesium chloride density 
gradient centrifugation (Figure 5.4) were compared. All methods resulted in the isolation of 
plasmid DNA contaminated with genomic DNA. 
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Figure 5.1 Isolation of plasmid DNA using QIAprep kit (Qiagen) 
 
 
 
 
 
Lane Isolate / Strain Donor / Recipient / Transconjugant Plasmid DNA? 
1 P1984 Donor Present 
2 P1983 Recipient Absent 
3 P2238 Transconjugant Present 
4 P1131 Donor Present 
5 P1983 Recipient Absent 
6 P2241 Transconjugant Present 
7 P1931 Donor Present 
8 P1983 Recipient Absent 
9 P2244 Transconjugant Present 
10 P270 (NCTC11168) Plasmid-free control Absent 
 
HL1, HyperLadder 1 
 +/- indicates presence or absence of plasmid DNA. 
Five microlitres of plasmid DNA isolated from donors recipients and transconjugants was 
electrophoresed on a 0.8% (w/v) agarose gel at 80 V for approximately four hours. 
Contaminating genomic DNA is present in all samples. 
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Figure 5.2 Isolation of plasmid DNA using PureYield™ Plasmid Miniprep System 
(Promega) 
 
 
 
 
HL1, HyperLadder 1 
Five microlitres of plasmid DNA isolated from the transconjugants P2238, P2241 and P2244 
was electrophoresed on a 0.8% (w/v) agarose gel at 80 V for approximately four hours. 
Contaminating genomic DNA is present in all samples. 
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Figure 5.3 Isolation of plasmid DNA using the alkaline lysis method of Kado and Liu  
(Kado and Liu 1981) 
 
 
 
 
 
 
HL1, HyperLadder 1 
Five microlitres of plasmid DNA isolated from the plasmid free control P270 (NCTC11168) 
and the transconjugants P2238, P2241 and P2244 was electrophoresed on a 0.8% (w/v) 
agarose gel at 80 V for approximately four hours. 
Contaminating genomic DNA is present in all samples. 
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Figure 5.4 Isolation of plasmid DNA by alkaline lysis using the method of Birnboim and 
Doly followed by purification by caesium chloride density gradient centrifugation 
(Birnboim and Doly 1979) 
 
 
 
Lane Plasmid DNA Sample 
1 P2241 before CsCl    
2 P2244 before CsCl 
3 P2241 following CsCl density gradient centrifugation (fraction1)  
4 P2241 following CsCl density gradient centrifugation (fraction 2) 
5 P2241 following CsCl density gradient centrifugation (fraction 3) 
6 P2244 following CsCl density gradient centrifugation (fraction 1) 
7 P2244 following CsCl density gradient centrifugation (fraction 2) 
8 P2241 following CsCl density gradient centrifugation  and further purification (fraction 1) 
9 P2241 following CsCl density gradient centrifugation  and further purification (fraction 2) 
10 P2241 following CsCl density gradient centrifugation  and further purification (fraction 3) 
11 P2244 following CsCl density gradient centrifugation  and further purification (fraction 1) 
12 P2244 following CsCl density gradient centrifugation  and further purification (fraction 2) 
 
HL1, HyperLadder 1 
Five microlitres of plasmid DNA isolated from the transconjugants P2241 and P2244 was 
electrophoresed on a 0.8% (w/v) agarose gel at 80 V for approximately four hours.    
Contaminating genomic DNA is present in all samples. 
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QIAGEN’s large construct kit was the only method by which a large volume (1 ml) of 
concentrated (approximately 1 µg/ml), pure plasmid DNA could be isolated (Figure 5.5). 
Plasmid DNA was isolated from P2241 and P2244. From here on these plasmids are referred 
to as pBla1 and pBla2, respectively. Five micro litre aliquots from the 15ml of each of the 
plasmid samples eluted from the QIAGEN column was retained and electrophoresed at the 
same time as a 5 µl aliquot of the plasmid DNA samples once they had been concentrated by 
ethanol precipitation (Figure 5.5).  DNA was clearly less concentrated when first eluted. 
Following ethanol precipitation samples were more concentrated and linearised plasmid 
DNA was seen.  Three bands were seen for pBla1 and two for pBla2 (excluding linearised 
DNA). It cannot be determined at this stage whether the numerous bands in each samples 
represent different forms of one plasmid (closed circular, open circular and supercoiled) or 
whether the samples each contain more than one plasmid. All of the bands are likely to be 
plasmid DNA (not contaminating genomic DNA) as QIAGENs Large Construct Kit contains an 
exonuclease digestion step to remove genomic DNA as well as any nicked or damaged 
circular DNA. 
5.4.2 Plasmid mediated antibiotic resistance  
Minimum inhibitory concentrations (MICs) of a range of beta-lactam (Table 5.2) and non-
beta-lactam (Table 5.3) antibiotics for donor, recipient and transconjugant strains were 
determined using the agar doubling-dilution method recommended by the CLSI 
Campylobacter Working Group (McDermott, Bodeis et al. 2004).  
Both donors (P1131 and P1931) were resistant to tetracycline (MIC = 256 μg/ml and 128 
µg/ml) and sensitive to kanamycin (MIC = 16 μg/ml); the recipient was sensitive to  
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Figure 5.5 Isolation of plasmid DNA using Large construct kit (Qiagen) 
 
 
 
 
 
 
Lane Sample 
1 pBla1 following elution from column 
2 pBla2 following elution from column 
3 pBla1 following concentration by ethanol precipitation 
4 pBla2 following concentration by ethanol precipitation 
 
 
 
HL1, HyperLadder 1 
Five microlitres of plasmid DNA isolated from the transconjugants, P2241 (pBla1) and P2244 
(pBla2) was electrophoresed on a 0.8% (w/v) agarose gel at 80 V for approximately four 
hours. 
Linearised plasmid DNA can be seen in the pBla1 preparation following ethanol precipitation 
that wasn’t present before ethanol precipitation (Lanes 1 and 3). 
No contaminating genomic DNA is present in any of the samples. 
 
  
 
 
Table 5.2 Minimum inhibitory concentration (MIC) of beta-lactam antibiotics for donor, recipient and transconjugant strains 
 
Laboratory Code Description 
MIC (μg/ml) 
PEN AMP OXA CEF CXM CTX FOX MER 
P1131 pBla1 donor 128 128 512 1024 256 16 256 0.25 
P1931 pBla2 donor 256 256 512 256 128 4 128 0.12 
P1983 Conjugation recipient 16 4 128 256 128 4 128 0.06 
P2241 pBla1 transconjugant 128 128 512 1024 256 8 256 0.12 
P2244 pBla2 transconjugant 128 256 256 256 128 8 128 0.12 
 
 
PEN, penicillin; AMP, ampicillin; OXA, oxacillin; CEF, cephalothin; CXM, cefuroxime, CTM, cefotaxime; CXM, cefoxitin; MER,  meropenem. 
Bold, red text indicates a significant increase (two or more doubling dilutions) in MIC of an antibiotic in the transconjugants when 
compared to the recipient. Values given are the median value of at least three biological replicates. 
 
  
1
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Table 5.3 Minimum inhibitory concentration (MIC) of non beta-lactam antibiotics for donor, recipient and transconjugant strains 
 
Laboratory 
code 
Description 
MIC (μg/ml) 
KAN TET NAL CHL CIP ERY STR TRM ETB ACO SDS TRIC 
P1131 pBla1 donor 16 256 128 4 32 8 1 512 4 128 256 32 
P1931 pBla2 donor 16 128 16 2 0.25 4 1 512 4 64 256 32 
P1983 Conjugation recipient 256 0.25 8 2 0.12 8 1 256 2 32 256 32 
P2241 pBla1 transconjugant 256 256 128 4 32 8 1 512 4 64 256 32 
P2244 pBla2 transconjugant 256 128 8 2 0.25 8 1 512 2 32 256 32 
 
 
KAN, kanamycin; TET, tetracycline; NAL, nalidixic acid; CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; STR, streptomycin; 
TRM, trimethoprim; ETB, ethidium bromide; ACO, acridine orange; SDS, sodium dodecyl sulphate; TRIC, triclosan. 
Bold, red text indicates a significant increase (two or more doubling dilutions) in MIC of an antibiotic in the transconjugants when 
compared to the recipient. Values given are the median value of at least three biological replicates. 
  
1
5
3 
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tetracycline (MIC = 0.25 µg/ml) and resistant to kanamycin (MIC = 256 µg/ml). All 
transconjugants were resistant to both agents. P1131 and P1931 were resistant to ampicillin 
(MIC = 128 μg/ml and MIC = 256 µg/ml) whereas the recipient was susceptible to the 
antimicrobial (MIC = 4 µg/ml).  The transconjugants P2241 and P2244 have similar levels of 
resistance as their respective donor strains for ampicillin, penicillin and in the case of P2241 
oxacillin and cephalothin, the MICs of which are all more than two doubling dilutions higher 
than those of the recipient (differences of two or more doubling dilutions are considered to 
be significant) suggesting that resistance to these agents is plasmid associated. 
The MICs of nalidixic acid and ciprofloxacin suggested that plasmid pBla1 may contain 
resistance determinant(s) to these agents as the MIC of nalidixic acid and ciprofloxacin in 
P2241 were four and eight doubling dilutions higher than in the recipient strain; this takes 
the MICs to a similar level as found in the donor strain, P1131. 
5.4.3 Beta-lactamase activity 
Beta-lactamase activity can be determined by use of a chromogenic cephalosporin, 
nitrocefin, which when hydrolysed turns from yellow to red. Sonicated samples of the 
recipient strain (P1983), the two donor strains (P1131 and P1931) and the two 
transconjugants (P2241 and P2244) were tested for beta-lactamase production by the 
addition of nitrocefin.  
The donor and transconjugant strains (P1131, P1931, P2241 and P2244) produced a beta-
lactamase as there was a colour change from yellow to red upon addition of nitrocefin. No 
colour change was seen for recipient strain P1983 suggesting that it has no detectable beta-
lactamase activity (Figure 5.6).  
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Figure 5.6 Detection of beta-lactamase activity using nitrocefin 
 
 
 
 
 
 
Well Sample Beta-lactamase activity 
1 P854 (+ve control) + 
2 P270 (-ve control) - 
3 P1983 - 
4 P1131 (contains pBla1) + 
5 P1931 (contains pBla2) + 
6 P2241 (contains pBla1) + 
7 P2244 (contains pBla2) + 
 
 
Sonicated bacterial cell suspensions were mixed with nitrocefin and viewed after 30 minutes 
incubation at 37°C. A change of colour from yellow to red indicates a nitrocefin positive 
result, i.e. beta-lactamase activity. If the yellow colour of the nitrocefin remains unchanged 
the result was negative, i.e. no beta-lactamase activity detected.  
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5.4.4 flaA typing 
Typing using the flaA SVR region was performed on all strains to confirm that any DNA 
transfer was the result of conjugation rather than natural transformation. Donor, recipient 
and transconjugant strains were flaA typed, the short variable region of the flaA gene was  
PCR amplified and sequenced then compared to the flaA database to determine the allele 
(Table 5.4). All transconjugants possessed the flaA239 allele, the same allele as the recipient 
strain. 
5.4.5 Growth kinetics 
Following an observation that the transconjugant and donor strains often grew better than 
the recipient strain it was decided that the growth kinetics of these should be investigated. 
The growth kinetics of donor, recipient and transconjugant strains were investigated by 
measuring the change in absorbance (at an optical density of 600nm) of broth cultures over 
48 hours using a Bioscan spectrophotometer. Data was gathered for each strain on three 
separate occasions and on each occasion ten replicates were used to calculate mean values.  
In order to determine whether the plasmid pBla1 affects the growth of the recipient strain, 
data for the transconjugant P2241 was compared with that of the recipient strain P1983 
(Figure 5.7). The final absorbance of P1983 at OD600nm was 0.17  0.03 whereas P2241 had a 
final absorbance of 0.15  0.07. When these two values were compared using a student’s 
two-tailed T-test P=0.726, there was no significant difference between the final absorbance 
achieved. The generation time was calculated during log phase (3-7hours) and was found to 
be 213 minutes  38.8 for P1131 and for P2241 was found to be 212 minutes  73.3. There 
was no significant difference between these generation times (P = 0.989). 
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Table 5.4 flaA typing of donor, recipient and transconjugant strains 
 
Strain Description flaA allele FlaA peptide 
P1984 Control (pTet) donor 359 9 
P1131 pBla1 donor 18 20 
P1931 pBla2 donor  66 1 
P1983 Conjugation recipient 239 9 
P2238 Control (pTet) transconjugant 239 9 
P2241 pBla1 transconjugant 239 9 
P2244 pBl2 transconjugant 239 9 
 
flaA typing was performed on donor recipient and transconjugants by sequencing the short 
variable region, sequencing data was compared to the flaA database to determine the flaA 
type and the FlaA peptide. 
This work made use of the Campylobacter jejuni Multi Locus Sequence Typing website 
(http://pubmlst.org/ campylobacter/) developed by Keith Jolley and Man-Suen Chan and 
sited at the University of Oxford (Jolley et al. 2004, BMC Bioinformatics, 5:86). The 
development of this site has been funded by the Wellcome Trust. 
  
 
 
Figure 5.7 Growth kinetics of pBla1 donor, recipient and transconjugant 
 
 
 
 
Strain Final OD600 P value Generation time (minutes) P value 
P1131 0.15 ± 0.05 N/A 231.1 ± 19.9 N/A 
P1983 0.17 ± 0.03 N/A 213.3 ± 38.8 N/A 
P2241 0.15 ± 0.07 0.73 212.2 ± 73.7 0.989 
 
Data shown is the average of three biological repeats each consisting of ten technical replicates. 
The T-tests performed were two-tailed and compared the growth of the transconjugant to that of the recipient during log phase (3-7 hours) to determine whether the 
presence of plasmid pBla1 had an effect on growth.  
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There was also no significant difference between the final absorbance of the pBla2 
transconjugant P2244 and the recipient P1983 (P = 0.115); neither was there any difference 
in generation time during log phase (P = 0.191) (Figure 5.8). However, it is also clear by 
examination of these graphs that the log phase of the recipient strain is delayed by 
approximately four hours when compared to the donor and transconjugant strains (Figure 
5.7 and 5.8). 
5.5 Discussion 
Preliminary experiments performed previously in this laboratory (unpublished data) 
suggested that some strains of Campylobacter may be able to transfer ampicillin resistance 
alongside tetracycline resistance during conjugation. Two plasmids; pBla1 from C. coli P1131 
and pBla2 from C. coli P1931 have been successfully transferred to an ampicillin and 
tetracycline sensitive plasmid free strain of C. jejuni, P1983. The conjugation frequency of 
the plasmids was found to be 1.2X10-8 and 4.03X10-7 respectively, this transfer frequency is 
much less (approximately 100 to 1000 times less) than the conjugation frequency of the 
control plasmid, pTet, which was found to be 3X10-4, the same level as found in other studies 
(Batchelor, Pearson et al. 2004). The lower frequency of transfer may be plasmid specific or 
due to the fact that the transfer of pBla1/2 was from a C. coli donor to a C. jejuni recipient. 
Further experiments would be required to determine which is the case and would include 
transferring the plasmids from a C. jejuni donor to a C. jejuni recipient and from a C. coli host 
to a C. coli recipient.  
An acknowledged problem of assessing conjugation in Campylobacter is the fact that the 
bacteria are naturally competent and so able to acquire DNA without conjugation taking  
  
 
 
Figure 5.8 Growth kinetics of pBla2 donor, recipient and transconjugant 
 
Strain Final OD600 P value Generation time (minutes) P value 
P1931 0.21 ± 0.01 N/A 186.08 ± 40.62 N/A 
P1983 0.17 ± 0.03 N/A 213.32 ± 67.2 N/A 
P2244 0.11 ± 0.03 0.115 277.34 ± 21.9 0.191 
 
Data shown is the average of three biological repeats each consisting of ten technical replicates. 
The T-tests performed were two-tailed and compared the growth of the transconjugant to that of the recipient during log phase (3-7 hours) to determine whether 
the presence of plasmid pBla2 had an effect on growth. 
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place. In order to ensure that effects seen are the result of conjugation a method of 
distinguishing ‘donor’ and ‘recipient’ strains must be established (Bacon, Alm et al. 2002). 
In this study flaA typing was use to distinguish between the plasmid donors P1131 (flaA 18)  
and P1931 (flaA 66) and the plasmid free recipient strain, P1983 (flaA 239). All putative 
transconjugants were the same flaA type as the recipient strain (flaA 239) therefore 
conjugation was confirmed as the mechanism of DNA transfer.  
The MIC data obtained confirm that the preliminary data which suggested that ampicillin 
resistance had co-transferred with tetracycline resistance was correct. Plasmids pBla1 and 
pBla2 appear to transfer resistance to tetracycline and the beta-lactams penicillin, ampicillin 
and in the case of pBla1, oxacillin. The level of resistance in the transconjugants was 
equivalent to that of the donor stains.  
Data from the experiments with nitrocefin suggest that the transferrable beta-lactam 
resistance determinant is a beta-lactamase as the recipient strain had no beta-lactamase 
activity whereas the transconjugants containing pBla1 and pBla2 did. 
The plasmid Bla1 also appears to confer resistance to nalidixic acid and ciprofloxacin. This 
was unexpected as resistance to fluoroquinolone antibiotics in Campylobacter is usually 
through mutation of DNA gyrase (gyrA) (Power, Munoz-Bellido et al. 1992; Smith and 
Fratamico 2010). Natural transformation of the gyrA gene from the ‘conjugation recipient’ to 
the ‘conjugation donor’ was originally thought to be the cause of the fluoroquinolone 
resistance in the transconjugant strains but as flaA typing confirmed that the mutants were 
created by conjugation, this appears not to be the case. However unlikely, it is not 
impossible that both conjugation and natural transformation have taken place between the 
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same bacteria. Further experimentation including the sequencing of the flaA gene and the 
pBla1 plasmid would be necessary to identify the source of the fluoroquinolone resistance. 
Growth kinetics data generated using the Bioscan spectrophotometer indicates that 
acquisition of either plasmid Bla1 or Bla2 had no affect on generation time or final 
absorbance suggesting that presence of these plasmids does not adversely affect the growth 
of the host bacterium; strains containing either plasmid pBla1 or pBla2 actually appeared to 
enter a logarithmic phase of growth approximately four hours before the equivalent strain 
lacking any plasmids. Having no detrimental effect on their host bacterium’s growth may aid 
the persistence of theses plasmids. 
The Bioscan spectrophotometer which was used to generate the growth kinetics data in this 
study does not regulate the atmosphere within the unit therefore growth is dependent on 
the atmosphere within the microtitre tray remaining constant and is unlikely to result in 
optimal growth.  
Future Work 
 Sequence the plasmids pBla1 and pBla2. Once assembled and annotated the sequence of 
these plasmids would be analysed to identify the gene(s) responsible for the 
transferrable beta-lactam resistance. 
 Following the sequencing of pBla1 and pBla2 assess how similar the two plasmids are, 
determine whether they share a common ancestor or whether two distinct beta-lactam 
resistance plasmids are circulating within Campylobacter in UK poultry flocks. 
 Screen the panel of Campylobacter isolates gathered from Defra funded studies VM0220 
and OZO501 for the presence of pBla1 and pBla2 in order to determine how prevalent 
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the plasmids are within Campylobacter isolated from UK chicken flocks. Also acquire and 
screen Campylobacter isolated from other sources. 
 Conjugate pBla1 and pBla2 from between two isolates of C. jejuni and between two 
isolates of C. coli to determine whether Campylobacter species is a restriction barrier for 
conjugation of these plasmids.  
 Sequence the gyrA genes of donor, recipient and transconjugant strains to determine the 
source of the fluoroquinolone resistance.  
164 
 
Bacon, D. J., R. A. Alm, et al. (2002). "DNA Sequence and Mutational Analyses of the pVir 
Plasmid of Campylobacter jejuni 81-176." Infect. Immun. 70(11): 6242-6250. 
Batchelor, R. A., B. M. Pearson, et al. (2004). "Nucleotide sequences and comparison of two 
large conjugative plasmids from different Campylobacter species." Microbiology 
150(Pt 10): 3507-17. 
Birnboim, H. C. and J. Doly (1979). "A rapid alkaline extraction procedure for screening 
recombinant plasmid DNA." Nucleic Acids Res 7(6): 1513-23. 
Bush, K. (2001). "New B-lactamases in Gram-Negative Bacteria: Diversity and Impact on the 
Selection of Antimicrobial Therapy." Clinical Infectious Diseases 32: 1085-1089. 
Bush, K. and S. Mobashery (1998). "How beta-lactamases have driven pharmaceutical drug 
discovery. From mechanistic knowledge to clinical circumvention." Adv Exp Med Biol 
456: 71-98. 
Datta, N. (1969). "Drug resistance and R factors in the bowel bacteria of London patients 
before and after admission to hospital." Br Med J 2(5654): 407-11. 
Gibreel, A., O. Skold, et al. (2004). "Characterization of plasmid-mediated aphA-3 kanamycin 
resistance in Campylobacter jejuni." Microb Drug Resist 10(2): 98-105. 
Humphrey, T. J., F. Jorgensen, et al. (2005). "Prevalence and Subtypes of Ciprofloxacin-
Resistant Campylobacter spp. in Commercial Poultry Flocks before, during, and after 
Treatment with Fluoroquinolones." Antimicrob. Agents Chemother. 49(2): 690-698. 
Kado, C. I. and S. T. Liu (1981). "Rapid procedure for detection and isolation of large and 
small plasmids."  145(3): 1365-1373. 
McDermott, P. F., S. M. Bodeis, et al. (2004). "Development of a Standardized Susceptibility 
Test for Campylobacter with Quality-Control Ranges for Ciprofloxacin, Doxycycline, 
Erythromycin, Gentamicin, and Meropenem." Microbial Drug Resistance 10(2): 124-
131. 
Medeiros, A. A. (1997). "Evolution and dissemination of beta-lactamases accelerated by 
generations of beta-lactam antibiotics." Clin Infect Dis 24 Suppl 1: S19-45. 
Piddock, L. J. V., D. Griggs, et al. (2008). "Persistence of Campylobacter species, strain types, 
antibiotic resistance and mechanisms of tetracycline resistance in poultry flocks 
treated with chlortetracycline." J. Antimicrob. Chemother. 62(2): 303-315. 
Power, A. G., J. L. Munoz-Bellido, et al. (1992). "Detection of ciprofloxacin resistance in Gram 
negative bacteria due to alterations in gyrA." J Antimicrob Chemother 29(1): 9-17. 
Smith, J. L. and P. M. Fratamico (2010). "Fluoroquinolone resistance in Campylobacter." J 
Food Prot 73(6): 1141-52. 
Taylor, D. E., S. A. D. Gradis, et al. (1981). "Transmissible Plasmids from Campylobacter 
jejuni." Antimicrob. Agents Chemother. 19(5): 831-835. 
Tenover, F. C. and P. M. Elvrum (1988). "Detection of two different kanamycin resistance 
genes in naturally occurring isolates of Campylobacter jejuni and Campylobacter coli." 
Antimicrob Agents Chemother 32(8): 1170-3. 
Wang, Y. and D. E. Taylor (1990). "Chloramphenicol resistance in Campylobacter coli: 
nucleotide sequence, expression, and cloning vector construction." Gene 94(1): 23-
28. 
 
 
1 
 
CONTENTS 
6.1 Background .............................................................................................................. 164 
6.2 Aims and Hypotheses .............................................................................................. 165 
6.3 Do all sequenced Campylobacter isolates encode an oxacillinase? ........................ 165 
6.4 Are all Campylobacter oxacillinase genes within the same genomic context? ....... 171 
6.5 Is the presence of Campylobacter oxacillinases always associated with resistance 
to penicillin type beta-lactams? ......................................................................................... 177 
6.6 Discussion ................................................................................................................ 177 
References .............................................................................................................................. 182 
 
  
164 
 
Chapter 6 – Results and Discussion 
The oxacillinases of Campylobacter 
6.1 Background  
For the last twenty five years beta-lactamases have been thought to be the main 
mechanism responsible for beta-lactam resistance in Campylobacter (Fliegelman, Petrak 
et al. 1985; Lucain, Goosses et al. 1985). Beta-lactamases have been consistently found to 
be produced by a large proportion of Campylobacter isolates, often around 90% of 
ampicillin or amoxicillin resistant isolates test positive for beta-lactamase production 
(Fliegelman, Petrak et al. 1985; Lariviere, Gaudreau et al. 1986; Tajada, Gomez-Garces et 
al. 1996; Elviss, Williams et al. 2009; Griggs, Peake et al. 2009). When the activity profile 
of Campylobacter beta-lactams is investigated they are found to be active against the 
penicillin type beta-lactamases but show weak to no hydrolysis of the cephalosporins and 
imipenem (Lucain, Goosses et al. 1985; Lachance, Gaudreau et al. 1991; Alfredson and 
Korolik 2005; Griggs, Peake et al. 2009).  
The first Campylobacter beta-lactamase protein to be identified was an Ambler Class D 
beta-lactamase and was assigned the classification of OXA-61 from the Lahey clinic 
(http://www.lahey.org/studies/)(Alfredson and Korolik 2005). OXA-61 was found to vary 
by only one amino acid substitution, GluGly  at position 202, when compared to the 
predicted putative Class D beta-lactamase encoded by the cj0299 gene of Campylobacter 
jejuni NCTC11168, now known as OXA-193 (Alfredson and Korolik 2005; Griggs, Peake et 
al. 2009). 
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With the whole genome sequences of twenty one Campylobacter jejuni isolates, two 
Campylobacter coli isolates and three Campylobacter lari isolates now available it is now 
possible to determine how common it is for these isolates to carry an oxacillinase. 
6.2 Aims and Hypotheses  
It was hypothesised that most Campylobacter jejuni would encode an oxacillinase on 
their genome.  
The aims of this work were to:  
a) Determine which sequenced isolates encode an oxacillinase. 
b) Determine how varied these Campylobacter oxacillinases are from each other and 
from other known beta-lactamases. 
c) Determine whether the genes encoding these Campylobacter oxacillinases are in a 
similar genomic context to each other. 
d) Determine whether the presence of Campylobacter oxacillinases is always linked 
to resistance to penicillin-type beta-lactams. 
6.3 Do all sequenced Campylobacter isolates encode an oxacillinase? 
Of the twenty four Campylobacter jejuni, coli and lari genome sequences listed in 
GenBank, only eighteen could be used when BLAST searching, the remaining six were 
excluded from further study as their beta-lactamase genes were not accessible for 
analysis. C. jejuni strains GC015, P854, P852 were also included for comparison as they 
encode the oxacillinases OXA-61, OXA-184 and OXA-185 (Chapter 4)(Alfredson and 
Korolik 2005). 
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The C. jejuni NCTC11168 oxacillinase protein, OXA-193, was used to query the seventeen 
Campylobacter genomes (using protein BLAST) to determine whether they encoded an 
oxacillinase protein.   
Of the C. jejuni, C. coli and C. lari genome sequences submitted to GenBank available for 
BLAST searching and including C. jejuni NCTC11168, GC015, P854 and P852, the majority, 
66% (14/21) encode an oxacillinase (Table 6.1). The oxacillinase encoded by C. jejuni 
NCTC11168, OXA-193, was the most common Campylobacter oxacillinase, 50% (7/14) of 
isolates with an oxacillinase gene encode an oxacillinase protein indistinguishable from 
this one (Table 6.1 and Table 6.2). The strains which encode OXA-193 include both C. 
jejuni and C. coli and were isolated from both human and ovine sources showing that it is 
not found in only a single Campylobacter species or animal host (Table 6.2)  
There are seven other distinct oxacillinases encoded by Campylobacter, these vary in size 
from 248 to 257 amino acids in length and when compared to OXA-193 share between 
52% and 99% identity with the protein (Table 6.3). The oxacillinase of C. jejuni GC015 and 
OXA-61 have only one amino acid difference when compared to OXA-193, although the 
substituted amino acid is different in each case, both of these therefore share 99% 
identity with OXA-193 (Table 6.3 and Figure 6.1). The oxacillinase of C. jejuni RM1221 also 
shares 99% identity with OXA-193, in this instance however the protein is four amino 
acids shorter than OXA-193 and there is an amino acid substitution in the final residue of 
the RM1221 oxacillinase when compared to the amino acid at position 253 of OXA-193 
(Table 6.3 and Figure 6.1). The remaining three oxacillinases from C. jejuni (1336, P854 
and P852) are 248-249 amino acids in length and share only 65% (C1336_000060032) and 
64% (OXA-184 and OXA-185) identity with OXA-193; similarly the oxacillinase from C. lari  
 
 
Table 6.1 All Campylobacter jejuni, coli and lari genomes listed in GenBank and whether or not they encode an oxacillinase 
 
Campylobacter strain Putative oxacillinase? GenBank Accession No. Similarity to Cj0299 (Identity) 
Campylobacter jejuni GC015 Yes (OXA-61) * 99%   
Campylobacter jejuni P854 Yes (OXA-184) * 64% 
Campylobacter jejuni P852 Yes (OXA-185) * 64% 
Campylobacter jejuni subsp. jejuni NCTC 11168 Yes (OXA-193) YP_002343737 100% ** 
Campylobacter jejuni subsp. jejuni IA3902 Yes ADC27923 100% 
Campylobacter jejuni subsp. jejuni 81116 Yes YP_001481852 100% 
Campylobacter jejuni subsp. jejuni 84-25 Yes ZP_01100440 100% 
Campylobacter jejuni subsp. jejuni CF93-6 Yes ZP_01067390 100% 
Campylobacter jejuni subsp. jejuni CG8486 Yes ZP_01810676 100% 
Campylobacter coli JV20 Yes ZP_07402011 100% 
Campylobacter jejuni subsp. jejuni HB93-13 Yes ZP_01072081 99% 
Campylobacter jejuni RM1221 Yes YP_178363 99% 
Campylobacter jejuni subsp. jejuni 1336 Yes ZP_06373212 65% 
Campylobacter lari RM2100 Yes YP_002575950 52% 
Campylobacter jejuni subsp. jejuni 260.94 No N/A N/A 
Campylobacter jejuni subsp. jejuni BH-01-0142 No N/A N/A 
Campylobacter jejuni subsp. jejuni CG8421 No N/A N/A 
Campylobacter jejuni subsp. jejuni 414 No N/A N/A 
Campylobacter jejuni subsp. jejuni 81-176 No N/A N/A 
Campylobacter jejuni subsp. doylei 269.97 No N/A N/A 
Campylobacter coli RM2228 No N/A N/A 
Campylobacter jejuni subsp. jejuni 305 *** N/A N/A 
Campylobacter jejuni subsp. jejuni 327 *** N/A N/A 
Campylobacter jejuni subsp. jejuni DFVF1099 *** N/A N/A 
Campylobacter jejuni subsp. jejuni ICDCCJ07001 *** N/A N/A 
Campylobacter jejuni subsp. jejuni M1 *** N/A N/A 
Campylobacter jejuni subsp. jejuni S3 *** N/A N/A 
*  Genome not submitted to GenBank 
**  Is OXA-193 
*** Genome listed in GenBank but not available to be searched using the Basic Local Alignment Search Tool (BLAST) 
The presence or absence of an oxacillinase was determined by using the sequence of the C. jejuni NCTC11168 beta-lactamase (OXA-193) to interrogate the test 
genome using Protein BLAST. All data from GenBank (http://www.ncbi.nlm.nih.gov/) last accessed 06/09/2010. 
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Table 6.2 Campylobacter oxacillinases identical to OXA-193 
 
GenBank Accession No. Organism Strain Origin Locus Tag Description of protein Reference 
YP_002343737 C. jejuni NCTC 11168 Human Cj0299 putative periplasmic beta-lactamase 
(Parkhill, Wren et al. 2000; 
Gundogdu, Bentley et al. 2007) 
ADC27923 C. jejuni IA3902 
Sheep , aborted 
placenta 
CJSA_0273 putative periplasmic beta-lactamase  
YP_001481852 C. jejuni 81116 Human C8J_0276 putative periplasmic beta-lactamase (Pearson, Gaskin et al. 2007) 
ZP_01810676 C. jejuni CG8486 Human Cj8486_0288 putative periplasmic beta-lactamase (Poly, Read et al. 2007) 
ZP_01100440 C. jejuni 84-25 Unknown CJJ8425_0323 beta-lactamase  
ZP_01067390 C. jejuni CF93-6 Unknown CJJCF936_0321 beta-lactamase  
EFM36662 C. coli JV20 Human HMPREF9399_1369 possible beta-lactamase  
 
All of the above have the following protein sequence (257 aa): 
MKKITLFLLFLNLVFGQDKILNNWFKEYNTSGTFVFYDGKTWASNDFSRAMETFSPASTFKIFNALIALDSGVIKTKKEIFYHYRGEKVFLSSWAQDMNLSSAIKYSNVLA
FKEVARRIGIKTMQEYLNKLHYGNAKISKIDTFWLDNSLKISAKEQAILLFRLSQNSLPFSQEAMNSVKEMIYLKNMENLELFGKTGFNDEQKIAWIVGFVYLKDENKYKA
FALNLDIDKFEDLYKREKILEKYLDELVKKVKNDG 
 
All data from GenBank (http://www.ncbi.nlm.nih.gov/) last accessed 06/09/2010. 
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Table 6.3 Campylobacter oxacillinases not identical to OXA-193 
 
GenBank 
Accession No. 
Organism Strain Locus Tag Description of protein 
Number of 
amino acids 
Similarity to 
Cj0299 (Identity) 
Reference 
AAT01092 C. jejuni GC015 * OXA-61 257 99% 
(Alfredson and 
Korolik 2005) 
ZP_01072081 C. jejuni HB93-13 CJJHB9313_0308 class D beta-lactamase 257 99%  
YP_178363 C. jejuni RM1221 CJE0344 beta-lactamase 253 99% 
(Fouts, Mongodin et 
al. 2005) 
ZP_06373212 C. jejuni 1336 C1336_000060032 hypothetical protein 249 65%  
** C. jejuni P854 P854_1490 OXA-184 248 64% This study 
** C. jejuni P852 * OXA-185 248 64% This study 
ACM64698 C. lari RM2100 Cla_1383 / CLA0304 
conserved hypothetical protein, 
possible beta-lactamase 
248 52%  
 
* Full genome not available therefore no locus tag has been described 
**Sequence not yet submitted to GenBank  
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Figure 6.1 An alignment of oxacillinases including the putative Campylobacter 
oxacillinases 
 
 
All the putative Campylobacter oxacillinases align with known oxacillinases and contain all the identical and 
conserved/variable regions associated with an oxacillinase (Poirel, Naas et al. 2010). 
#OXA-02         ------MAIR IFAILFSIFS LATFAHAQEG TL-------- ----ERSDWR KFFSEFQAKG TIVVADERQA DRAMLVFDPV RSKKRYSPAS 
#OXA-20         ------MIIR FLALLFSAVV LVSLGHAQEK TH-------- ----ESSNWG KYFSDFNAKG TIVVVDERTN GNSTSVYNES RAQQRYSPAS 
#OXA-10         --------MK TFAAYVIIAC LSSTALAGSI TE-------- ----NTS-WN KEFSAEAVNG VFVLCKS--S SKSCATNDLA RASKEYLPAS 
#OXA-48         -----MRVLA LSAVFLVASI IGMPAVAKEW QE-------- ----NKS-WN AHFTEHKSQG VVVLWNE--N KQQGFTNNLK RANQAFLPAS 
#OXA-40         ----MKKFIL PIFSISILVS LSACSSIKTK SEDNFHIS-S QQ--HEKAIK SYFDEAQTQG VIIIKEG--K NLSTYGNALA RANKEYVPAS 
#OXA-51         ----MN--IK TLLLITSAIF ISACSPYIVT ANPNHSASKS DE--KAEKIK NLFNEVHTTG VLVIQQG--Q TQQSYGNDLA RASTEYVPAS 
#OXA-23         ----MN--KY FTCYVVASLF LSGCTVQHNL IN-ETPSQIV QG--HNQVIH QYFDEKNTSG VLVIQTD--K KINLYGNALS RANTEYVPAS 
#OXA-58         ----MK-LLK ILSLVCLSIS IGACAEHSMS RAKTSTIPQV NNSIIDQNVQ ALFNEISADA VFVTYDG--Q NIKKYGTHLD RAKTAYIPAS 
#OXA-50         ----MR---- -PLLFSALLL LSGHTQASEW ND-------- -----SQAVD KLFGAAGVKG TFVLYDV--Q RQRYVGHDRE RAETRFVPAS 
#OXA-63         -MS--KKNFI LIFIFVILIS CKNTEKISN- ---------- ----ETTLID NIFTNSNAEG TLVIYNL--N DDKYIIHNKE RAEQRFYPAS 
#OXA-18         MQRSLSMSGK RHFIFAVSFV ISTVCLTFSP AN-------- ----AAQKLS CTLVIDEASG DLLHREGS-- ---------- -CDKAFAPMS 
#OXA-42         MKFRHALSS- -------AFV L----LGCIA AS-------- ----AHAKTI CTAIADAGTG KLLVQDGD-- ---------- -CGRRASPAS 
#OXA-30         MKNTIHINF- -----AIFLI IANIIYSSAS AS-------- ----TDISTV ASPLFEGTEG CFLLYDASTN AEI-AQFNKA KCATQMAPDS 
#OXA-61         ----MK--KI TLFLLFLNLV FGQDK----- ---------- -------ILN NWFKEYNTSG TFVFY----D GKTWASNDFS RAMETFSPAS 
#OXA-184        ----LKK-IL LLFSLFYSFA LANDK----- ---------- --------LK DFFKDYNTSG VFITF----D GKHYASNNFK RAKEPFSPAS 
#OXA-185        ----LKK-IL LLFSLFYSFA LANDK----- ---------- --------LK DFFKDYNTSG VFITF----D GKHYASNNFK RAKEPFSPAS 
#OXA-193        ----MK--KI TLFLLFLNLV FGQDK----- ---------- -------ILN NWFKEYNTSG TFVFY----D GKTWASNDFS RAMETFSPAS 
#CJJHB9313_0308 ----MK--KI TLFLLFLNLV FGQDK----- ---------- -------VLN NWFKEYNTSG TFVFY----D GKTWASNDFS RAMETFSPAS 
#CJE0344        ----MK--KI TLFLLFLNLV FGQDK----- ---------- -------ILN NWFKEYNTSG TFVFY----D GKTWASNDFS RAMETFSPAS 
#ZP_06373212    ----MRN--F IVFILFLNIA IGEDK----- ---------- -------ILG NFFKDCNTSG TFIVF----D GKNYASNDFK RAKQAFSPAS 
#ACM64698       ----MKK-IF LLFGLFCSFA LANEN----- ---------- --------LK DLFKDYNESG VFIAY----D GKNYYSNDFK KANKRILPAS 
 
#OXA-02         TFKIPHTLFA LDAGAVRDEF QIFR-WDGV- -NRGFAGHNQ DQDLRSAMRN STVWVYELFA KEIGDDKARR YLKKIDYGNA DPST------ 
#OXA-20         TFKIPHTLFA LDAGAVRDEF HVFR-WDGA- -KRSFAGHNQ DQNLRSAMRN STVWVYQLFA KEIGENKARS YLEKLNYGNA DPST------ 
#OXA-10         TFKIPNAIIG LETGVIKNEH QVFK-WDGK- -PRAMKQWER DLTLRGAIQV SAVPVFQQIA REVGEVRMQK YLKKFSYGNQ NISG------ 
#OXA-48         TFKIPNSLIA LDLGVVKDEH QVFK-WDGQ- -TRDIATWNR DHNLITAMKY SVVPVYQEFA RQIGEARMSK MLHAFDYGNE DISG------ 
#OXA-40         TFKMLNALIG LEN-HKATTN EIFK-WDGK- -KRTYPMWEK DMTLGEAMAL SAVPVYQELA RRTGLELMQK EVKRVNFGNT NIGT------ 
#OXA-51         TFKMLNALIG LEH-HKATTT EVFK-WDGQ- -KRLFPEWEK DMTLGDAMKA SAIPVYQDLA RRIGLELMSK EVKRVGYGNA DIGT------ 
#OXA-23         TFKMLNALIG LEN-QKTDIN EIFK-WKGE- -KRSFTAWEK DMTLGEAMKL SAVPVYQELA RRIGLDLMQK EVKRIGFGNA EIGQ------ 
#OXA-58         TFKIANALIG LEN-HKATST EIFK-WDGK- -PRFFKAWDK DFTLGEAMQA STVPVYQELA RRIGPSLMQS ELQRIGYGNM QIGT------ 
#OXA-50         TYKVANSLIG LSTGAVRSAD EVLP-YGGK- -PQRFKAWEH DMSLRDAIKA SNVPVYQELA RRIGLERMRA NVSRLGYGNA EIGQ------ 
#OXA-63         TFKIYNSLIG LNEKAVKDVD EVFYKLMA-- -KSFLESWAK DSNLRYAIKN SQVPAYKELA RRIGIKKMKE NIEKLDFGNK SIGD------ 
#OXA-18         TFKLPLAIMG YDADILLDAT TPRWDYKPEF NGY--KSQQK PTDPTIWLKD SIVWYSQELT RRLGESRFSD YVQRFDYGNK DVSGDPGKHN 
#OXA-42         TFKIAISLMG YDAGFLRNEH DPVLPYRDSY IAWGGEAWKQ PTDPTRWLKY SVVWYSQQVA HHLGAQRFAQ YAKAFGYGNA DVSGDPGQNN 
#OXA-30         TFKIALSLMA FDAEIIDQKT IFKWDKTP-- --KGMEIWNS NHTPKTWMQF SVVWVSQEIT QKIGLNKIKN YLKDFDYGNQ DFSGDKERNN 
#OXA-61         TFKIFNALIA LDSGVIKTKK EIFYHYRGE- -KVFLSSWAQ DMNLSSAIKY SNVLAFKEVA RRIGIKTMQE YLNKLHYGNA KIS------- 
#OXA-184        TFKIFNALIA LDNGVVKDTK EIFYHYKGE- -KVFLPSWKQ DASLSSAIKR SQVPAFKELA RKIGLKTMQE SLNKLSYGNT KIS------- 
#OXA-185        TFKIFNALIA LDNGVVKDTK EIFYHYKGE- -KVFLPSWKQ DASLSSAIKR SQVPAFKELA RKIGLKTMQE SLNKLSYGNT KIS------- 
#OXA-193        TFKIFNALIA LDSGVIKTKK EIFYHYRGE- -KVFLSSWAQ DMNLSSAIKY SNVLAFKEVA RRIGIKTMQE YLNKLHYGNA KIS------- 
#CJJHB9313_0308 TFKIFNALIA LDSGVIKTKK EIFYHYRGE- -KVFLSSWAQ DMNLSSAIKY SNVLAFKEVA RRIGIKTMQE YLNKLHYGNA KIS------- 
#CJE0344        TFKIFNALIA LDSGVIKTKK EIFYHYRGE- -KVFLSSWAQ DMNLSSAIKY SNVLAFKEVT RRIGIKTMQE YLNKLHYGNA KIS------- 
#ZP_06373212    TFKIFNALIA LDNGVVRDTK EIFYHYKGE- -KVFLPSWKQ DASLSSAIKR SQVPAFKELA RKIGLKTMQE SLNKLSYGNA KIS------- 
#ACM64698       TFKIFNALIA LNEGVVKDTN EIFYHYKGE- -KVFLPSWKN NANLALAMQR SQLPAYKELA RKIGLEKMQK NLNKLNYGNQ KIS------- 
 
#OXA-02         SNGDYWIEGS LAISAQEQIA FLRKLYRNEL PFRVEHQRLV KDLMIVEAGR N-WILRAKTG WEG------- -----RMGWW VG-WVEWPTG 
#OXA-20         KSGDYWIDGN LAISANEQIS ILKKLYRNEL PFRVEHQRLV KDLMIVEAKR D-WILRAKTG WDG------- -----QMGWW VG-WVEWPTG 
#OXA-10         GIDKFWLEGQ LRISAVNQVE FLESLYLNKL SASKENQLIV KEALVTEAAP E-YLVHSKTG FSGVG----- TESNPGVAWW VG-WVEKETE 
#OXA-48         NVDSFWLDGG IRISATEQIS FLRKLYHNKL HVSERSQRIV KQAMLTEANG D-YIIRAKTG YS-------- TRIEPKIGWW VG-WVELDDN 
#OXA-40         QVDNFWLVGP LKITPVQEVN FADDLAHNRL PFKLETQEEV KKMLLIKEVN G-SKIYAKSG WGMG------ --VTPQVGWL TG-WVEQANG 
#OXA-51         QVDNFWLVGP LKITPQQEAQ FAYKLANKTL PFSPKVQDEV QSMLFIEEKN G-NKIYAKSG WGWD------ --VDPQVGWL TG-WVVQPQG 
#OXA-23         QVDNFWLVGP LKVTPIQEVE FVSQLAHTQL PFSEKVQANV KNMLLLEESN G-YKIFGKTG WAMD------ --IKPQVGWL TG-WVEQPDG 
#OXA-58         EVDQFWLKGP LTITPIQEVK FVYDLAQGQL PFKPEVQQQV KEMLYVERRG E-NRLYAKSG WGMA------ --VDPQVGWY VG-FVEKADG 
#OXA-50         VVDNFWLVGP LKISAMEQTR FLLRLAQGEL PFPAPVQSTV RAMTLLESGP G-WELHGKTG WCFD------ --CTPELGWW VG-WVKR-NE 
#OXA-63         SVDTFWLEGP LEISAMEQVK LLTKLAQNEL QYPIEIQKAI SDITITRANL H-ITLHGKTG LADSK----- NMTTEPIGWF VG--WLEEND 
#OXA-18         GLTHAWLASS LKISPEEQVR FLRRFLRGEL PVSEDALEMT KAVVPHFEAG D-WDVQGKTG TGS--LSDAK GGKAP-IGWF IG-WATR-DD 
#OXA-42         GLDRAWIGSS LQISPLEQLE FLGKMLNRKL PVSPTAVDMT ERIVESTTLA DGTVVHGKTG VSYPLLADGT RDWARGSGWF VG-WIVR-GN 
#OXA-30         GLTEAWLESS LKISPEEQIQ FLRKIINHNL PVKNSAIENT IENMYLQDLD NSTKLYGKTG AGF------T ANRTLQNGWF EG-FIISKSG 
#OXA-61         KIDTFWLDNS LKISAKEQAI LLFRLSQNSL PFSQEAMNSV KEMIYLKNME N-LELFGKTG FNDG------ ----QKIAWI VGFVYLKDEN 
#OXA-184        KIDTFWLDNS LQISAKNQAD LLFKLSQNSL PFSKKSQEEV KKIILFK-ED KIQKIYAKTG FNDGIN---- ------LAWI VGFIESK--N 
#OXA-185        KIDTFWLDNS LQISAKNQAD LLFKLSQNSL PFSKKSQEEV KKIILFK-ED KIQKIYAKTG FNDGIN---- ------LAWI VGFIESK--N 
#OXA-193        KIDTFWLDNS LKISAKEQAI LLFRLSQNSL PFSQEAMNSV KEMIYLKNME N-LELFGKTG FNDE------ ----QKIAWI VGFVYLKDEN 
#CJJHB9313_0308 KIDTFWLDNS LKISAKEQAI LLFRLSQNSL PFSQEAMNSV KEMIYLKNME N-LELFGKTG FNDE------ ----QKIAWI VGFVYLKDEN 
#CJE0344        KIDTFWLDNS LKISAKEQAI LLFRLSQNSL PFSQEAMNSV KEMIYLKNME N-LELFGKTG FNDE------ ----QKIAWI VGFVYLKDEN 
#ZP_06373212    KIDTFWLDNS LQISAKNQAD LLFKLSQNSL PFSKKIQEEV KEIILFK-ED KIQKIYAKTG FNDNIN---- ------LAWI VGFVKTE--N 
#ACM64698       KIDEFWIDDS LQISLKEQAT LLFKLANLTL DYPKHIQEEV INIIKLK-EN DHYELFAKTG WGLR------ -----QYGWI VGFIKSKKSD 
 
#OXA-02         -SVFFALNID -TPNRMDDLF KREAIVRAIL RSIEALPPNP AVNSDAAR 
#OXA-20         -PVFFALNID -TPNRMEDLH KREAIARAIL QSVNALPPN- -------- 
#OXA-10         -VYFFAFNMD -IDN-ESKLP LRKSIPTKIM ESEGIIGG-- -------- 
#OXA-48         -VWFFAMNMD -MPT-SDGLG LRQAITKEVL KQEKIIP--- -------- 
#OXA-40         KKIPFSLNLE -MKEG-MSGS IRNEITYKSL ENLGII---- -------- 
#OXA-51         NIVAFSLNLE -MKKG-IPSS VRKEITYKSL EQLGIL---- -------- 
#OXA-23         KIVAFALNME -MRSE-MPAS IRNELLMKSL KQLNII---- -------- 
#OXA-58         QVVAFALNMQ -MKAG-DDIA LRKQLSLDVL DKLGVFHYL- -------- 
#OXA-50         RLYGFALNID -MPGGEADIG KRVELGKASL KALGILP--- -------- 
#OXA-63         NIYVFALNID NINS--DDLA KRINIVKESL KALN-LLK-- -------- 
#OXA-18         RRVVFAR-LT -VGARKGEQP AGPAARDEFL NTLPALSENF -------- 
#OXA-42         QTLVFAR-LT -QDERKQPVS AGIRTREAFL RDLPRLLAAR -------- 
#OXA-30         HKYVFVS-AL -TGNLGSNLT SSIKAKKNAI TILNTLNL-- -------- 
#OXA-61         KYKAFALNLD -IDKF-EDLY KREKILEKYL DELVKKVKND G------- 
#OXA-184        KILSFALNVD -IKNI-KNLK IREELLEKYI YSLN------ -------- 
#OXA-185        KILSFALNVD -IKNI-KNIK IREELLEKYI YSLN------ -------- 
#OXA-193        KYKAFALNLD -IDKF-EDLY KREKILEKYL DELVKKVKND G*------ 
#CJJHB9313_0308 KYKAFALNLD -IDKF-EDLY KREKILEKYL DELVKKVKND G*------ 
#CJE0344        KYKAFALNLD -IDKF-EDLY KREKILEKYL DELVKKS*-- --------      KEY: 
#ZP_06373212    KILSFALNVD -IKDI-KNIK IREELLEKYL AIITN----- --------      Identical amongst all OXAs 
#ACM64698       KIYAFALNMN -ISDF-NKLY LREEIVQLYL DQL*------ --------      Conserved (but variable) amongst OXAa 
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RM2100 is 248 amino acids in length and shares 52% identity with OXA-193 (Table 6.3 and 
Figure 6.1). The identified Campylobacter oxacillinases were aligned by their amino acid 
sequences to a selection of oxacillinases (covering all the evolutionary groups of 
oxacillinases). When aligned, the Campylobacter oxacillinases contained all the identical and 
conserved/variable regions of an oxacillinase, including the active site tetrad STFK (Figure 
6.1). 
A neighbour-joining tree was created based on the amino acid sequences of the oxacillinases 
(Figure 6.2). The Campylobacter beta-lactamases formed a group distinct from other 
oxacillinases of different origin.  The C. jejuni 1136 oxacillinase, OXA-184 and OXA-185, 
which share 64-65% homology to OXA-193, are grouped together as a separate sub-group to 
the oxacillinases which share 99% homology to OXA-193 (Figure 6.2). The C. lari oxacillinase 
shares a similar level of homology to OXA-193 (52%) as the oxacillinases of C. jejuni 1336, 
OXA-184 and OXA-185. This oxacillinase however is evolutionally distinct and does not 
cluster directly with them (Figure 6.2). Despite this the Campylobacter oxacillinases as a 
group are still very much distinct from oxacillinases isolated from other organisms.  
6.4 Are all Campylobacter oxacillinase genes within the same genomic 
context? 
When the oxacillinase gene containing region of C. jejuni NCTC11168 was aligned with the 
corresponding region of the genomes of some C. jejuni strains which encode identical 
oxacillinases, the beta-lactamase gene was located in approximately the same region on 
each genome (Figure 6.3). However, there were some differences between the regions; the  
  
172 
 
Figure 6.2 The evolutionary relationship between Campylobacter oxacillinases 
and those derived from other species 
 
 
 
 
 
Neighbour-Joining tree of oxacillinase proteins  produced using MEGA 4(Tamura, Dudley et 
al. 2007).
 
 
Figure 6.3 The genomic context of genes encoding Campylobacter oxacillinases identical to OXA-193 
 
 
 
An alignment of the oxacillinase containing region of C. jejuni NCTC11168 (269064:279358) with three other C. jejuni genomes, each of 
which encodes an oxacillinase identical to Cj0299 of C. jejuni NCTC11168. Figure produced using xBase (http://xbase.bham.ac.uk).    
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alignment C. jejuni CG8486 revealed that it lacks the panB gene (upstream of blaOXA-193 in C. 
jejuni NCTC11168) from the pantethonate biosynthesis operon panBCD (Figure 6.3).   
Although panB is not annotated on the genome of CG8486, BLAST searching revealed it to be 
present in the correct region of the genome (GenBank accession number AASY01000000). 
When the genomes from strains which produce different oxacillinases were compared the 
beta-lactamase genes were seen in approximately the same position within their respective 
genomes, however there were some differences in the region as a whole. C. jejuni HB93-13 
contains two truncated moeB/thiF family genes rather than one (Figure 6.4a). The GC 
content of the modB and modC genes (GC=32%) of C. jejuni RM1221 was higher than the 
corresponding genes in C. jejuni NCTC1168 (GC=29%) and HB93-13 (GC=29%), although the 
genes were in the same location (Figure 6.4a).  C. jejuni RM1221 also lacks the acetyl 
transferase gene upstream of the beta-lactamase gene which is conserved within the other 
C. jejuni genomes (Figure 6.3 and Figure 6.4a). 
The structure of the region containing the beta-lactamase gene was different in the C. lari 
RM2100 isolate. Nonetheless some of the surrounding genes echoed those present in the 
corresponding region of C. jejuni NCTC11168; surE, moeB and a hypothetical protein 
between a bioC and a bioF gene were common to both C. lari and C. jejuni (Figure 6.4b).  
One example of an isolate which lacked an oxacillinase gene was aligned with the 
oxacillinase containing region of C. jejuni NCTC11168; as well as lacking an oxacillinase gene, 
C. jejuni 260.94 also lacked an acetyl transferase gene upstream of the usual oxacillinase 
site, and so this region is similar to that in C. jejuni RM1221 (Figure 6.4a and Figure 6.5). 
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Figure 6.4 The genomic context of Campylobacter oxacillinases genes encoding 
oxacillinases distinct from OXA-193 
 
 
 
a) An alignment of the oxacillinase containing region of C. jejuni NCTC11168 
(269064:279358) with two other C. jejuni genomes, each of which encodes an oxacillinase 
not identical to blaOXA-193  of C. jejuni NCTC11168.  
 
b) The oxacillinase containing region of C. lari RM2100 (147486:155891). 
Figure produced using xBase (http://xbase.bham.ac.uk).   
 
 
Figure 6.5 The oxacillinase containing region of C. jejuni NCTC11168 aligned with the corresponding region of a strain that 
does not encode an oxacillinase 
 
 
 
An alignment of the oxacillinase containing region of C. jejuni NCTC11168 (269064:279358) with C. jejuni 260.94 an isolate that does not 
encode an oxacillinase. 
Figure produced using xBase (http://xbase.bham.ac.uk).    
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6.5 Is the presence of Campylobacter oxacillinases always associated 
with resistance to penicillin type beta-lactams? 
A database containing 4678 poultry isolates of Campylobacter from two Defra funded 
studies was used to select Campylobacter isolates for further study (Griggs, Johnson et al. 
2005; Humphrey, Jorgensen et al. 2005; Piddock, Griggs et al. 2008). Isolates that were 
recorded to (i) contain an oxacillinase gene (detectable by PCR using primers for blaOXA-193), 
(ii) lack beta-lactamase activity detectable by a spot test with nitrocefin and also (iii) 
ampicillin sensitive (minimum inhibitory concentration ≥16 µg/ml) were identified. Eight 
isolates contained an oxacillinase gene by DNA sequencing, lacked beta-lactamase activity 
and were ampicillin sensitive (Table 6.4) (McDermott, Bodeis et al. 2004).  
6.6 Discussion 
The production of beta-lactamases by Campylobacter has long been linked to resistance to 
penicillin type beta-lactams (Lucain, Goosses et al. 1985; Lachance, Gaudreau et al. 1991; 
Alfredson and Korolik 2005; Griggs, Peake et al. 2009). Following the identification of an 
oxacillinase type beta-lactamase (OXA-61) from a clinical isolate of C. jejuni and genome 
sequencing of over 20 strains of Campylobacter a better understanding of the diversity and 
context of genomically encoded Campylobacter oxacillinases can be obtained (Parkhill, Wren 
et al. 2000; Alfredson and Korolik 2005; Fouts, Mongodin et al. 2005; Pearson, Gaskin et al. 
2007; Poly, Read et al. 2007). 
The majority of Campylobacter (12/19) were found to contain a gene which encoded a 
putative oxacillinase. The most prevalent was the OXA-193 oxacillinase encoded by C. jejuni 
NCTC11168, 58% of those Campylobacter which contained a beta-lactamase gene encoded a 
 
 
Table 6.4 Campylobacter isolates found to contain an oxacillinase gene and be sensitive to ampicillin 
 
Ampicillin break point (assigned by laboratory); Minimum inhibitory concentration ≥16 µg/ml. Minimum inhibitory concentrations 
represent the modal average from three biological replicates. Beta-lactamase activity was confirmed by three positive biological 
replicates of nitrocefin spot test.  
 
Isolate Species Sequenced beta-lactamase gene Beta-lactamase activity 
Minimum Inhibitory Concentration (µg/ml) 
ampicillin penicillin oxacillin 
NCTC11168 C. jejuni Yes, blaOXA-193  Negative 4 8 64 
P323 C. coli Yes, identical to  blaOXA-193 Negative 8 32 128 
P324 C. coli Yes, identical to  blaOXA-193 Negative 8 32 512 
P851 C. jejuni Yes, identical to  blaOXA-193 Negative 4 16 512 
P1102 C. jejuni Yes, identical to  blaOXA-193 Negative 8 16 512 
P1154 C. jejuni Yes, identical to  blaOXA-193 Negative 4 16 512 
P1197 C. jejuni Yes, identical to  blaOXA-193 Negative 4 16 512 
P1199 C. jejuni Yes, identical to  blaOXA-193 Negative 8 16 512 
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protein identical to this one. Other Campylobacter oxacillinases shared 52-99% homology 
with OXA-193. 
When the oxacillinases of Campylobacter were compared with other known oxacillinases, 
they form a distinct ‘Campylobacter oxacillinase group’ distinct from the other oxacillinases. 
The proteins with 99% homology to OXA-193 unsurprisingly form a cluster with OXA-193. 
The oxacillinases from C. jejuni P854 and 1336 form a cluster of their own, the C. lari 
RM2100 oxacillinase, although of a similar size and homology to OXA-193 appears to have 
evolved separately from the C. jejuni oxacillinases, perhaps as the species themselves have 
diverged. 
The oxacillinases of Campylobacter are quite varied, sharing as little as 64% homology with 
one another. As a single amino acid change denotes a new enzyme and would be entitled to 
an OXA number from the Lahey clinic (Jacoby and Bush 2010), a difference of 64% is striking.  
Despite the breadth of oxacillinase protein sequences encoded by Campylobacter, there was 
a dominance of OXA-193 and OXA-193-like beta-lactamases. This could be due to these 
enzymes having an improved spectrum or rate of activity, alternatively this could simply 
reflect an unknown sequencing bias in terms of the isolates which are being sequenced.  
All of the oxacillinase genes are present within approximately the same genomic context, 
although this region was flexible. As well as maintaining a range of possible beta-lactamase 
genes or lack of a beta-lactamase gene, other genes varied in their GC content such as the 
modABC operon, whereas others such as the acetyl transferase (in C. jejuni RM1221) and the 
panABC operon (in P854 and 1336) were not always present. This region also appears to be 
able to gain potentially useful genes; C. jejuni 1336 has acquired an extra cdt operon 
(GenBank accession number C1336_000060027-9) which codes for the known 
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Campylobacter virulence factor, cytolethal distending toxin (Frisan, Cortes-Bratti et al. 2002; 
Biswas, Fernando et al. 2006; Lindmark, Rompikuntal et al. 2009). C. jejuni 1336 also 
contains a cdt operon in its usual position within the genome, which is distinct in sequence 
to the extra copy, i.e. the operon is not simply duplicated suggesting that the ‘extra’ cdt  
could have been acquired from a different source. The cdtA gene in the usual position 
appears to be truncated so it is hypothesised that the protein encoded by this gene is not 
fully functional. If this is indeed the case, then the presence of another copy of this gene 
would be an advantage to the bacterium. 
It has also been noted that presence of an oxacillinase gene does not necessarily lead to 
ampicillin resistance. Seven Campylobacter poultry isolates and the reference strain C. jejuni 
NCTC1168 were all found to contain oxacillinase encoding genes, yet the MIC values of 
ampicillin were below the laboratory breakpoint (16µg/ml) meaning these isolates were all 
susceptible to the drug. It may be the case that these isolates show little or no expression of 
their oxacillinase genes, further experiments would be able to clarify this point. 
The flexibility of this region has been noted previously and may allow the bacterium to 
acquire advantageous genes from other bacteria (Parker, Quinones et al. 2006). 
Campylobacter are naturally competent, it has been demonstrated that they show a 
preference for the uptake DNA of Campylobacter origin (Wang and Taylor 1990) however if 
the bacteria are acquiring these oxacillinases from another species they have yet to be 
identified.  Obtaining beta-lactamases from other species is a well described phenomenon, a 
good example of which is the mobilization of CTX-M type beta-lactamases from the genomes 
of three species of the soil dwelling bacterium Kluyvera (K. georgiana, K. ascorbata and K. 
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cryocrescens) onto plasmids which have been able to widely disseminate through the 
enterobacteriaceae (Hawkey 2008).  
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Chapter 7 –Overall Discussion and 
Conclusions 
 
The aim of this study was to better understand mechanisms of beta-lactam resistance in 
Campylobacter. 
The original hypotheses to be investigated during this study included the following: 
 beta-lactam resistance can be conferred by the efflux pumps CmeABC and/or CmeDEF 
 a novel beta-lactamase(s), CjBla2, which is distinct from the characterised OXA-61 and 
OXA-193 of C. jejuni, are responsible for beta-lactam resistance in Campylobacter. 
 the purU gene encodes the novel beta-lactamase CjBla2 
 beta-lactam resistance may be transferred alongside tetracycline resistance in 
Campylobacter 
 penicillin binding proteins may play a role in beta-lactam resistance in Campylobacter. 
In other bacterial species functioning RND type efflux pumps have been shown to be 
necessary for resistant bacteria to be selected and for “full” bacterial resistance to be 
achieved  (Ricci, Tzakas et al. 2006; Li and Nikaido 2009). In Campylobacter two multidrug 
efflux pumps CmeABC and CmeDEF have been identified and partially characterised in terms 
of their ability to efflux beta-lactams (Lin, Michel et al. 2002; Pumbwe and Piddock 2002; 
Pumbwe, Randall et al. 2004; Pumbwe, Randall et al. 2005). During my study I determined 
that not only does the efflux pump CmeABC play a role in the efflux of ampicillin (as had 
been previously described), but it is also responsible for the innate resistance of 
Campylobacter to the cephalosporin group of antibiotics. Similar findings were published in 
parallel to my work (Guo, Lin et al. 2010). To elucidate whether efflux is required for ‘full’ 
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beta-lactam resistance in Campylobacter, as in other species, (Ricci and Piddock 2009) 
multiple attempts were made to inactivate the cmeB gene in two, beta-lactamase producing 
C. jejuni isolates. However, no mutants were obtained.  
Although efflux plays a role in innate beta-lactam resistance in Campylobacter, beta-
lactamase production has been associated with ampicillin resistance in these bacteria for 
over 25 years (Fliegelman, Petrak et al. 1985; Lucain, Goosses et al. 1985). Studies have 
consistently shown that the majority of Campylobacter isolates (83-95%) produce beta-
lactamases  (Fliegelman, Petrak et al. 1985; Lariviere, Gaudreau et al. 1986; Tajada, Gomez-
Garces et al. 1996) and that production of a beta-lactamase is associated with resistance to 
penicillin type beta-lactamases (Lachance, Gaudreau et al. 1991). In 2005 an oxacillinase, 
OXA-61, was identified in a human clinical isolate of C. jejuni and shown to have activity 
against penicillin, ampicillin and carbenicillin (Alfredson and Korolik 2005). It was then shown 
that an enzyme with a single amino acid substitution to OXA-61 (GE at position 202) was 
encoded by the cj0299 gene of C. jejuni NCTC11168 and was shown to be present in 91% 
(347/380) of ampicillin resistant poultry isolates (Griggs, Peake et al. 2009). During this study 
the number OXA-193 was assigned to Cj0299 by the Lahey clinic 
(http://www.lahey.org/studies/) upon my request (Jacoby and Bush 2010). 
In the experiments completed preceding my study another beta-lactamase was identified 
from two poultry isolates of C. jejuni, P843 and P854, which had a different isoelectric point 
and molecular mass to that of OXA-61 or OXA-193 (both P843 and P854 had been shown to 
lack blaOXA-193 by PCR), this novel beta-lactamase was termed CJBla2. Preliminary mass 
spectrometry of the protein had identified the predicted product of the purU gene (cj0790) 
as most likely to be CjBla2  (Griggs, Peake et al. 2009). During my study inactivation of purU 
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(cj0790) in one of the CjBla2 producing strains suggested that the gene was unlikely to 
encode CjBla2, as the purU mutant showed the same level of beta-lactamase activity as the 
parental strain. Southern blot analysis and further PCR for blaOXA-193 determined that CjBla2 
was not the product of a mutated blaOXA-193 gene.  
Following the full genome sequencing of CjBla2 producing strain P854, four putative beta-
lactamase genes were identified. Only one of these, P854_1490, was novel. It was 
subsequently determined that the product of this gene was likely to be an oxacillinase and it 
was awarded the number OXA-184 from the Lahey clinic (http://www.lahey.org/studies/) 
(Jacoby and Bush, personal communication). The closest relative of OXA-184 was 
determined to be Cj0299 of C. jejuni NCTC11168; however the two proteins share just 64% 
identity.  Screening a panel of fourteen isolates with the ‘CjBla2 phenotype’ (i.e. ampicillin 
resistant, detectable beta-lactamase activity but lacks amplimers following PCR of cj0299) 
revealed six of these (including P843) also encode OXA-184. A further six isolates encode a 
variant of OXA-184 which has a single leucine to isoleucine amino acid substitution, this 
variant was assigned the number OXA-185 from the Lahey clinic (Jacoby and Bush, personal 
communication). The remaining two isolates of the ‘CjBla2’ panel may encode either OXA-
184 or OXA-185 but within a different genomic context as external gene primers based upon 
amplifying the genomic context of P854 did not produce amplimers following PCR.  
The genes encoding OXA-184 and OXA-185 were within a similar genomic location to OXA-
193. This region of the Campylobacter genome appears to tolerate a variety of oxacillinase 
genes or not contain any at all, this fits with previous findings that this region of the genome 
is hypervariable (Parker, Quinones et al. 2006).  
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As well as encoding an oxacillinase gene on their genome, data produced in my study 
suggest that beta-lactamase resistance may also be transferrable between isolates of 
Campylobacter. Two plasmids, pBla1 and pBla2, were identified from two poultry isolates of 
C. coli, P1131 and P1931, respectively. Conjugation experiments revealed that pBla1 and 
pBla2 were able to transfer resistance to tetracycline and the beta-lactams penicillin, 
ampicillin, oxacillin and cephalothin. Transconjugants were shown to have gained beta-
lactamase activity suggesting that this beta-lactam resistance determinant is a gene 
encoding a beta-lactamase. Interestingly, experimental results also suggested that pBla1 
transconjugants had acquired fluoroquinolone resistance, usually determined by a mutation 
in the genomically encoded gyrA gene. This is an intriguing result and warrants further 
investigation but was beyond the time-frame of this thesis. Sequencing of the plasmids 
pBla1 and pBla2 is now required to determine the gene(s) responsible for transferrable beta-
lactam resistance.  
Time limitations also did not allow for the study of the role of Campylobacter penicillin 
binding proteins (PBPs) in beta-lactam resistance. 
Campylobacter is known to be the leading cause of bacterial gastroenteritis in the world.  
During the first quarter of 2010 the incidence of bacteriologically confirmed cases of 
Campylobacter disease in England and Wales had risen from 2158 cases (in 2009) to 2777 
cases (HPA 2010). Recommended treatment for such cases is with the antibiotics 
erythromycin or ciprofloxacin (BNF 2009), although empirical treatment with ciprofloxacin is 
the most often administered despite some reports of 15% of isolates in England and Wales 
being resistant to ciprofloxacin and in some countries being as high as 90% (ECDC 2009). This 
study has highlighted the major role of oxacillinases in beta-lactam resistance in 
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Campylobacter. As 95% of C. jejuni isolates are susceptible to augmentin (a combination 
beta-lactam and beta-lactamase inhibitor) (ECDC 2009), augmentin may be useful in the 
treatment of Campylobacter infection. 
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Appendix A 
Functional Genomics (University of Birmingham) protocol for setting up 
sequencing reactions 
 Prepare your DNA using a recommended isolation kit in the normal way. 
 Quantify the DNA to check the concentration is correct using the table below as a guide. 
 Add your Primer to the DNA template and make up to a total volume of 10ul. 
Template Quantity 
PCR product  
100-200bp 1-3ng 
200-500bp 3-10ng 
500-1000bp 5-20ng 
1000-2000bp 10-40ng 
>2000bp 40-100ng 
Single Stranded DNA 50-100ng 
Double Stranded DNA 200-500ng 
Cosmid, BAC 0.5-1.0ug 
Bacterial Genomic 2-3ug 
Example: 
Double stranded DNA  200 - 500 ng 
Primer    3.2 pmol 
Sterile water    q.s 
Total Volume    10ul 
Primer Annealing Temperature = 55°C – 
60°C 
 
PCR Conditions Used. 
96°C    10 secs 
50°C    5 secs 
60°C  4 mins 
Check your primers annealing temperature. To use this service your primer annealing 
temperature needs to be between 50°C to 65°C 
X25 
191 
 
Appendix B 
Southern Blotting Recipes 
Depurination solution  
Distilled water  987.5 mls 
10M HC1  12.5 mls 
 
Denaturing solution 
NaCl   87.7g 
NaOH   20.0g 
Water to   1 litre 
 
Neutralizing solution   
NaC1   87.7g 
Tris   60.6g 
EDTA (Na2 salt) 0.37g 
Adjust to pH 7.2 with 10M HCL 
Water to   1 litre 
 
20X SSC 
NaCl   175.3g  
Sodium Citrate  88.2g  
Adjust pH to 7.0 with 10M NaOH  
Adjust volume to 1L  
Hybridisation buffer (Supplied with kit)  
Add NaCl to a final concentration of 0.5M 
Add 4% (w/v) blocking reagent 
Add reagents and mix at room 
temperature for 1h (can aliquot and store 
at –20 C) 
 
Primary wash buffer (1L)  
Urea   120g 
SDS   1g 
0.5M NaP04*  100ml 
NaCl   8.7g 
1.0M MgCl2  1ml 
Blocking reagent 2g 
*can make by adjusting pH of sodium 
dihydrogen phosphate to 7 with NaOH 
 
Secondary wash buffer (20X stock) 
Tris  121g 
NaCl  112g 
For (1X) secondary wash buffer:  
Dilute stock 1:20 and add 2ml/L of 1M 
MgCl2
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Appendix C 
 Antibiotic concentrations for agar doubling dilutions 
The table below shows how much of a particular stock should be added to 20ml of molten 
agar in order to achieve the required final concentration of antibiotic in the agar plate. 
 
Final concentration required (µg/ml) 1024 512 256 128 64 32 
Volume of  10,000µg/ml stock to add 2048 1024 512 256 128 64 
Final concentration required (µg/ml) 16 8 4 2 1  
Volume of  1000µg/ml stock to add 320 160 80 40 20  
Final concentration required (µg/ml) 0.5 0.25 0.12 0.06   
Volume of  100µg/ml stock to add 100 50 25 13   
Final concentration required (µg/ml) 0.03 0.015 0.008    
Volume of  10µg/ml stock to add 60 30 15    
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Appendix D 
 Recipe for SOC 
 
1. Add the following to 900ml of distilled H2O 
 20g Bacto Tryptone 
 5g Bacto Yeast Extract 
 2ml of 5M NaCl. 
 2.5ml of 1M KCl. 
 10ml of 1M MgCl2 
 10ml of 1M MgSO4 
 20ml of 1M glucose 
2. Adjust to 1L with distilled H2O 
3. Sterilize by autoclaving 
 
Recipe obtained from http://www.thelabrat.com/protocols/15.shtml 
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